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ABSTRACT 
 Alzheimer’s disease (AD) is a complex neurodegenerative disease 
characterized by progressive memory loss and caused by a combination of 
genetic, environmental, and lifestyle factors. AD susceptibility is highly heritable 
at 58-79%, but only about one third of the AD genetic component is accounted 
for by common variants discovered through genome-wide association studies 
(GWAS). Rare variants may contribute to some of the unexplained heritability of 
AD and have been demonstrated to contribute to large gene expression changes 
across tissues, but conventional analytical approaches pose challenges because 
of low statistical power even for large sample sizes. Recent studies have 
demonstrated by expression quantitative trait locus (eQTL) analysis that changes 
in gene expression could play a key role in the pathogenesis of AD. However, 
regulation of gene expression has been shown to be context-specific (e.g., tissue 
and cell-types), motivating a context dependent approach to achieve more 
	
	 vi 
precise and statistically significant associations. To address these issues, I 
applied a strategy to identify new AD risk or protective rare variants by examining 
mutations occurring only in cases or only controls, observing that different 
mutations in the same gene or variable dose of a mutation may result in distinct 
dementias. I also evaluated the impact of rare variation on expression at the 
gene and gene pathway levels in blood and brain tissue, further strengthening 
the rare variant findings with functional evidence and finding evidence for a large 
immune and inflammatory component to AD. Lastly, I identified cell-type specific 
eQTLs in blood and brain tissue to explain underlying genetic associations of 
common variants in AD, and also discovered additional evidence for the role of 
myeloid cells in AD risk and potential novel blood and brain AD biomarkers. 
Collectively, these findings further explain the genetic basis of AD risk and 
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CHAPTER 1: Introduction 
	
 Alzheimer’s disease (AD) is a complex neurodegenerative disease 
characterized by progressive memory loss with no current effective prevention or 
treatment [1]. It is the most common type of dementia that affects an estimated 
5.7 million individuals just in the United States, with the number projected to rise 
to 14 million by 2050 [1] as well as the 6th leading cause of death in the United 
States [1]. Abnormal deposits of proteins form amyloid plaques and tau tangles 
throughout the brain leading to brain cell death [1]. Brain damages seems to 
begin in the hippocampus (which controls memory) and spreads throughout the 
brain as more neurons die, resulting in significantly shrunken brain tissue [1].  
 AD is caused by a combination of genetic, environmental, and lifestyle 
factors [2]. AD susceptibility is highly heritable at 58-79% [2]. Early-onset 
autosomal dominant AD (EOAD) is caused by highly penetrant variants in a few 
known risk genes, whereas late-onset AD (LOAD), which is diagnosed in patients 
over 65, is caused by many different low penetrance mutations [3]. About 30 
LOAD susceptibility loci are known, and risk is very polygenic [3]. Only about one 
third of the AD genetic component is accounted for by common variants 
discovered through genome-wide association studies (GWAS), with a sizable 
portion of the genetic risk unexplained [2]. 
Rare variants may contribute to some of the unexplained heritability of AD 
and have been demonstrated to contribute to large gene expression changes 




associations with rare variants in relatively few genes and methods to evaluate 
rare variants are still under development [3]. Chapter 2 will focus on a strategy to 
identify new AD risk or protective rare variants by looking at mutations in only 
cases or only controls.  
Genetic variation in AD risk is mostly studied through association analysis 
of single-nucleotide polymorphisms (SNPs). AD risk may also be associated with 
SNPs influencing changes in gene expression. Recent studies have 
demonstrated by expression quantitative trait locus (eQTL) analysis that changes 
in gene expression could play a key role in the pathogenesis of AD [5, 6]. 
Chapter 3 will show the impact of rare variation on gene expression in both 
blood and brain tissue, also further strengthening the rare variant findings from 
Chapter 2 with functional evidence.  
However, regulation of gene expression, as well as many biological 
functions, has been shown to be context-specific (e.g., tissue and cell-types, 
developmental time point, sex, disease status, and response to treatment or 
stimulus) [7-10]. These findings motivate a context dependent analysis to 
achieve more precise associations that may help elucidate regulatory networks. 
Chapter 4 will identify cell-type specific eQTLs in blood and brain tissue to 
explain underlying genetic associations of common variants in AD. One of the 
largest studies of this kind classified 12% of over 23,000 eQTLs as cell-type 
specific [9] and much of the protocol used in this study will be followed. 




AD cases and cognitively and pathologically normal controls, noting that brain 
studies have several limitations. Specifically, large samples of brain specimens 
are difficult to obtain. There is also concern that brains undergo changes post-
mortem that may affect gene expression [11]. Results of previous brain eQTL 
studies in AD are inconsistent; two studies that examined expression in prefrontal 
cortex showed less than 10% of overlapping eQTLs [5]. Also, although neurons 
are arguably the most relevant cell type for AD research, several studies 
demonstrated that peripheral monocytes play crucial roles in AD pathogenesis 
[12, 13]. Most eQTL and genetic studies to date have considered only a single 
tissue, typically blood [5].  
The overall aim of this dissertation is to further explain undiscovered AD 
genetic risk with rare and common variants and increase our understanding of 
the genetic architecture of AD though a series of analyses of multi-omics data. 
Novel findings can be identified by integrating multiple types of ‘omics data. In 
addition, the proposed multi-tissue analysis will likely yield more consistent 
findings and identify tissue-specific differences. Tissue-dependent and cell-type 
dependent association patterns will improve our understanding about 
pathophysiology underlying AD risk and provide insight about strategies to slow 
progression and for prevention. Finally, a reliable AD-associated biomarker found 





CHAPTER 2: Identification of novel AD risk variants and genes in Alzheimer 
Disease Sequencing Project (ADSP) data 
2.1 Abstract  
Background: Much of the unexplained heritability of Alzheimer disease (AD) may 
be due to rare variants whose effects are not captured in GWAS because very 
large samples are needed to observe statistically significant associations.  
Methods: Rare variants were identified by whole exome sequencing (WES) in 
unrelated samples, including 5,396 AD cases and 4,415 controls of European 
ancestry (EA), from the Alzheimer’s Disease Sequencing Project (ADSP). Minor 
alleles genome-wide and in 95 genes previously associated with AD, AD-related 
traits, or other dementias were tabulated and filtered for predicted functional 
impact and occurrence in AD cases, but not controls. Top findings were further 
evaluated using multiple analytical approaches. Support for several findings was 
sought in a WES dataset comprised of 19 affected relative pairs from Utah high-
risk pedigrees and several whole genome sequencing (WGS) datasets from the 
ADSP and Alzheimer Disease Neuroimaging Initiative (ADNI). 
Results: A total of 24 variants with moderate or high functional impact from 19 
genes were observed in 10 or more AD cases but not in controls. These include 
a missense mutation (rs149307620, n=10) in NOTCH3, coding mutations in 
which are associated with CADASIL, a diagnostically distinct disorder marked by 
severe headaches in young adulthood followed by stroke and dementia later in 




AD symptoms with progressive memory loss, moderate to severe amyloid and 
tau pathology at autopsy and limited evidence of stroke or microvascular 
disease. The rare rs149307620 was identified in one AD case and one subject 
with mild cognitive impairment in the WGS datasets. Two additional rare 
NOTCH3 missense mutations that may be disease-causal were found in one 
Utah family. The TREM2 Q33X high-impact mutation was identified in four AD 
cases	that in homozygous form causes Nasu-Hakola disease, a very rare 
disorder characterized by early-onset dementia and multifocal bone cysts, 
suggesting an intermediate inheritance model for the mutation with respect to 
dementia outcome. In addition, AD cases have a significantly higher burden of 
deleterious rare coding variants in known AD, AD-related or other dementia 
genes compared to controls. 
Conclusions: We identified several novel rare variants predicted to have high 




AD susceptibility is highly heritable (h2=58-79%) [2], but only about one third of 
the genetic component is accounted for by common variants discovered through 
genome-wide association studies (GWAS) [2]. Some of the unexplained 
heritability of AD may be due to rare variants, which remain challenging to 




sample sizes [3]. Genome-wide searches have identified robust AD associations 
with rare variants in relatively few genes including TREM2, AKAP9, UNC5C, 
ZNF655, IGHG3, and CASP7 [14-18], and methods to evaluate rare variants are 
still under development [3]. We applied a strategy focused on rare variants 
occurring only in cases to identify and characterize additional high penetrance 
risk variants in AD that would be otherwise undetected in analyses that do not 
render results when a variant is not observed in the control group.  
 
2.3 Methods 
2.3.1 Study Population and Data Processing 
The Alzheimer’s Disease Sequencing Project (ADSP) performed whole-exome 
sequencing (WES) on DNA samples obtained from non-Hispanic subjects of 
European ancestry (EA) and Caribbean Hispanics (CH). All subjects were at 
least 60 years old. AD cases met NINCDS-ADRDA criteria for possible, probable 
or definite AD after clinical and/or neuropathologic examination [19] and controls 
were cognitively normal and showed no signs of AD pathology if examined at 
autopsy. ADSP participants were selected using a risk score based on age, sex, 
and APOE ε4 carrier status to maximize cases most likely to have AD risk 
variants and controls most likely to have AD protective variants. Subject 
characteristics are provided in Table S2.1. DNA sequencing was performed at 
the Broad Institute, the Baylor College of Medicine’s Human Genome 




Genotypes for bi-allelic single nucleotide variants (SNVs) and short insertion-
deletion polymorphisms (indels) were called using ATLAS2 [20]. Only variants 
that overlapped the target regions captured by kits used by the three sequencing 
centers (Illumina and Nimblegen) were included. Variants that showed extreme 
departure from Hardy-Weinberg equilibrium (HWE, P<10-6) among unrelated 
controls, were monomorphic, or had call rates <80% or average read depth <10 
were excluded. In addition, samples that were outliers according to population 
substructure analysis or had a genetically determined sex that was inconsistent 
with the reported sex were excluded [17]. Cryptic relatedness was estimated 
using pairwise identity-by-descent (IBD) in PLINK [21] and one member from 
each of 69 pairs of individuals with !" (proportion of alleles shared IBD)>0.4 was 
excluded [17]. After quality control (QC), there remained for analysis a total of 
10,211 EA (5,617 AD cases, 4,594 controls) and 400 CH (221 cases, 179 
controls) subjects. The CH sample was deemed too small for in-depth studies of 
rare variants and thus excluded from the analysis. 
2.3.2 Variant Selection and Annotation 
Minor allele counts (MAC) genome-wide and in a group of 95 genes previously 
associated with AD, AD-related traits, or dementia by genetic association or 
experimental approaches (Table S2.2) were tabulated for rare variants occurring 
only in AD cases. Variants were annotated with the Variant Effect Predictor tool 
(VEP) [22] and Combined Annotation Dependent Depletion (CADD) scores [23] 




gained, frameshift, stop lost, start lost, or transcript amplification variants) or 
moderate functional impact (includes in-frame insertion, in-frame deletion, 
missense, or protein altering variants). A scaled CADD score of 20, for example, 
means that a variant is among the top 1% of deleterious variants in the human 
genome, and a scaled CADD score of 30 means that the variant is in the top 
0.1%. Synonymous mutations and variants with a MAC < 2 were excluded. The 
study design is illustrated in Figure S2.1 and the filtering of variants at each step 
in the pipeline is shown in Table S2.3.  
2.3.3 Haplotype Analysis 
PLINK was used to find common SNPs near the rare variant of interest within a 
specified kilobase (kb) window. The wildcard option was used to infer haplotypes 
and estimate haplotype frequencies [21]. Haploview was used to visualize 
regional LD and confirm haplotypes and frequencies among different SNP 
combinations using multi-marker haplotype association tests [24].  
2.3.4 Gene-set Burden Test 
A gene-set burden test was performed using the Combined and Multivariate 
Collapsing (CMC) method [25] in R to compare the burden of high and moderate 
impact mutations occurring in only cases for known AD/dementia genes between 
AD cases and controls. Logistic regression models included covariates for sex, 





2.3.5 Protein Homology Modeling and Pathway Analysis 
Protein homology modeling was performed for several high-impact variants in 
NOTCH3 with BLAST-P [26], SWISS-MODEL [27] and Maestro software [28]. 
Since the NOTCH3 structure could not be found in any protein databases, 
homologous proteins were considered for modeling the region containing the 
NOTCH3 mutations. Considering the AD-associated mutation on exon 6 
(rs149307620), the closest matching sequence was identified in NOTCH1 which 
had 44% homology of amino acid sequence identity suggesting that these 
proteins may have similar functions. SWISS-MODEL was used to create a model 
for the NOTCH3 region using homologous Protein Data Bank (PDB) structure 
5UK5 in NOTCH1 [29]. The same procedure was applied for other mutations in 
NOTCH3 that are associated with Cerebral Autosomal Dominant Arteriopathy 
with Subcortical Infarcts and Leukoencephalopathy (CADASIL). A high-
confidence (confidence score >0.7) human protein-protein interaction network 
was then created with the latest version (v10) of the STRING database for 
NOTCH3 and its ligand JAG1 [30]. The set of genes forming the protein network 
was tested for gene-set enrichment using PANTHER pathways using the Fisher's 
Exact test with FDR multiple test correction [31].  
2.3.6 Rare Variant Analysis in an Independent Dataset 
To extend and enhance discovery of novel associations, we evaluated WES data 
obtained from 19 AD-affected first- or second-cousin pairs identified in the Utah 




AD risk. Genealogical records indicate that these pairs do not share any common 
ancestors as far back as the early 1800s. Details of the UPDB, case 
classification, and identification of high-risk pedigrees are published elsewhere 
[32]. We retained 564 rare variants that were shared between at least one cousin 
pair and had a minor allele frequency (MAF) < 0.1% in one of several public 
whole exome and whole genome sequencing databases including 1000 
Genomes [33], Exome Aggregation Consortium (ExAC) [34], the Genome 
Aggregation Database (gnomAD) [34], and NHLBI GO Exome Sequencing 
Project (ESP) [35] resulting in 400 candidate variants. Variants were then 
assessed for pathogenicity based on (1) American College of Medical Genetics 
and Genomics criteria [36] for “pathogenic” or “likely pathogenic”, (2) association 
with loss or gain of gene function, and (3) prediction of haploinsufficiency. The 
genes containing the remaining 389 variants were screened for relevance to AD 
or β-amyloid pathology, after which 118 variants remained. Twelve variants were 
added to the group of 118 variants for further evaluation that were (1) reported in 
the literature as an AD risk variant (n=2), (2) had a p value < 0.09 for association 
of increased risk of AD in the ADGC GWAS [37] (n=2), (3) absent in whole 
genome sequences of 1,354 participants of the Wellderly cohort who are >80 
years old with no chronic diseases and who are not taking chronic medications 
[38], suggesting that the variant is never seen in healthy elderly population [n=3], 






2.4.1 Rare Variants in NOTCH3 
Evaluation of high and moderate impact rare variants in genes that were 
previously established as genetically or functionally related to AD or dementia 
revealed a missense mutation in NOTCH3 (rs149307620; A284T) that was 
present in 10 AD cases, but no controls (Table 2.1). This variant is extremely rare 
in EAs (MAF= 0.0005) [34] and was verified by Sanger sequencing in eight of 
these subjects for whom DNA was available. Because several other high or 
moderate impact NOTCH3 mutations have been associated with CADASIL, a 
diagnostically distinct disorder marked by severe headaches in young adulthood 
followed by strokes and dementia later in life [39], we sought clinical and autopsy 
data from the AD cases with the rs149307620 mutation to determine whether 
they are enriched for cerebrovascular risk factors. Neuropathological information 
that was available for one of these subjects revealed moderate atherosclerosis 
but no arteriosclerosis, lacunes or microinfarcts, which are hallmarks of CADASIL 
(Table S2.4). Autopsy also confirmed the presence of AD pathology (CERAD 
neuritic plaques: moderate; CERAD diffuse plaques: moderate; Braak 
neurofibrillary degeneration: stage VI). The mean age of symptom onset for the 
10 NOTCH3 mutation carriers was approximately 80 years, similar to that for the 
entire sample of ADSP EA cases (mean=76.4 years) and much greater than age 
at onset of cognitive impairment among individuals with CADASIL (usually <50 




(though one had multiple infarcts on MRI and a history of diabetes and 
cardiovascular disease) and all had prominent memory impairment as the initial 
presentation with a progressive course. One other NOTCH3 mutation 
(rs114447350) was observed in four AD cases but not in controls (Table 2.1). 
Unlike rs149307620, this variant is not particularly rare in EAs (MAF=0.024) or in 
persons of African ancestry (MAF=0.091) [33], suggesting it is unlikely to be 
pathogenic. 
Because rs149307620 is very rare, we investigated the possibility that this 
mutation occurred once or only a few times by performing a haplotype analysis 
with common SNPs. This analysis revealed a 5-SNP haplotype with a frequency 
of 15% in the AD cases and 14% in controls that is common to all 10 cases with 
the NOTCH3 mutation (Figure S2.2). Although the degree of IBD sharing across 
the genome is higher among the 10 cases (!"= 0.028) than among the entire 
ADSP sample (!"= 0.013), this small difference indicates that they are not more 
closely related to each other than to all subjects. Taken together, these results 
suggest that the mutation in these subjects originated in a common ancestor who 
lived many generations ago.  
To investigate the possibility that the mutation carriers belong to a particular 
subpopulation, we plotted the first 2 principal components of ancestry that were 
derived previously for the entire sample [17] and observed that 8 of the 10 




S2.3). Analysis of mitochondrial DNA variants revealed that most individuals in 
this cluster had mitochondrial haplogroups K1a1b1a or K1a9 that are common 
among Ashkenazi Jewish individuals [40]. Moreover, NOTCH3 mutations carriers 
accounted for 4.0% of the participants with AD who have either the K1a1b1a or 
K1a9 haplogroup. The proportion of mutation carriers in this cluster was 
significantly greater among participants with AD (8 of 358 [2.2%]) than controls (0 
of 337) (Z = 2.76, P = .006). The frequency of the rs149307620 mutation is about 
25 times higher in Ashkenazi Jewish individuals (MAF, 0.0046) compared with 
other EA groups (MAF, 0.00019) [34]. 
Analysis of the 130 variants that met the filtering criteria in the 19 affected cousin 
pairs from the Utah high-risk pedigrees provided additional support for a role of 
NOTCH3 in AD. Both affected subjects in one family who are half-first cousins 
had two rare NOTCH3 missense mutations, rs141402160 and rs140914494, 
each with a frequency of 0.0002 [33]. Review of available clinical and family 
history information for this family did not indicate findings consistent with 
CADASIL in the probands or relatives. The pedigree of the carriers of the 
rs141402160 and rs140914494 mutations includes seven additional members 
who had AD or dementia listed on death certificates. All but one of the individuals 
in the line of descent from the common ancestor of the probands died before age 
60 and thus may have developed AD type dementia had they lived longer. Two 




rs112197217 that has a frequency of 0.010 in EAs [33], but is much rarer in other 
populations. The evidence of AD among other relatives in this family was 
inconclusive.  
To further distinguish NOTCH3 variants that may be causally related to AD, we 
screened for these variants in whole genome sequence (WGS) data obtained 
from a multi-ethnic sample of unrelated 1,432 AD cases and 1,660 controls in the 
ADSP Extension Study, 550 AD cases and 283 controls in the ADSP multi-ethnic 
Family Study [41] and 809 participants of the ADNI Study (239 AD cases, 321 
MCI cases, 249 controls) [42] . Characteristics of subjects in these datasets are 
provided in Table S2.5. The minor alleles for rs11219217 (n=70) and 
rs114447350 (n=286) were observed appreciably in AD cases, MCI cases and 
controls of multiple ethnicities suggesting that they are not associated with AD 
risk. The rs149307620 variant was found in one AD case (age at onset = 89 
years) and one MCI case (age at onset = 76 years), but not in controls. The rare 
rs141402160 and rs140914494 variants were not detected in any of the WGS 
samples. 
Protein modeling showed that the rs149307620 mutation is located in the EGF 
repeat region between EGF10 and EGF11 and more precisely in the EGF 
calcium binding (EGF_CA) domain, near the Jagged-1 (JAG1) - NOTCH3 
binding site [29]. Modeling predicted that the major allele for rs149307620 results 




Alanine is non-polar and would not be predicted to have any intra or inter-protein 
interactions. The minor allele for rs149307620 results in mutant notch-3 with a 
corresponding amino acid threonine (Figure 2.1B). Threonine is polar and will 
form hydrogen bonds where possible with itself and with polar arginine at the site 
of JAG1-NOTCH3 binding (Figure 2.1C). These results suggest that the mutant 
Notch-3 causes greater interaction with the ligand, possibly changing 
downstream processes. The other AD-associated NOTCH3 mutations, 
rs141402160 and rs140914494 also involve either the gain or loss of an alanine. 
In both instances, the mutation change leads to increased polarity and hydrogen 
bonding with possible increased interactions, to a greater or lesser extent that 
observed with rs149307620.  
Unlike the AD-associated rs149307620 and rs141402160 mutations, but similar 
to the AD-associated rs140914494 mutation, most of the >25 reported distinct 
NOTCH3 mutations causing CADASIL are located in exons 3 and 4 (Table 2.2) 
[43]. However, one CADASIL-associated variant, rs137852641, is a missense 
mutation in codon 332 in exon 6, resulting in the replacement of an arginine 
residue with a cysteine [44] that is proximate to rs149307620 (codon 284 in exon 
6) (Figure 2.2).  
To further explore the biological functions and pathways for NOTCH3 in AD, a 
high confidence protein-protein interaction network was constructed including 




contains several AD related genes including BACE1, PSEN1, PSEN2, and APP 
(Figure 2.3). Gene-set enrichment analysis revealed the network genes were 
significantly enriched in the Notch signaling pathway (P = 6.48×10-49), 
angiogenesis (P = 1.61×10-12), and two AD-related pathways involving secretase 
mediated amyloid precursor protein cleavage (P = 3.50×10-16) and presenilin γ-
secretase complex (P =5.78×10-26) (Table 2.3).  
2.4.2 TREM2 Q33X 
We also identified the high impact TREM2 Q33X mutation (rs104894002) in four 
out of 5,617 (0.071%) AD cases (Table 2.1), a frequency that is slightly lower 
than that observed in a TREM2 sequencing study of AD cases and controls in 
2013 (2/1,084 = 0.17% of AD cases) [14]. Because this mutation in homozygous 
state causes Nasu-Hakola disease, a rare autosomal recessive disorder 
characterized by early-onset dementia and multifocal bone cysts [45], we 
evaluated clinical data obtained from the four TREM2 Q33X mutation carriers to 
assess potential pleiotropic effects (Table S2.6). All of these participants met the 
criteria for probable AD and none had reported bone cysts or unusual behavioral 
symptoms. 
2.4.3 Other Rare Mutations 
A total of 32 moderate or high impact variants in 24 previously established genes 
for AD or other dementias were each observed in four or more AD cases and no 
controls (Table 2.1). Five of these variants were previously reported as 




[46, 47]; rs63750592, n=4 [48, 49]), SORL1 (rs139710266, n=5) [50], and MAPT 
(rs63750424, n=4) [51-53] and a stop-gain mutation in ABCA7 (E1769X, n=4) 
[54]. A previously unreported mutation observed only in AD cases in PSEN1 
(rs375376095, n=5) is only 2,779 bp from the known AD-associated rs63749824 
variant. Genome-wide, 24 variants in 19 genes with moderate/high functional 
impact were observed in 10 or more AD cases but absent in controls (Table 2.4). 
Further examination of the genes represented by multiple variants revealed that 
10 subjects have three ABCD4 missense variants (rs57773157, rs34992370, 
rs58272575) that co-occur in a rare 8-SNP haplotype spanning 12.9 kb with a 
frequency of 0.3% in cases and 0% in controls (Figure S2.4A). Another 10 
subjects have two CELSR1 missense variants (rs61741871 and rs75983687), 
and eight of these subjects also have two GTSE1 missense variants. One 
subject is homozygous for all four variants. The subjects who have the CELSR1 
and GTSE1 variants (rs61741871, rs75983687, rs34404175, rs35503220) share 
a rare 12-SNP haplotype spanning 77.6 kb with a frequency of 0.1% in cases 
and 0.1% in controls (Figure S2.4B). IBD estimates for the 10 cases with the 
ABCD4 variants (!"=0.028) and the eight AD cases with the CELSR1 and GTSE1 
variants (!"=0.029) are only slightly higher than genome-wide IBD sharing and 
indicate that these individuals are not more closely related to each other than to 
all subjects. Of note, there are very few common SNPs in the 500 kb region 
including the rare ABCD4 variants, suggesting high sequence conservation in 




To identify additional genes which may have over-representation of deleterious 
AD-related variants, we filtered genes which contained at least three distinct 
variants each occurring in at least five AD cases but absent in controls (Table 
S2.7). The ABCD4 rs61744947 variant appears on the same haplotype 
containing the other three ABCD4 variants. Three LAMC3 variants were 
observed in the same seven subjects. TTN had the greatest number of distinct 
variants (n=6) that were observed in AD cases only. Genome-wide, nine genes 
not previously associated with AD contained a high functional impact variant that 
was present in at least seven AD cases but absent in controls (Table S2.8).  
2.4.4 Rare Variant Burden 
To test if disease is associated with greater burden of rare deleterious variants, 
gene burden tests were performed for models including high impact variants and 
high and moderate impact variants for MAF≤0.01 and MAF≤0.5 in genes 
previously associated with AD risk, AD-related traits, or other dementias (Table 
2.5). These analyses showed that AD cases have a significantly higher burden of 
moderate and high impact rare deleterious variants in this group of genes 
compared to controls (p=0.006).  
 
2.5 Discussion 
We identified several rare variants that are predicted to have high impact on 
protein structure and may increase AD risk. These variants were not detected in 




respect to functional impact of the variants and conducted using current 
statistical testing approaches [17]. Our focus on variants observed in AD cases 
but not controls yielded results that are often undetected by traditional genetic 
association methods that cannot evaluate empty cells, regardless of sample size 
or frequency of variants among cases. Several of our top-ranked results confirm 
previously identified AD associations with rare variants including PSEN1 
rs63749824 [46] and rs63750592 [49], SORL1 rs139710266 [50], MAPT 
rs63750424 [51], and ABCA7 E1769X [54] which suggest that novel findings 
identified by our approach may be robust. Two of our novel findings suggest 
evidence of shared genetic mechanisms between AD and other rare dementia 
syndromes, namely CADASIL and Nasu-Hakola disease. Our study also showed 
that AD cases have a significantly higher burden of deleterious rare coding 
variants in known AD, AD-related or other dementia genes compared to controls. 
This observation generalizes previous findings in SORL1 [50, 55], MAPT [56], 
TREM2 [57, 58] and ABCA7 [59] that both common and rare variants in the same 
gene may independently contribute to AD risk.  
We observed the rare NOTCH3 rs149307620 allele in 11 AD cases and one MCI 
case, but not in controls, in the combined ADSP WES, ADSP WGS and ADNI 
WGS datasets. The most remarkable finding from analysis of the Utah high-risk 
pedigree WES dataset were rare NOTCH3 rs140914494 and rs141402160 
alleles in a pair of affected half first-cousins. These mutations in exons 4 




binding site and involve the gain or loss of an alanine residue (Table 2.2). In 
contrast, the rs114447350 and rs112197217 variants are located near the end of 
the coding sequence (exons 33 and 21, respectively) and predicted to be 
clinically benign [60], and are thus unlikely to be causally related to AD. Many 
other NOTCH3 variants have been associated with CADASIL which typically 
replace the wild-type amino acid with a cysteine residue or replace a highly 
conserved cysteine residue with another amino acid [39, 43, 44] although there 
are several exceptions [61]. Available clinical and autopsy data for the individuals 
with NOTCH3 mutations were consistent with the diagnosis of AD and not 
CADASIL. Our protein modeling demonstrated that the AD-associated NOTCH3 
mutations in exons 4-6 result in quantitative changes in hydrogen bonding 
causing increased ligand interaction, whereas CADASIL NOTCH3 mutations lead 
to qualitative changes involving disrupted di-sulfide bonding that affect overall 
protein structure and receptor maturation, and differ with respect to their 
consequences both on ligand binding and ligand-induced signaling [43, 44].  
Our protein-protein interaction network and gene-set enrichment analyses 
demonstrated that NOTCH3 is closely tied to AD pathways and biological 
processes. Notch-3 signaling can be triggered by both Delta-JAG-type ligands 
and requires ADAM10 and presenilin-1 or -2, making it part of the AD related 
presenilin pathway [62]. Previous studies showed JAG1-Notch signaling and 
subsequent hippocampal neurogenesis and astrogenesis are regulated by 




more active during early development and decreases in adulthood, affects 
normal neuronal development and alters neurogenesis and thus can have long-
term effects [62]. In addition, Notch-3 is a substrate for γ-secretase (presenilin) 
inhibition, which when dysregulated, can cause mis-processing of the amyloid 
precursor protein resulting in accumulation of the toxic amyloid-β peptide [63]. 
Our collective genetic and bioinformatics findings provide the strongest 
pathogenic link to date between NOTCH3 and AD. A previous study reported 
association of AD with a distinct NOTCH3 mutation (p.R1231C) in a Turkish 
family [64], however this variant was detected in only one affected member and 
there is conflicting information about its pathogenicity [65]. Sassi et al. tested the 
hypothesis that genes associated with Mendelian adult onset leukodystrophy are 
also associated with AD in a sample including 332 sporadic AD cases and 676 
controls, and found significant gene-based association with NOTCH3, a result 
driven primarily by a common synonymous coding variant [66].  
The TREM2 Q33X mutation that was observed in four AD cases in our sample 
and in four AD cases and one unaffected relative with an unspecified age of an 
AD Q33X carrier in gene resequencing studies targeting TREM2 [14, 67, 68] is 
much rarer than the well-documented R47H variant that has been associated 
with increased risk of AD in several studies [14, 69] including the ADSP cohort 
[7,8]. Homozygosity of this mutation causes Nasu-Hakola disease (NHD), a very 




[45], and has also been observed in a member of a Turkish family with 
frontotemporal dementia (FTD)-like syndrome including the appearance of 
aggressive behavior and generalized tonic-clonic seizures before age 30 but 
without bone involvement [70]. Because persons with NHD and the FTD 
syndrome case have a more severe phenotype overall and much earlier onset of 
dementia symptoms than late-onset AD cases who are heterozygous for Q33X, 
the behavior of this mutation may more resemble an intermediate inheritance 
than an autosomal dominant model. This idea is consistent with the observation 
that an NHD patient’s living the parents, who were obligate Q33X heterozygotes, 
both had evidence of $-amyloid deposition by cerebrospinal fluid analysis and 
florbetapir-PET imaging [71].  
Furthermore, unlike the TREM2 R47H mutation and rare coding variants at other 
loci that have been associated with AD [4-8], the NOTCH3 rs149307620 and 
TREM2 Q33X mutations appear to be fully penetrant among persons surviving to 
late age, which perhaps would be the first examples of causative mutations for 
late-onset AD. Obviously, this assertion is somewhat speculative given the small 
number of AD cases documented to have these mutations. 
Our study also implicated multiple functional variants in several novel genes as 
risk factors for AD. Mutations in ABCD4 cause an inborn error of vitamin B12 
metabolism [72]. B12 deficiency is associated with cognitive impairment and the 




encodes an ATP binding cassette transporter that is in the same family as well-
established AD gene ABCA7 [37, 58, 74]. The AD-associated CELSR1 
rs61741871 (P2983A) missense variant has also been associated with 
craniorachischisis, a severe neural tube defect [75], and other CELSR1 variants 
have been identified as ischemic stroke risk factors in Japanese individuals [76]. 
The CELSR1-3 family of genes has multiple functions in the nervous system and 
has distinct roles in brain development and maintenance [77]. GTSE1 regulates 
G1/S cell cycle transition and microtubule stability and is involved in pivotal 
neurodegeneration pathways [78]. It is not clear which of these CELSR1 and 
GTSE1 mutations may directly influence AD risk. LAMC3 encodes laminin 
subunit gamma 3 and multiple experimental studies have linked laminins to AD 
[79, 80]. LAMC3 has been significantly associated with age at onset of AD [81].  
Our study has several noteworthy limitations. Because we focused on very rare 
variants, our sample of more than 10,000 subjects was inadequate to establish 
statistical significance. Thus, our findings require replication in independent 
samples. Unfortunately, we were unable to replicate these findings in the ADGC 
GWAS dataset because of low and inconsistent imputation quality for these very 
rare variants, despite the use of the large HRC reference panel [82]. In addition, 
our genome-wide MAC cutoffs for focusing on particular variants are arbitrary 
and, therefore, some important findings may have been overlooked. Finally, 
although one of the explicit goals of the ADSP is to identify variants that protect 




variants (i.e., a “controls-only” analysis) is less rigorous because in the absence 
of statistically significant tests it is difficult to demonstrate a protective effect if the 
variant has reduced penetrance.  
Conclusions and Future Directions. We identified associations with novel variants 
in previously established AD genes and with several novel potential AD genes 
that did not emerge in previous analyses of a large WES dataset using 
conventional statistical thresholds [17]. Our findings with the NOTCH3 and 
TREM2 variants demonstrate that mutations in the same gene can result in very 
dissimilar types of dementia. Moreover, variable dose of a particular mutation 
(i.e., TREM2 Q33X) can cause different types of dementia. These findings 
suggest that minor differences in protein structure or amount of wild type protein 
can result in different clinical outcomes. Understanding these genotype-
phenotype relationships may provide further insight into the pathogenic nature of 




Table 2.1 High and moderate impact rare variants in previously established AD 





allele: minor allele) * 
MAC 










19:15302421:C:T 10 NOTCH3 rs149307620 Missense Moderate 26.6 No 
14:73637653:C:T 7 PSEN1 rs63749824 Missense Moderate 18.8 [26, 27] 
9:4118361:G:C 6 GLIS3 rs200263979 Missense Moderate 15.1 No 
14:93154397:G:A 6 RIN3 Novel Missense Moderate 10 No 
17:44143925:C:T 6 KANSL1 rs138698439 Missense Moderate 21.8 No 
11:121384991:A:G 5 SORL1 rs139710266 Missense Moderate 26.3 [30] 
14:73640432:G:A 5 PSEN1 rs375376095 Missense Moderate 10.5 No 
16:31193959:ATTC:A 5 FUS Novel 
In-frame 
deletion 
Moderate 11.9 No 
17:56385997:G:A 5 BZRAP1 rs61732758 Missense Moderate 15.4 No 
19:1054190:A:G 5 ABCA7 rs376824416 
Splice 
acceptor 
High 21.7 No 
2:234113197:C:T 4 INPP5D rs532718867 Missense Moderate 1.387 No 
4:7731386:G:A 4 SORCS2 rs371407070 Missense Moderate 25.4 No 





High 5.4 [4] 
7:143088779:C:T 4 EPHA1 rs201365734 Missense Moderate 20 No 
7:51096830:C:G 4 COBL rs112568753 Missense Moderate 0.319 No 
8:17478643:A:G 4 PDGFRL rs144384825 Missense Moderate 17.96 No 
9:4118324:C:A 4 GLIS3 rs200959196 Missense Moderate 2.739 No 
11:59949160:A:G 4 MS4A6A Novel Missense Moderate 22.9 No 
14:105396368:T:G 4 PLD4 Novel Missense Moderate 23.6 No 
14:73637521:G:A 4 PSEN1 
rs63750592, 
R35Q 
Missense Moderate 15.68 [28, 29] 
14:93154353:T:TGT 
GCGCGCA 
4 RIN3 Novel 
In-frame 
insertion 
Moderate 16.91 No 
15:102192524:A:G 4 TM2D3 rs201415552 Missense Moderate 8.863 No 
16:81972496:A:G 4 PLCG2 Novel Missense Moderate 22.4 No 
17:42429772:C:T 4 GRN Novel 
Stop 
Gained 
High 18.4 No 
17:44101427:C:T 4 MAPT 
rs63750424,  
R406W 
Missense Moderate 18.49 [31-33] 




17:61574683:C:T 4 ACE Novel Missense Moderate 5.394 No 
19:1043794:G:A 4 ABCA7 rs147846250 Missense Moderate 8.041 No 
19:1055151:T:C 4 ABCA7 rs145987355 Missense Moderate 26 No 





High 37 [34] 
19:1059029:G:A 4 ABCA7 rs143615723 Missense Moderate 0.011 No 
19:15272218:G:A 4 NOTCH3 rs114447350 Missense Moderate 16.05 No 
 

















rs140914494 15,192,046 4 198 Ala>Glu AD-affected relative pair 
rs141402160 15,191,804 5 248 Gly>Ala 11 AD cases, 1 MCI case 
rs149307620 15,191,610 6 284 Ala>Thr AD-affected relative pair 
 




















Direction Unadjusted P value FDR 
Notch 
signaling  
42 22 0.06 > 100 + 3.98E-51 
6.48E-
49 





69 7 0.10 > 100 + 8.59E-18 
3.50E-
16 





PANTHER = Protein ANalysis THrough Evolutionary Relationships) 
Classification System  
 
*Expected probability of observing at least x number of genes out of the total n 
genes in the PANTHER list annotated to a particular pathway, given the 
proportion of genes in the reference Homo Sapiens whole genome that are 




Table 2.4 High and moderate impact rare variants genome-wide occurring in > 
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11:5474894:T:C 12 OR51I2 rs74049540 Missense Moderate 15.5 
19:38742032:G:A 12 PPP1R14A rs140507040 Missense Moderate 15.5 




17:42433931:C:G 11 FAM171A2 rs190723348 Missense Moderate 22.2 
17:7164266:G:A 11 CLDN7 rs149308129 Missense Moderate 21.9 
20:62198583:G:A 11 HELZ2 rs35691275 Missense Moderate 5.6 
22:46759981:G:C 11 CELSR1 rs61741871 Missense Moderate 3.6 
22:46762988:C:T 11 CELSR1 rs75983687 Missense Moderate 17 
1:93682193:A:T 10 CCDC18 rs191574433 Missense Moderate 15.1 
7:150389837:TC:T 10 GIMAP2 Novel Frameshift High 5.9 
9:33941796:C:T 10 UBAP2 rs150194348 Missense Moderate 23.2 
11:67957408:C:T 10 SUV420H1 rs138431226 Missense Moderate 17.4 
12:88456506:T:C 10 CEP290 Novel Missense Moderate 22.1 
14:31119819:C:A 10 SCFD1 rs35187633 Missense Moderate 32 
17:74288944:A:G 10 QRICH2 Novel Missense Moderate 9.1 
14:74754936:G:A 10 ABCD4 rs57773157 Missense Moderate 18.4 
14:74763064:C:T 10 ABCD4 rs34992370 Missense Moderate 8.7 
14:74766360:T:C 10 ABCD4 rs58272575 Missense Moderate 15.7 
17:58260659:A:C 10 USP32 rs201933998 Missense Moderate 11 
19:15302421:C:T 10 NOTCH3 rs149307620 Missense Moderate 26.6 
19:49123796:G:A 10 SPHK2 Rs158184205 Missense Moderate 15.4 
22:41605776:G:C 10 L3MBTL2 rs143455680 Missense Moderate 27.4 




22:46708152:G:A 10 GTSE1 rs35503220 Missense Moderate 0.001 




Table 2.5 Rare variant burden for established AD genes. 
 
 
Model Beta SE P-value 
High Impact, MAF≤ 0.01  0.005 0.166 0.977 
High/Moderate Impact, 
MAF≤ 0.01  0.062 0.023 0.006* 
High Impact, MAF≤ 0.05  0.005 0.166 0.977 
High/Moderate Impact, 
MAF≤ 0.05  0.061 0.022 0.006* 
 





Figure 2.1 Notch-3 protein model highlighting position of the AD-
associated SNP rs149307620. Predicted model for: A. wild type allele with 
alanine at mutation site, B.  mutant allele with threonine at mutation site, and C. 
binding of notch-3 (in red) to JAG1 ligand (in yellow). Possible hydrogen bonding 



































Figure 2.2 Homologous Protein Modeling of CADASIL NOTCH3 
rs137852641 mutation. Predicted model for: A. wild type allele with arginine at 
the mutation site and B. mutant allele with cysteine at the mutation site. Gain of a 






























Figure 2.3 Protein-protein interaction network including NOTCH3 and 
JAG1. Network includes 30 genes showing high-confidence interactions in 
humans according to the STRING database [18]. The colors of the edges refer to 
the type of evidence linking the corresponding proteins: red=gene fusion, dark 
blue=co-occurrence, black=co-expression, magenta=experiments, 
cyan=databases, light green=text mining, mauve=homology. Genes present in 
AD pathways determined by gene-set enrichment analysis (Table 2.3) are 



































CHAPTER 3: Identification of rare variants that influence AD gene 
expression in blood and brain tissue data 
3.1 Abstract 
Background: Some of the unexplained heritability of Alzheimer’s disease (AD) 
may be due to rare variants, and AD risk is also associated with changes in gene 
expression. Rare variants have been to have a large impact on gene expression 
changes across tissues. However, gene expression studies face the same 
challenges as genome-wide association studies (GWAS) studies for rare 
variants, so we investigated set-based methods for rare expression quantitative 
trait loci (eQTL) analysis. 
Methods: Gene-level and pathway-level cis rare-eQTL mapping was performed 
genome-wide in blood from 713 Alzheimer's Disease Neuroimaging Initiative 
(ADNI) participants and in brain donated by 475 Religious Orders Study/Memory 
& Aging Project (ROSMAP) participants. The association of gene or pathway 
expression with a set of all cis potentially regulatory low frequency and rare 
variants within 1 Mb of genes was evaluated using linear regression models in 
blood and brain tissues to further assess AD risk. 
Results: A total of 65 genes were significant brain gene-level rare eQTLs and a 
total of 307 genes were significant blood gene-level rare eQTLs. Significant brain 
gene-level results contain two established AD genes: HLA-DRB1 and HLA-
DRB5. Interestingly, 17% (11/65) of all significant brain gene-level results were 




also appear to be a number of cytoskeleton related genes in blood gene-level 
findings such as NUMA1, ACTG1, and DNAAF3. 5 genes were seen in both 
blood and brain gene-level results: GNMT, LDHC, RBPMS2, DUS2, and HP 
(Table 3.1). Of the matching genes, 4 out of 5 had similar p-values but RBPMS2 
was much more significant in blood (Blood p=1.69x10-36 vs. brain p=9.90x10-08). 
In brain, an aggregate of low frequency and rare variants in CCL7 and CCL8 
were each associated with the Inflammation mediated by chemokine and 
cytokine signaling pathway. Of the 22 significant genes associated with pathway 
expression in blood, 6 (ALOX5AP, CXCR2, FPR2, GRB2, IFNAR1, RAF1) were 
associated with the inflammation pathway as well, and 5 out of the 6 have 
previously been associated with AD. 
Conclusions: This study identified a number of significant gene-level and 
pathway level significant rare eQTL results, found additional evidence for the 
importance of the immune/inflammatory system in AD, and highlighted the 




Late-onset Alzheimer’s disease (AD) is the most common type of 
dementia that affects an estimated 5.7 million individuals older than 65 years old 
just in the United States, with the number projected to rise to 14 million by 2050 




discovered through genome-wide association studies (GWAS) can only explain 
one third of its heritability [2]. Rare variants with large effects may contribute to 
some of the missing heritability of AD. [3]. Recent sequencing studies have 
identified robust AD associations with rare variants in gene loci including TREM2, 
AKAP9, UNC5C, ZNF655, IGHG3, CASP7 and NOTCH3 [14-18, 83], and more 
AD-related rare variants will be identified from large-scale whole-genome 
sequencing (WGS) studies including rare variants in non-coding regions. 
However, the underlying mechanism by which these rare variants impact AD risk 
and their target/functional genes remain challenging to discover.  
AD risk variants are associated with gene expression levels, as 
demonstrated by recent expression quantitative trait locus (eQTL) studies [5, 6]. 
Rare variants contribute to extreme gene expression within single tissues and  
multi-tissues [4, 84-86]. However, eQTL studies face the same challenges as 
GWAS studies for rare variants. Although gene-based tests, which test 
aggregate effects of rare variants, are commonly used in rare variant association 
analysis in complex diseases, only a few studies have applied this type of model 
for eQTL studies of rare variants. Recent eQTL studies that have used a set-
based eQTL approach include testing gene expression with multiple SNPs 
chosen by variable selection [87, 88], using a gene-based partial least squares 
method to correlate multiple gene transcript probes with multiple SNPs [89], and 
identifying variants associated with transcript and protein modules [90]. These 




power with a potential to find significant variants with lower frequency.  
Few studies have applied a set-based eQTL method for rare variants. Lutz 
et al. very recently applied burden and SKAT tests to normalized read counts in 
RNA-seq studies [91]. In this study, a set-based eQTL method focusing on low 
frequency (MAF<0.05) and rare (MAF <0.005) variants using SKAT-O [92] is 
implemented with sets defined as genes and gene modules/pathways. A gene-
based cis eQTL approach will be applied to identify genes which have a set of 
potentially regulatory rare variants significantly associated with their expression. 
A pathway-based approach is applied to identify which gene with its set of 
regulatory rare variants most contributes to the overall gene expression profile of 
a significant pathway containing a set of co-expressed genes/functional-related 
genes. These methods will identify rare-eQTLs in human blood and brain to 
further assess their effect on AD risk and prioritize function genes for AD. 
 
3.3 Methods 
3.3.1 Study Cohorts  
Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI is a longitudinal 
multisite study that aims to develop clinical, imaging, genetic, and biochemical 
biomarkers to improve the prevention and treatment of AD [93]. The study began 
in 2004 and is currently funded until 2021 with 63 sites in the US and Canada 
enrolling subjects across three stages: AD dementia, mild cognitive impairment 




array gene expression data from whole blood and whole-genome sequencing 
(WGS) genotype data are used in this study.   
Religious Orders Study (ROS)/ Memory and Aging Project (MAP). ROS enrolled 
older nuns and priests from across the US, without known dementia for 
longitudinal clinical analysis and brain donation. MAP enrolled older subjects 
without dementia from retirement homes who agreed to brain donation at the 
time of death [94, 95]. RNA-sequencing brain gene expression data generated 
from DLPFC region and WGS genotype data were obtained from the AMP-AD 
knowledge portal (https://www.synapse.org/#!Synapse:syn3219045) [96]. 
Characteristics of these subjects are provided in Table S3.1.  
3.3.2 Data Processing 
Downloaded ADNI microarray gene expression data were normalized, 
background-correction and log-transformed. ROSMAP RNA-seq data were 
normalized by library size (i.e., FPKM), then log-transformed. Then we applied 
surrogate variable analysis (SVA) [97] on the log-transformed data to obtain 
surrogate variables for global technical effects and hidden effects which were 
included as covariates in analysis models for eQTL discovery. Additional filtering 
steps of ADNI and ROSMAP GWAS and gene expression data included 
eliminating subjects and values with missingness, restricting gene expression 
data to protein coding genes (12,971 genes in ROSMAP and 16,025 genes in 





3.3.3 Set-based eQTL Analysis 
A flowchart of the analysis in blood and brain tissues to identify set-based eQTLs 
is shown in Figure 3.1, including the total number of tests performed and the 
Bonferroni-corrected P-value thresholds used for defining gene-level and 
pathway-level significant eQTL results. Rare eQTLs throughout will refer to 
eQTLs with an aggregate of low frequency and rare variants (MAF<0.05).  
Gene-level cis-eQTL Analysis 
For common variants, eQTL analysis tests the association between the 
expression of one gene and one variant. Gene-level eQTL analysis will test the 
association between the expression of one gene and many rare variants in and 
near the gene, comparable to how gene-based analysis in genetics tests the 
association of a trait such as AD status with more than one variant within one 
gene. The gene-based test SKAT-O combines the best features of variance 
component (SKAT) and burden tests into one test with optimal power [92] and is 
implemented in this study design for set-based eQTLs by setting the outcome as 
the gene expression value. The gene expression value for each gene is 
evaluated for association in a linear regression model with the aggregation of all 
low frequent and rare cis-regulatory SNPs within 1 Mb of the gene. In ROSMAP, 
the regression model also includes covariates for age, sex, post-mortem interval 
(PMI), study (ROS or MAP), and a term for a surrogate variable (SV1) derived 
from the gene expression data matrix to account for unmeasured/hidden 




baseline age, sex, RIN, year of collection, and also SV1. RIN refers to the RNA 
Integrity Number, an indicator of the quality of the RNA. SKAT-O was 
implemented with groupwise tests using EPACTS 
software(https://genome.sph.umich.edu/wiki/EPACTS). A total of 12,971 tests 
were performed in ROSMAP and a total of 16,025 tests were performed in ADNI, 
examining the associations between each of the genes and low frequency and 
rare variants within 1 Mb of the gene in the datasets. After a Bonferroni 
correction for multiple testing, the significance thresholds to define significant 
gene-level rare eQTLs were as follows: P < 3.86 x 10-6 (0.05/12,971) in 
ROSMAP and P < 3.12 x 10-6 (0.05/16,024) in ADNI.  
To determine which particular variants are driving significant results, eQTL tests 
using linear regression models in R [98] were performed afterwards for all 
significant genes and each individual cis-regulatory bi-allelic low frequency and 
rare variant (MAF ≤ 0.05) within 1Mb of the gene that was included in the 
aggregate group of SNPs from the gene-level tests. After a Bonferroni correction 
for multiple testing, the significance thresholds to define significant individual 
gene-SNP eQTLs were as follows: P < 1.83 x 10-6 (0.05/ 27,393) in ROSMAP 
and P < 1.17 x 10-7 (0.05/ 425,995) in ADNI.  
Pathway-level cis-eQTL Analysis 
Pathway-level eQTL analysis will test the association of a pathway, containing 
many genes, with sets of variants in each of the genes in the pathway one at a 




of co-expressed genes with Weighted Gene Co-expression Network Analysis 
(WGCNA) in R [99]. With all protein coding genes in ADNI and ROSMAP 
datasets, a co-expression network was created in WGCNA and gene 
modules(clusters) of highly correlated genes were identified. WGCNA network 
construction and module detection was run with the following default parameters: 
soft threshold power beta = 6.00, deepSplit = 2(medium sensitivity), minimum 
module size of 20, and a merge cut height of 0.15. These default parameters 
were chosen because they have worked well in several applications as 
referenced by the WGCNA methods paper [99] and similar AD studies [100]. 
Each gene module can be summarized with its module eigengene (ME) value, 
the first principal component of a module. The ME is considered to be 
representative of the gene expression profiles in a gene module. 
Each gene module was then input into PANTHER for pathway enrichment 
analysis; only the significantly enriched pathways in the gene modules were 
analyzed further. Pathway-level eQTL analysis was performed on each 
significantly enriched pathway with the ME of the gene module as the outcome. 
Associations between the ME and each gene in the gene module were tested 
individually using all cis SNP genotypes with MAF<0.05 within 1 Mb of the gene 
that were annotated as potentially regulatory. The same covariates were used for 
ADNI and ROSMAP datasets as in the gene-level eQTL tests and analyses were 
also implemented in EPACTS. A total of 77 tests (9 enriched pathways vs. genes 




(16 enriched pathways vs. genes in each pathway=100 genes) were performed 
in ADNI, examining the associations between each significant pathway 
expression and the potentially regulatory low frequency and rare variants within 1 
Mb of each gene from the gene module in the pathway. After a Bonferroni 
correction for multiple testing, the significance thresholds to define significant 
gene-level rare eQTLs were: P < 6.49 x 10-4 (0.05/77) in ROSMAP and P < 5.0 x 
10-4 (0.05/100) in ADNI. The same covariates for ROSMAP and ADNI used in the 
gene-level analyses are applied to the pathway-level analyses.  
3.3.4 Functional Annotation of Variants 
Annotations were collected CADD v1.6 (hg19) and gwava v1.0 (hg19). Genomic 
coordinates of the ADNI GRCh38 genome build dataset were converted using 
liftOver software (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to hg19 to use 
EPACTS software which only supports VCFs aligned with NCBI build 37. ADNI 
and ROSMAP WGS SNPs were annotated by matching chromosome, position, 
reference, and alternative alleles. To detect potentially regulatory variants, 
variants having a CADD score > 15 or a gwava region score > 0.5 were selected. 
3.3.5 Pathway Enrichment Analysis 
Gene-set pathway enrichment analysis was performed using the PANTHER 
(Protein ANalysis THrough Evolutionary Relationships) software tool [31] to 
determine which pathways are significantly enriched in the gene modules 
identified from the WGCNA for pathway-level eQTL analysis. Significance of the 




discovery rate (FDR) < 0.05. 
 
3.4 Results 
3.4.1 Gene-level rare cis-eQTL associations 
A total of 65 genes (P < 3.86 x 10-6) were significant brain gene-level low 
frequency and rare eQTLs (Table S.2) and a total of 307 genes (P < 3.12 x 10-6) 
were significant blood gene-level rare eQTLs (Table S.3). The average number 
of cis bi-allelic variants used in significant result tests is 416 in brain and 678 in 
blood, which is a somewhat larger dataset. Significant brain gene-level results 
contain two established AD genes: HLA-DRB1 [101] and HLA-DRB5 [58] (Table 
S.2). Interestingly, 17% (11/65) of all significant brain gene-level results were on 
chromosome 6, including two other HLA genes- HLA-A and HLA-DOB. 
Significant blood gene-level results contain three established AD genes: ABCA7 
[58], ECHDC3 [101], and MS4A6A [58] (Table S.3). 5 genes were seen in both 
blood and brain gene-level results: GNMT, LDHC, RBPMS2, DUS2, and HP 
(Table 3.1). Of the matching genes, 4 out of 5 had similar p-values but RBPMS2 
was much more significant in blood (Blood p=1.69 x 10-36 vs. brain p=9.90 x 10-
08). Overall, all 5 genes have many more variants in blood gene-level tests.   
When testing each significant gene with each individual low frequency and rare 
variant within 1 Mb of the gene, there were 61 significant eGene-eSNP eQTL 
pairs (with 22 unique eGenes) in brain and 832 significant eQTL pairs (with 185 




most significant eQTL p-value in brain with one eSNP (p= <1.0 x 10-314), but its 
gene-level rare eQTL p-value is not as strong (p= 3.54 x 10-11). There are also a 
total of 7 eSNPs for eGenes COPZ1 and TMPRSS6, with most of these variants 
having strong p-values. Significant eGene-eSNP eQTL results in blood has 
numerous variants associated with expression of the following genes: KRT79 
(n=36), TAC3 (n=32), CDK12 (n=24), and SOS1 (n=20). In brain, there were two 
variants that were both significantly associated with the expression of two 
different zinc finger protein genes (ZNF101 and ZNF253). There were 28 eSNPs 
that were duplicates in blood results, with each eSNP associated with two 
different eGenes that are located close together (GSDMA and IKZF3, DHRS4 
and DHRS4L2, CMTM2 and ATP6V0D1).  
3.4.2 Significant gene module pathways  
There were 17 co-expressed gene modules in brain data with 4,481 genes in the 
largest module M1 and 38 genes in the smallest module M17 (Table S3.6), while 
there were 34 gene modules in blood data with 2,065 genes in the largest 
module M1 and 29 genes in the smallest M34 (Table S3.7). These modules and 
their eigengenes are summarized in Figure S3.1. In brain, module 14 seems to 
have very different expression compared to the rest of the modules and modules 
1 and 2 seem to be highly related, as evidenced by their lowest merging heights. 
In blood, more ‘meta-modules’ exist of groups of eigengene clustering with 
related expression. The proportion of variance explained by the module 




S3.9), suggesting the module eigengenes captured a significant proportion of 
gene module variance. 
Pathway enrichment analysis of each gene module revealed 9 significant 
enriched pathways in brain (Table 3.2) and 16 in blood (Table 3.3). The 
apoptosis signaling pathway, the CCKR signaling map, and inflammation 
mediated by chemokine and cytokine signaling pathway (appears 3 times 
separately in different gene modules in blood) all appear in both brain and blood 
enriched pathways and have all been previously linked to AD. When looking 
closer at the genes within each enriched pathway, HSPA6 and TNFRS10C are in 
the apoptosis signaling pathway and MMP-9 is in CCKR Signaling Map in both 
tissues (Figure S3.2). Of these shared genes in both tissues, only TNFRSF10C 
is significantly contributing to pathway expression at a Bonferroni threshold, 
though all shared genes contribute more significantly to their pathway in blood 
compared to brain (Table S3.10). Though there is no overlap in genes between 
the enriched inflammation pathways in both tissues, there is an intersect of 4 
genes between the gene modules in which these pathways occur: CCL3, CCL4, 
SPOCD1, and CXCL5 (Table S3.11). The module eigengenes for the gene 
modules for the brain enriched pathways all occur in the rightmost branch of the 
eigengene clustering tree (Table 3.2, Figure S3.1-A2). A large proportion (5/16) 
of the blood enriched pathways occur in gene module 5 (Table 3.3).  
3.4.3 Pathway-level rare cis-eQTL associations 




pathway expression in brain (Table 3.4) and a total of 22 genes had rare eQTLs 
significantly associated (P < 5.0 x 10-4) with pathway expression in blood (Table 
3.5). The average number of cis bi-allelic variants used in significant result tests 
is 329 in brain and 740 in blood, which is a somewhat larger dataset. In brain, the 
aggregated variants in CCL7 and CCL8 were each associated with the 
Inflammation mediated by chemokine and cytokine signaling pathway (Table 
3.4). Of the 22 significant genes associated with pathway expression in blood, 6 
(ALOX5AP, CXCR2, FPR2, GRB2, IFNAR1, RAF1) were associated with the 
inflammation pathway as well, including the top 2 most significant, and 5 out of 
the 6 have previously been associated with AD. There were also 3 genes 
(CFLAR, TMBIM6, and blood/brain pathway shared gene TNFRSF10C) 
significantly associated with the apoptosis signaling pathways and 1 heat shock 
protein gene (HSPA5) significantly associated with the Parkinson’s disease (PD) 
pathway. Both gene-level and pathway-level significant results contain rare 
eQTLs with the gene ALOX5AP (Table S3.3, Table 3.5). 
 
3.5 Discussion 
Low frequency and rare variants have a significant impact on gene-level 
and pathway-level expression, as evidenced by these results. By applying set-
based rare eQTL tests, many novel significant associations were identified that 
would be missed with single rare variant analysis, which highlights the 




widely used, numerous new findings could be found such as there have been 
with gene-based genetics tests for complex disease. These findings can also be 
utilized to add functional support and strengthen previous single rare variant 
findings 
Results in this study are biased to over-select for AD because of the large 
number of AD cases in the dataset, making the findings especially noteworthy for 
AD. At the brain gene-level (Table S3.2), the top most significant genes include a 
number of genes previously linked with AD. RNF39 (p=7.71x 10-27) is an AD-
associated differentially methylated region in multiple previous studies [102, 103]. 
A zinc finger protein ZNF253 (p= 7.45x 10-19) is an upregulated gene and 
transcription factor (TF) correlated with initial stages of AD [104], while POLD2 
(p= 1.56 x 10-13) is an up-regulated gene in a mouse tau pathology study [105], 
and lipid metabolism gene ACOT1 (p= 2.34 x 10-12) is upregulated in the parietal 
cortex of patients with AD [106]. FAM154B (p=7.71 x 10-27), also known as 
SAXO2, a microtubule-stabilizing protein, is seen in gene-based testing for 
shared genes between AD and ischemic stroke (IS) [107]. Gene level significant 
rare eQTLs also include known AD genes HLA-DRB1 and HLA-DRB5 [58, 101] 
which are located in the human leukocyte antigen (HLA) region, a key 
susceptibility locus in many immunological diseases [108]. Moreover, as 
discussed 17% (11/65) of significant brain gene-level results are on chromosome 
6 including other HLA genes- HLA-DOB and HLA-A, RNF39 which lies within the 




shared gene GNMT, and RPL10A (Table S3.2). HLA-DOB was previously found 
as an eGene with cell-type specific eQTLs in microglia and 
monocytes/macrophages [109], which are both considered myeloid cells. It is 
believed that a large proportion of AD genetic risk can be explained by genes 
expressed in myeloid cells and not by genes expressed in other cell-types [110]. 
Meanwhile, RPL10A was one of top 50 proteins that had significantly increased 
expression in rpAD (rapidly progressive) plaques [111]. Besides the immune 
related genes on chromosome 6, IL27 (p=1.69 x 10-30) is also part of the cytokine 
family and CARD17 (p= 6.73 x 10-13) is a regulatory protein of inflammasomes 
which are responsible for the activation of inflammatory responses [112]. 
In blood gene-level significant findings (Table S3.3), the most significant 
result was for the nuclear mitotic apparatus protein 1 gene NUMA1 (p= 6.01 x 10-
76) and was much more significant than the top brain gene-level significant finding 
(C5orf17, p=4.56 x 10-49). NUMA1 is a common gene in hippocampus 
upregulated in an AD study [113], and other top significant gene GAD1 (p= 1.49 x 
10-58) was downregulated with reduced neuronal activity [114]. There were 
several top genes linked to AD, aside from known AD genes MS4A6A, ECHDC3, 
and ABCA7 [58, 101]. SOS1(also known as SOS-1, p= 3.58 x 10-48) is increased 
in the pyramidal neurons of AD patients [115]. Another ribosomal protein similar 
to RPL10A, RPS23 regulates beta-amyloid (Aβ) levels and tau phosphorylation in 
mice [116] and regulates synaptic plasticity in humans [117]. KIF1B (p= 4.49 x 




associated with accelerated progression in neurodegenerative diseases [118, 
119]. A potential new therapeutic target, SFRP1 (p= 2.16 x 10-20) is secreted by 
established AD gene ADAM10 and is significantly increased in the brain and 
cerebrospinal fluid (CSF) of AD patients [120]. There also appear to be a number 
of cytoskeleton related genes such as NUMA1, actin gene ACTG1, Kinesin 
Family Member 1B gene KIF1B, and dynein gene DNAAF3 [121].  
Five genes (GNMT, LDHC, RBPMS2, DUS2, and HP) were shared in 
gene-level results in brain and blood (Table 3.1) and of note, 4 out of 5 have 
clear associations to AD. GNMT expression is detected in the hippocampus and 
its deficiency results in reduced neurogenic capacity, spatial learning, and 
memory impairment [122]. LDHC has differentially methylated regions in blood in 
AD [123]. Overexpression of flavoprotein DUS2 reduces Aβ42 toxicity [124]. 
There is a significantly higher mean serum HP or haptoglobin (Hpg) level among 
the AD patients compared to healthy controls [125]. RBPMS2, a RNA-binding 
protein, has not been linked to AD but was very significant in blood compared to 
the rest of these in both tissues (p=1.7 x 10-36) and has been seen in a leukocyte 
signature of Traumatic Brain Injury [126].  
There a large number of unique low frequency and rare variants in each 
gene for these gene-level tests. Particular variants seem to be driving significant 
results in blood based on the large number of significant individual eGene-eSNP 
eQTL results (n=832) and because all 10 of the most significant eGenes in gene-




Whereas, there are much fewer significant eGene-eSNP eQTL results in brain 
(n=61) and only 6/10 of the most significant gene-level results are eGenes, so 
the aggregate of SNPs may be more important for testing the association of low 
frequency and rare variants in brain. 
The significant enriched pathways are representative of the AD enriched 
gene expression datasets (Table 3.2 + 3.3). All shared pathways in blood and 
brain- Wnt signaling, Apoptosis signaling, and Inflammation mediated by 
chemokine and cytokine signaling pathways- function in AD. In brain, the Wnt 
signaling pathway and in blood, the PD pathway also can be connected to AD. In 
addition, it is not surprising that significant pathways in blood include blood 
coagulation and heme biosynthesis. Examining the shared genes in the shared 
pathways, HSPA6, which appeared in the apoptosis signaling pathways, is 
involved in neuronal responses to proteotoxic stress in neurodegenerative 
diseases that have been characterized as protein misfolding disorders [127]. 
TNFR10C, also from the apoptosis signaling pathways and significantly 
associated in blood(Table 3.5), is inducible by DNA damage, is not expressed in 
the brain, but its receptors are found on neurons, astrocytes and 
oligodendrocytes, and has been seen in a protein signature from an AD dataset 
[128]. Increased levels of plasma MMP-9, the shared gene from the CCKR 
signaling maps, have been observed in AD patients and CSF levels of MMP-9 
have correlated with both CSF T-tau and P-tau in elderly controls, suggesting 




genes appear to be making a larger impact on the apoptosis and CCKR signaling 
pathways in blood due to the more significant p-values compared to brain (Table 
S3.10). Looking at the complete gene modules which were enriched in the 
Inflammation pathway, the shared genes included CCL3, CCL4, SPOCD1, and 
CXCL5 (Table S3.11). CCL3 and CCL4 could be key to microglial function in 
aging and disease possibly through recruiting peripheral immune cells for the 
CNS [130]. Specifically, CCL3 increases BACE1 and Aβ deposition in the brain 
and is expressed by peripheral T cells to enhance transmigration through the 
blood-brain-barrier in AD [131]. CCL4 has been expressed in astrocytes and 
microglia in studies evaluating inflammation with AD, is secreted increasingly by 
macrophages when treated with Aβ, and has genetic associations with AD 
related CSF levels [132]. SPOCD1 was a down-regulated gene in the 
hippocampus and entorhinal cortex tissues in a previous study [133] and CXCL5 
is a chemokine, having a large role in inflammatory diseases [134].  
The significance of the inflammation pathway continues to be illustrated 
with the pathway level results (Table 3.4 + 3.5). In brain, 2 genes- CCL7 and 
CCL8- were each associated with the Inflammation mediated by chemokine and 
cytokine signaling pathway. Both genes are chemokines which regulate immune 
cells involved in inflammatory responses, specifically monocytes/macrophages 
for CCL7 [121]. Chemokine levels have been found be significantly changed in 
AD patients in serum, CSF and brain tissue [135]. There were 22 genes with rare 




genes, including the most significant, in the inflammation pathway. This includes 
GRB2, which was the most significant of pathway level results (p= 6.04 x 10-07), 
and plays a preventive role in AD by protecting cytoskeletal architecture [136]. 
The chemokine receptor CXCR2 produces Aβ peptides [137] while Aβ activation 
of fyn disrupts neuronal PAK1 kinase and its cytoplasmic levels are decreased in 
moderate to severe AD [138]. Removal of another significant gene IFNAR1 
provides neuro-protection after Aβ1-42 insult, decreasing type-1 interferon (IFN) 
production and apoptosis, presenting type-I IFNs as a potential therapeutic target 
for AD [139]. FPR2 is another potential AD target that is involved in the uptake 
and clearance of Aβ and contributes to innate immunity and inflammation [140]. 
ALOX5AP is a microglial gene upregulated in both pathologic and normal aging 
[141], and is significant in both gene-level and pathway-level results in blood. 
Though the inflammation pathway appears 3 separate times in different gene 
modules in blood, only the enriched inflammation pathway in gene module 14 
has genes that are significantly contributing to its pathway expression (Table 
3.5). An endoplasmic reticulum (ER) chaperone heat shock protein, HSPA6 is 
involved in amyloid precursor protein metabolism and neuronal death in AD 
[142], and is seen associated with the PD pathway, a neurodegenerative disease 
with clinical similarities with AD [143]. Several heat shock proteins have also 
previously been seen in AD [144]. An AD-related gene significantly associated 
with the apoptosis signaling pathway is CFLAR, which is upregulated at the 




based significant results are not seen in pathway results, suggesting the 
regulation of gene expression is not affected by pathways and instead are 
downstream targets.  
It is clear there is a large immune and inflammatory component to the rare 
eQTL gene-level and pathway-level results, and thus providing further evidence 
for importance of the immune system in AD. Though the inflammation pathway is 
seen in results in both brain and blood, the genes that are significantly 
contributing to pathway expression differ between the tissues. There is no 
overlap in the genes in the enriched gene module pathway either, regardless of 
significance. This suggests that different genes and biological mechanisms are 
affecting the inflammatory pathology of AD in blood and brain. The significant 
pathway-level genes have the potential to be target genes for the AD 
inflammatory response in blood and brain tissues.   
 This study has limitations. Most comparisons between brain and blood are 
based on independent groups in the ROSMAP brain and ADNI blood datasets. 
Our validation of top findings in recently released ROSMAP blood data is meant 
to alleviate some of this bias. Also, a limitation with brain expression findings is 
that it may reflect post-mortem changes unrelated to disease or cell-type different 
expression [11]. In addition, some findings may not be AD-related because we 
did not compare expression between AD cases and controls or test the 




 To conclude, this study identified of a number of significant gene-level and 
pathway level significant rare eQTL results, found additional evidence for the 
importance of the immune/inflammatory system in AD, and highlighted the 
advantages of using a set-based eQTL method for low frequency and rare 
variants. Future directions would involve comparing results among AD cases and 




Table 3.1. Intersection of significant genes between blood and brain gene-
level results 
 
ROSMAP Brain       
CHR BEGIN END NUM PASS VARS 
NUM SING 
VARS STATRHO P-VALUE GENE 
6 41942338 43929364 671 437 0 1.85E-06 GNMT 
11 17434230 19468040 429 273 0 2.07E-07 LDHC 
15 64039999 66063761 404 249 0 9.90E-08 RBPMS2 
16 67034867 69106452 714 482 0 1.98E-06 DUS2 
16 71090452 73094829 741 461 0 2.28E-09 HP 
        
        
ADNI Blood       
CHR BEGIN END NUM PASS VARS 
NUM SING 
VARS STATRHO P-VALUE GENE 
6 41933605 43930372 1006 640 0 2.87E-07 GNMT 
11 17434219 19472162 762 473 0 2.25E-10 LDHC 
15 64039217 66064168 648 417 0 1.69E-36 RBPMS2 
16 67022599 69106642 1085 723 0 6.41E-08 DUS2 
16 71089779 73094855 1206 750 0 2.43E-11 HP 
 
BEGIN POS: Beginning position of range for rare variants within 1 Mb of gene to be tested 
END POS: End position of range for rare variants within 1 Mb of gene to be tested 
NUM PASS VARS: Number of variants passing all thresholds for EPACTS software 
NUM SING VARS: Number of singletons among variants in NUM PASS VARS 
P-VALUE: P-value of burden tests 

























Cadherin signaling pathway 4 127 14 3.97 3.53 + 9.59E-05 7.77E-03 
Angiogenesis 4 126 12 3.94 3.05 + 9.95E-04 3.22E-02 
Gonadotropin-releasing 
hormone receptor pathway 4 152 14 4.75 2.95 + 5.28E-04 2.14E-02 
Wnt signaling pathway 4 235 21 7.35 2.86 + 3.49E-05 5.65E-03 
Apoptosis signaling pathway 7 77 12 1.64 7.3 + 3.09E-07 5.01E-05 
p53 pathway 7 62 7 1.32 5.29 + 5.76E-04 2.33E-02 
CCKR signaling map 7 111 10 2.37 4.22 + 2.22E-04 1.20E-02 
Toll receptor signaling 
pathway 8 32 6 0.46 12.97 + 1.45E-05 2.36E-03 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 16 173 5 0.51 9.89 + 1.54E-04 2.50E-02 
 
 
PANTHER = Protein ANalysis THrough Evolutionary Relationships) Classification System; 







Table 3.3. Significant pathway enrichment in gene modules in blood 
 
 All ADNI genes 
(REF) 















Histamine H2 receptor mediated 
signaling pathway 5 24 5 0.67 7.41 + 1.03E-03 3.37E-02 
Angiotensin II-stimulated signaling 
through G proteins and beta-arrestin 5 33 6 0.93 6.47 + 6.14E-04 3.34E-02 
Ras Pathway 5 64 8 1.8 4.44 + 7.61E-04 3.10E-02 
Apoptosis signaling pathway 5 112 12 3.15 3.81 + 1.51E-04 2.47E-02 
CCKR signaling map 5 164 14 4.61 3.04 + 3.94E-04 3.21E-02 
Heme biosynthesis 6 11 4 0.25 15.93 + 2.74E-04 4.47E-02 
JAK/STAT signaling pathway 7 17 4 0.28 14.33 + 3.21E-04 2.62E-02 
Integrin signalling pathway 7 180 11 2.96 3.72 + 2.84E-04 4.62E-02 
B cell activation 12 66 6 0.66 9.08 + 7.89E-05 1.29E-02 
PDGF signaling pathway 12 127 7 1.27 5.5 + 3.79E-04 2.06E-02 
Inflammation mediated by chemokine 
and cytokine signaling pathway 14 237 11 2.27 4.84 + 2.50E-05 4.08E-03 
Parkinson disease 15 85 7 0.79 8.82 + 2.28E-05 3.72E-03 
Inflammation mediated by chemokine 
and cytokine signaling pathway 20 237 8 1.78 4.48 + 5.07E-04 8.26E-02 
Blood coagulation 24 43 8 0.27 29.9 + 8.22E-10 1.34E-07 
Inflammation mediated by chemokine 
and cytokine signaling pathway 24 237 7 1.47 4.75 + 7.94E-04 4.32E-02 
T cell activation 32 73 4 0.18 22.02 + 3.87E-05 6.30E-03 
 
PANTHER = Protein ANalysis THrough Evolutionary Relationships) Classification System; 







Table 3.4. Pathway-level cis rare eQTL significant results in brain 
 
 

























BEGIN POS: Beginning position of range for rare variants within 1 Mb of gene to be tested 
END POS: End position of range for rare variants within 1 Mb of gene to be tested 
NUM PASS VARS: Number of variants passing all thresholds for EPACTS software 
NUM SING VARS: Number of singletons among variants in NUM PASS VARS 
P-VALUE: P-value of burden tests 






Table 3.5. Pathway-level cis rare eQTL significant results in blood 
 
CHR BEGIN POS END POS NUM PASS VARS 
NUM SING 
VARS STATRHO P-VALUE 
GENE 
MODULE PATHWAY GENE 














5 174085268 176108976 335 196 0.1 9.07E-06 5 




1 25859096 27901441 1208 790 0.1 1.01E-05 5 Ras Pathway RPS6KA1 
1 25859096 27901441 1208 790 0.1 1.01E-05 5 CCKR signaling map RPS6KA1 
11 76033278 78180311 565 355 0.1 1.83E-05 5 Ras Pathway PAK1 
11 76033278 78180311 565 355 0.1 1.83E-05 5 CCKR signaling map PAK1 














1 83964144 85961982 589 336 0 3.43E-05 5 









9 115150150 117160754 620 425 0 4.97E-05 6 Heme biosynthesis ALAD 
1 44478672 46476606 1061 649 0 5.92E-05 6 Heme biosynthesis UROD 
19 13202507 15228794 767 501 0.1 7.60E-05 5 




19 13202507 15228794 767 501 0.1 7.60E-05 5 CCKR signaling map PRKACA 
9 127005465 128998618 1235 692 0.1 7.91E-05 15 Parkinson disease HSPA5 
8 21946761 23968794 817 520 0.1 8.77E-05 5 Apoptosis signaling pathway 
TNFRSF10
C 














2 200984212 203030077 637 404 0 2.42E-04 5 Apoptosis signaling pathway CFLAR 
17 39458200 41463831 1093 708 0 3.08E-04 12 PDGF signaling pathway STAT5A 
14 50190597 52294891 516 323 1 3.65E-04 12 PDGF signaling pathway NIN 
12 49108257 51158233 1082 716 0.1 4.48E-04 5 Apoptosis signaling pathway TMBIM6 
 
BEGIN POS: Beginning position of range for rare variants within 1 Mb of gene to be tested 
END POS: End position of range for rare variants within 1 Mb of gene to be tested 
NUM PASS VARS: Number of variants passing all thresholds for EPACTS software 
NUM SING VARS: Number of singletons among variants in NUM PASS VARS 
P-VALUE: P-value of burden tests 






Figure 3. 1. Overview of set-based rare eQTL analysis.  Flowchart of the gene-level and pathway-level rare 
eQTL analysis in brain and blood tissues. Starting with all protein coding genes, for the gene-level analysis, tests 
are performed for each gene using an aggregate of all low frequency and rare potentially regulatory SNPs w/ MAF 
≤ 0.05 within 1Mb of each gene. For the pathway-level analysis, WCGNA is first performed to find co-expressed 
gene modules and PANTHER pathway enrichment analysis is applied next to find the significant enriched 
pathways in these gene modules. The pathway-level tests are then performed on each enriched pathway for the 
aggregate of SNPs for each gene in the gene module that exists in the pathway. Significant results are found at the 
Bonferroni corrected threshold (α = 0.05). Among the brain and blood gene-level results, there were 5 shared 










CHAPTER 4: Identification of cell-type specific eQTLs of common variants 
in blood and brain tissue data 
4.1 Abstract 
Background: Changes in gene expression are associated with Alzheimer disease 
(AD) risk. Because regulation of gene expression is heritable and context-
dependent, we investigated AD-related gene expression patterns in multiple cell-
types in blood and brain. 
Methods: Cis-expression quantitative trait locus (eQTL) mapping was performed 
genome-wide in blood from 5,257 Framingham Heart Study (FHS) participants 
and in brain donated by 475 Religious Orders Study/Memory & Aging Project 
(ROSMAP) participants. The association of gene expression with genotypes for 
all cis SNPs within genes was evaluated using linear regression models for 
unrelated subjects and linear mixed models for related subjects. Cell type-
specific eQTL (ct-eQTL) models included an interaction term for expression of 
“proxy” genes that discriminate the particular cell type.  
Results: A total of 173,857 eQTLs and 51,098 ct-eQTLs in brain, and 847,429 
eQTLs and 30,405 ct-eQTLs in blood were significant after Bonferroni correction. 
Ct-eQTL analysis identified 11,649 and 2,533 significant gene-SNP eQTL pairs in 
brain and blood, respectively, that were not detected in generic eQTL analysis. 
Of note, 24,028 significant gene-SNP eQTL pairs were shared between blood 
and brain results and the 386 unique eGenes in these shared eQTL pairs are 




(HLA-DRB5, HLA-DRB1, ECHDC3, CR1, and WWOX) are established AD loci. 
HLA-DRB1 and HLA-DRB5 are ct-eQTLs in both monocytes/macrophages and 
microglia, providing further evidence for the role of the immune pathway in AD. 
The potential importance and relevance to AD of eQTLs and ct-eQTLs in myeloid 
cell-types is supported by the observation that a large portion of GWS ct-eQTLs 
map within 1Mb of established AD loci and 58% (23/40) of the most significant 
eGenes in these eQTLs have previously been implicated in AD. Also, we 
identified several novel candidate AD genes and variants.  
Conclusions: This study identified cell-type specific expression patterns for 
established and potentially novel AD genes, found additional evidence for the 
role of myeloid cells in AD risk, and discovered potential novel blood and brain 
AD biomarkers that highlight the importance of cell-type specific analysis. 
 
4.2 Background 
Recent expression quantitative trait locus (eQTL) analysis studies suggest 
that changes in gene expression have a role in the pathogenesis of AD [5, 6]. 
However, regulation of gene expression, as well as many biological functions, 
has been shown to be context-specific (e.g., tissue and cell-types, developmental 
time point, sex, disease status, and response to treatment or stimulus) [7-10]. 
One study of 500 healthy subjects found over-representation of T cell-specific 
eQTLs in susceptibility alleles for autoimmune disease and AD risk alleles 




associated cis-eQTLs were more cell type specific than average cis-eQTLs [13]. 
Another study classified 12% of more than 23,000 eQTLs in blood as cell-type 
specific [9]. Large eQTL studies across multiple human tissues have been 
conducted by the GTEx consortium, with a study on genetic effects on gene 
expression levels across 44 human tissues collected from the same donors 
characterizing patterns of tissue specificity recently published [146].  
Microglia, monocytes and macrophages share a similar developmental 
lineage and are all considered to be myeloid cells [147]. It is believed that a large 
proportion of AD genetic risk can be explained by genes expressed in myeloid 
cells and not other cell-types [110]. Several established AD genes are highly 
expressed in microglia [147, 148] and a variant in the AD-associated locus 
CELF1 has been associated with lower expression of SPI1 in monocytes and 
macrophages [110]. AD risk alleles have been shown to be enriched in myeloid 
specific epigenomic annotations and in active enhancers of monocytes, 
macrophages, and microglia [149], and to be polarized for cis-eQTL effects in 
monocytes [13]. These findings suggest that a cell-type specific analysis in blood 
and brain tissue may identify novel and more precise AD associations that may 
help elucidate regulatory networks. In this study, we performed a genome-wide 
cis ct-eQTL analysis in blood and brain, respectively, then compared eQTLs and 
cell-type specific eQTLs (ct-eQTLs) between brain and blood with a focus on 






4.3.1 Study Cohorts  
Framingham Heart Study (FHS). The FHS is a multigenerational study of health 
and disease in a prospectively followed community-based and primarily non-
Hispanic white sample. Procedures for assessing dementia and determining AD 
status in this cohort are described elsewhere [150]. Clinical, demographic, and 
pedigree information, as well as 1000 Genomes Project Phase 1 imputed SNP 
genotypes and Affymetrix Human Exon 1.0 ST array gene expression data from 
whole blood, were obtained from dbGaP 
(https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000007.v31.p12) . Requisite information for this study 
was available for 5,257 participants. Characteristics of these subjects are 
provided in Table S4.1.  
Religious Orders Study (ROS)/ Memory and Aging Project (MAP). ROS enrolled 
older nuns and priests from across the US, without known dementia for 
longitudinal clinical analysis and brain donation and MAP enrolled older subjects 
without dementia from retirement homes who agreed to brain donation at the 
time of death [94, 95]. RNA-sequencing brain gene expression and whole-
genome sequencing (WGS) genotype data were obtained from the AMP-AD 





4.3.2 Data Processing 
Generation and initial quality control (QC) procedures of the FHS GWAS and 
expression data are described elsewhere and include all genotype QC and pre-
adjustment of gene expression levels for batch effects and other technical 
covariates [150]. ROSMAP gene expression data were log-normalized and 
adjusted for known and hidden variables detected by surrogate variable analysis 
(SVA) [97] in order to determine which of these variables should be included as 
covariates in analysis models for eQTL discovery.  Additional filtering steps of 
FHS and ROSMAP GWAS and gene expression data included eliminating 
subjects with missing data, restricting gene expression data to protein coding 
genes, and retaining common variants (MAF ≥ 0.05) with good imputation quality 
(R2 ≥ 0.3).  
4.3.3 Cis eQTL Mapping 
Cis-eQTL mapping was performed using a genome-wide design (Figure S4.1). 
The association of gene expression with SNP genotypes for all cis SNPs within1 
Mb of protein-coding genes was evaluated using linear mixed models adjusting 
for family structure in FHS and linear regression models for unrelated individuals 
in ROSMAP. In FHS, lmekin function in the R kinship package (version 1.1.3) 
[151] was applied assuming an additive genetic model with covariates for age 
and sex, and family structure modeled as a random-effects term for kinship - a 
matrix of kinship coefficients calculated from pedigree structures. The linear 




Yi =I + β1Gj + β2Aij + β3Sij + Uij + ɛij 
where Yi is the expression value for gene i, Gj is the genotype dosage for cis 
SNP j, Aij and Sij are the covariates for age and sex respectively, Uij is the 
random effect for family structure, and β1, β2, and β3 are regression coefficients.  
ROSMAP data were analyzed using the lm function in the base stats package in 
R [98]. The regression model, which included covariates for age, sex, post-
mortem interval (PMI), study (ROS or MAP), and a term for a surrogate variable 
(SV1) derived from analysis of high dimensional data, can be expressed as:  
Yi =I + β1Gj + β2Aij + β3Sij + β3Sij + β4PMij + β5ijS2 + β6ijSV1 + ɛij 
where Yi is the expression value for gene i, Gj is the genotype dosage for cis 
SNP j, Aij, Sij, PMij, S2ij, and SV1ij are the covariates for age, sex, PMI, study and 
SV1 respectively, ɛij is the residual error, and the βs are regression coefficients. 
4.3.4 Cis ct-eQTL Mapping 
Models testing associations with cell type-specific eQTLs (ct-eQTLs) included an 
interaction term for expression levels of “proxy” genes that represent cell types. 
Proxy genes representing 10 cell types in whole blood [9] and five cell types in 
brain [152-154] were incorporated in cell type-specific models (Table 4.1). These 
proxy genes for cell types in blood were established previously using 
BLUEPRINT expression data to validate cell-type-specific expression in each 




incorporated in several studies [152-154]. Cell type-specific expression analyses 
in blood of FHS participants were conducted using the following model:   
Yi =I + β1Gj + β2P + β3(P*Gj) + β4Aij + β5Sij + Uij + ɛij 
where in each eQTLij pair, Yi is the eQTL expression value for gene i, Gj is the 
genotype dosage for cis SNP j, P is the proxy gene, P*Gj is the interaction term 
representing the effect of genotype in a particular cell type, Aij and Sij are 
covariates for age and sex respectively, Uij is the random effect for family 
structure, and βs are regression coefficients. Models with significant interaction 
terms indicate cell type specific eQTLs.  
The following model was used to evaluate cell type-specific expression in brain in 
ROSMAP:  
Yi =I + β1Gj + β2P + β3(P*Gj) + β4Aij + β5Sij + β6PMij + β7ijS2 + β8ijSV1 + ɛij 
where in each eQTLij pair, variables Yi, Gj, P, Aij, Sij, Pij, ɛij and βs are as 
described above, and PMij, S2ij, and SV1ij are covariates for PMI, study, and SV1 
respectively.  
A Bonferroni correction was applied to determine the significance threshold for 
each analysis (Table S4.3).  
4.3.5 Selection of AD-related eQTLs and Gene-set Pathway Enrichment Analysis 
To assess significant eQTLs and ct-eQTLs for relevance to AD, eGenes (genes 




matched to 88 genes located near 80 distinct uncorrelated SNPs that have been 
associated with AD or AD-related traits by genetic association or experimental 
approaches (Table S4.2) and eSNPs (SNPs that significantly influence gene 
expression) under the 80 significant association peaks. Gene-set enrichment 
analysis was performed using the PANTHER (Protein ANalysis THrough 
Evolutionary Relationships) software tool [31] to determine if the unique genes in 
the significant eQTL/ct-eQTL pairs shared by both brain and blood datasets are 
associated with a specific biological process or molecular function. Significance 
of the pathways was determined by the Fisher's Exact test with False discovery 
rate (FDR) multiple test correction. 
4.3.6 Colocalization Analyses 
Assessment of causal variants shared by adjacent GWAS and eQTL signals was 
performed using a Bayesian colocalization approach implemented in the R 
package coloc [155]. This analysis incorporated information about significantly 
associated variants for AD risk obtained from a recent large GWAS [101] and 
lead eQTL variants each defined as the eSNP showing the strongest association 
with gene expression. Following recommended guidelines, the variants were 
deemed to be colocalized by a high posterior probability that a single shared 
variant is responsible for both signals (PP4 > 0.8) [155, 156]. A lower threshold 
for statistical significance with a false discovery rate (FDR) < 0.05 for eQTL 
significant results was applied to maximize detection of colocalized pairs. 





4.4.1 Shared eQTLs and ct-eQTLs in blood and brain  
A total of 173,857 eQTLs and 51,098 ct-eQTLs in brain, and 847,429 eQTLs and 
30,405 ct-eQTLs in blood were significant after Bonferroni correction (Table 
S4.3). Additional significant gene-SNP eQTLs pairs in brain (n=11,649) and 
blood (n=2,533) were observed in ct-eQTL analysis that were not detected in 
eQTL analysis (Figure 4.1A). Of note, 24,028 significant gene-SNP eQTL pairs 
were shared between blood and brain. The 386 distinct eGenes among these 
shared eQTL pairs (Table S4.4) are most enriched in the apoptosis signaling 
(p=0.023) and Wnt signaling (p=0.036) pathways (Table S4.5). Five of these 
eGenes (HLA-DRB5, HLA-DRB1, ECHDC3, CR1, and WWOX) were previously 
associated with AD [58, 101]. Three eSNPs in eQTLs involving HLA-DRB1/HLA-
DRB5 (rs9271058) and ARL17A/LRRC37A2 (rs2732703 and rs113986870) 
which are near KANSL1 and MAPT were previously associated with AD risk at 
the genome-wide significance level [56, 101] (Table 4.2).  
Notably, the eQTLs involving CR1, ECHDC3 and WWOX were much more 
significant in brain than blood and their tissue-specific effects were in opposite 
directions. ECHDC3 is a significant eGene in blood and brain eQTLs (specifically 
in neurons). HLA-DRB5 and HLA-DRB1 are the only eGenes ascribed to 
significant ct-eQTLs in both blood and brain noting that of the 10 distinct lead 
eSNPs, five are unique to each tissue (Table 4.2). Although the eQTLs involving 




types, the total number of significant eSNP-eGene combinations was far greater 
in brain (particularly in microglia and neurons). The only instance in which the 
lead eSNP is also associated with AD risk at the GWS level was observed in the 
blood eQTL pair of HLA-DRB1 with eSNP rs9271058 (Table 4.2A). Among the 
AD-associated SNPs at the GWS level, rs9271058 is a significant eSNP for HLA-
DRB1 in both blood and brain cell types (the most significant association by p-
value was observed in anti-bacterial cells and microglia) and rs9271192 is a 
significant ct-eQTL for the gene in multiple brain cell types (Table 4.2). Both of 
these SNPs are also eSNPs for HLA-DB5 in the brain in neurons only.  
There were 657 gene-SNP eQTL pairs comprising 16 unique eGenes that were 
significant in blood and brain overall as well as in specific cell types in both blood 
and brain (Table S4.6). None of these eGenes were observed in significant 
pathways enriched for AD genes, however, they included AD-associated genes 
HLA-DRB1 and HLA-DRB5.  
4.4.2 AD associated and co-localized results  
Slightly more than half (42/80 = 52.5%) of the established AD associations (Table 
S4.2) are eGene targets for significant eQTLs in blood (Table S4.7). By 
comparison, only seven established AD loci were eGene targets for significant 
eQTLs in brain, among which OARD1 was significant in endothelial cells only 
(Table S4.7). Many GWS SNPs for AD risk are eSNPs affecting expression of 
the nearest gene, which is usually recognized as the causative gene, but several 




rs113986870 and rs2732703 in the MAPT/KANSL1 region target ARL17A in 
blood, but are paired in seven of eight eQTLs and ct-eQTLs with LRRC37A2 in 
brain (Table S4.8). HLA-DRB1 is the only AD gene with a significant ct-eQTL in 
blood, whereas many AD genes have significant blood eQTLs. In brain, only four 
AD loci (CR1, HLA-DRB1/DRB5, IQCK and MAPT/KANSL1) have significant 
brain eQTLs of which HLA-DRB1/DRB5 and MAPT/KANSL1 are the only brain 
ct-eQTLs, noting that all are significant in microglia, neurons and endothelial 
cells. 
Next, we evaluated whether the most significant eSNPs and SNPs genome-wide 
significantly associated with AD status (i.e., AD-SNPs) co-localize and thus to 
identify a single shared variant responsible for both signals (Posterior probability 
of shared signals (PP4) > 0.8). This analysis revealed eight eQTL/ct-eQTL 
signals that colocalized with seven AD GWAS signals and half of the co-localized 
signals involved a ct-eQTL (Table 4.3 and Figure S4.2). Two different eSNPs for 
CD2AP, rs4711880 (eQTL p=1.4x10-104) and rs13201473 (ct-eQTL p= 1.47x10-
9), flank CD2AP GWAS SNP rs10948363 which is also the second most 
significant eQTL (p=2.32x10-104) and the second most significant ct-eQTL in NK 
cells / CD8+ T-Cells (p=2.66x10-9). These three SNPs span a 9.0 kb region in 
intron 2 and are in complete linkage disequilibrium (LD, r2 =1.0), indicating that 
any one or more of them could affect the function of target gene CD2AP. 
Rs6557994 is the most significant eSNP for and located in PTK2B (blood ct-




(rs28834970, r2=0.78, p=1.58x10-9). Thus, it is not surprising that rs6557994 is 
also significantly associated with AD risk (p=8.19x10-7). Rs6557994 is also 
correlated with a GWAS SNP in CLU, located approximately 150 kb from PTK2B, 
that is not significantly associated with expression of any gene. Because PTK2B 
and CLU are independent AD risk loci [58], it is possible that this eSNP has an 
effect on AD pathogenesis through independent pathways (Figure S4.2). The 
most significant eSNP in MADD (rs35233100, p=2.88x10-10) was predicted to 
have functional consequences because it is a stop-gained mutation. This brain 
eQTL is colocalized (PP4=0.95) and weakly correlated with a GWAS SNP 
(p=1.91x10-5) in CELF1 rs10838725 (r2=0.12). 
4.4.3 Significant results in myeloid cells 
Examination of the distribution of the significant ct-eQTL results genome-wide 
showed that nearly two-thirds of the ct-eQTLs in blood occurred in interferon 
response/anti-bacterial cells in blood, whereas brain ct-eQTLs are highly 
represented in endothelial cells, neurons and microglia (Figure 4.1B, Table S4.9). 
Further examination of significant results within myeloid cell lineages (i.e., 
microglia and monocytes/ macrophages) which account for a large proportion of 
the genetic risk for late-onset AD [110] revealed that 3,234 or 10.6% of all 
significant ct-eQTLs in blood were in monocytes/macrophages. This subset 
includes 128 unique eGenes which are significantly enriched in the AD amyloid 
secretase pathway (FDR p=0.013, Table S4.10). A total of 974 or 30.1% of ct-




are located within 1 Mb of established AD loci (Table 4.4A). One of the eGenes 
in this top-ranked group (HLA-DRB5) is an established AD locus, and three 
others that are near established AD loci (DLG2 near PICALM [158], C4BPA near 
CR1 [159], and MYO1E near ADAM10 [160]) are reasonable AD gene 
candidates based on evidence using non-genetic approaches.  Microglia 
accounted for 15,560 (30.5%) of significant ct-eQTLs in the brain (Table 4.9) 
which involved 304 unique eGenes. Approximately 52% of significant ct-eQTLs in 
microglia are located in AD regions including five of the 20 most significant ct-
eQTLs in this group (Table 4.4B). One of these five eGenes is an established AD 
locus (HLA-DRB1) and two others (ALCC [161] and WNT3 [162]) have been 
linked to AD in previous studies.  
Considering significant eGene-eSNP pairs in myeloid cell types, 251 pairs 
including five distinct eGenes (BTNL3, FAM118A, HLA-DOB, HLA-DRB1, and 
HLA-DRB5) are shared between microglia and monocytes/macrophages (Table 
4.5A and Figure 4.2A). Three of these pairs involving eSNPs rs3763355, 
rs3763354, and rs1183595100 have the same target gene HLA-DOB and occur 
only in microglia and monocytes/macrophages (Table 4.5B). Among the 
significant ct-eQTLs in brain, the cell types with the largest proportion that were 
also significant in monocytes/macrophages were microglia (1.6%) and neurons 
(1.3%) (Table 4.5C). Conversely, among the significant ct-eQTLs in blood, the 
cell types with the largest proportion that were also significant in microglia were 




which are significant only for one cell-type each in blood and one in brain, 
monocytes/ macrophages shared three ct-eQTLs with microglia but with no other 
brain cell-types (Figure 4.2B, Table 4.5C). By comparison, microglia shared 63 
ct-eQTLs with interferons/ anti-bacterial cells, but with no other blood cell types. 
The much larger number of ct-eQTLs in microglia that were common with 
interferons/bacterial cells than monocytes/ macrophages may reflect the 
substantially greater proportion of significant eQTLs in blood involving 
interferons/antibacterial cells (64%) than monocytes/macrophages (10.6%) 
(Table S4.9). The only other ct-eQTLs that were unique to a pair of cell types in 
brain and blood cell type involved neurons paired with neutrophils (n=3) and with 
interferons/anti-bacterial cells (n=65) (Figure 4.2B).  
 
4.5 Discussion 
We identified several novel AD-related eQTLs that highlight the 
importance of cell-type dependent context. It is noteworthy that there were more 
significant ct-eQTLs in brain (n=51,098) than blood (n=30,405) even though the 
dataset containing expression data from blood (FHS) is several times larger than 
the brain expression dataset (ROSMAP). This could be due to greater cell type 
heterogeneity in brain, the enrichment of AD cases in the ROSMAP dataset who 
may show different patterns of gene expression compared to persons without 
AD, or highly variable gene expression across cell-types in the nervous system 




number specimens compared to studies in other tissues, post-mortem changes 
that may affect gene expression in brain [11], and the growing recognition that 
AD is a systemic disease [164-166] , incorporating expression data from multiple 
tissues can enhance discovery of additional genetic influences on AD risk and 
pathogenesis.  
Although most significant findings were tissue-specific, the 386 distinct 
eGenes among more than 24,000 significant gene-SNP eQTL pairs that were 
shared between blood and brain were enriched in the apoptosis signaling 
pathway that contributes to much of the underlying pathology associated with AD 
[167, 168]. Five established AD genes (CR1, ECHDC3, HLA-DRB1, HLA-DRB5, 
and WWOX [58, 101]) were shared eGenes in brain and blood and could be 
playing a key role in the systemic AD mechanisms.  The complement receptor 1 
(CR1) gene encodes a transmembrane glycoprotein functioning in the innate 
immune system by promoting phagocytosis of immune complexes, cellular 
debris, and Aβ [169]. CR1 is an eGene for several eSNPs, including AD GWAS 
peak rs6656401 located within the gene, in brain and blood eQTLs and the 
effects on CR1 expression are opposite in blood and brain. There are multiple 
possible explanations for the effect direction differences across tissues. The 
effect of the eSNP rs6656401 on CR1 expression may be developmental, noting 
that the average age of the FHS subjects (group with expression data in blood) is 
more than 30 years younger than the ROSMAP subjects (group with expression 




mortem changes in brain that are not indicative of expression in vivo. 
Alternatively, these effects may be related to AD because few FHS subjects were 
AD cases at the time of blood draw whereas 60% of subjects in the ROSMAP 
sample are AD cases. This idea is supported by the observation of a larger and 
positive effect of rs6656401 on CR1 expression in AD (β=0.020) compared to 
control brains (β=-0.0086). GWS variants located in the region spanning 
ECHDC3 and USP6NL have previously been associated with AD [170]. We 
found that ECHDC3 is the target gene for eSNP rs866770710 located in its 
promoter region, and this eQTL was significant in brain and specifically in 
neurons. Altered ECHDC3 expression in AD brains [171] supports the idea that 
this gene has a role in AD. Knockout of WWOX in mice leads to aggregation of 
amyloid-β (Aβ) and Tau, and subsequent cell death [172, 173]. 
The human leukocyte antigen (HLA) region is the key susceptibility locus 
in many immunological diseases and many associations have been reported 
between neurodegenerative diseases and HLA haplotypes [108]. In addition, the 
most widely used marker to examine activated microglia in normal and diseased 
human brains is HLA-DR and microglia activation increases with the progression 
of AD [174, 175]. HLA-DRB5 and HLA-DRB1 have been implicated in numerous 
GWAS studies as significantly associated with AD risk [58, 101] and appeared 
frequently among significant results in blood and brain in this study. Rs9271058, 
which is located approximately 17.8 kb upstream of HLA-DRB1, is significantly 




a significant eQTL and ct-eQTL in multiple cell types in blood and brain including 
myeloid lineage cells (i.e., monocytes/macrophages and microglia). This eSNP is 
also a significant eQTL in brain and specifically in neurons when paired with 
HLA-DRB5. Rs9271192, which is adjacent to rs9271058 and also significantly 
associated with AD risk (p=2.9 × 10−12 [58]), is a significant eQTL and ct-QTL 
with multiple cell types in brain but not blood when paired with HLA-DRB5 and 
HLA-DRB1.  
Significant associations for AD have been reported with variants spanning 
a large portion of the major histocompatibility (MHC) region in HLA class I, II and 
III loci [108, 176, 177]. While the strongest statistical evidence for association in 
this region is with variants in HLA-DRB1 [101], fine mapping in this region 
suggests that a class I haplotype (spanning the HLA-A and HLA-B loci) and a 
class II haplotype (including variants in HLA-DRB1, HLA-DQA1 and HLA-DQB1) 
are more precise markers of AD risk. Given the complexity of the MHC region 
and extensive LD, further work is needed to confirm this is a true eQTL or a 
signal generated from a specific HLA allele or HLA haplotype. Although 
functional studies may be required to discern which HLA variants have functional 
consequences relevant to AD and methods accounting for HLA polymorphisms 
would be required to detect the differential gene expression between the HLA 
alleles, our findings support a role for the immune system in AD [164, 178] and 
the hypothesis that a large proportion of AD risk can be explained by genes 




The potential importance and relevance to AD of eQTLs and ct-eQTLs in 
myeloid cell-types is supported by the observation that a large portion of GWS ct-
eQTLs we identified map within 1 Mb of established AD loci, and 58% (12/20 in 
monocytes/ macrophages and 11/20 in microglia) of the most significant eGenes 
have been previously implicated in AD (Table 4.4). DLG2 encodes a synaptic 
protein whose expression was previously reported as down-regulated in an AD 
proteome and transcriptome network [179] and inversely associated with AD 
Braak stage [158]. Genome-wide significant associations of AD risk with PTPRG 
was observed in a family-based GWAS [180] and with CLNK in a recent large 
GWAS for which the evidence was derived almost entirely with a proxy AD 
phenotype in the UK Biobank [181]. NFXL1 is a novel putative substrate for 
BACE1, an important AD therapeutic target [182]. FCRL5 may interact with the 
APOE*E2 allele and also modifies AD age of onset [183]. FMOD is a putative 
CSF autoantibody biomarker for AD [184]. INPPF has been linked to AD and 
Parkinson disease (PD) [185]. C4BPA was shown to be a consistently down-
regulated in MCI and AD patients, and the protein encoded by this gene 
accumulates in Aβ plaques in AD brains [159, 186]. Lower levels of the PAM 
have been observed in the brains and CSF of AD patients compared to healthy 
controls [187] and MYO1E is expressed by anti-inflammatory disease associated 
microglia [160]. As a calcium channel protein, CACNB2 may affect AD risk by 
altering calcium levels which could cause mitochondrial damage and then induce 




Likewise, several eGenes of top-ranked ct-eQTLs in microglia that are not 
established AD loci (Table 4.4) may have a role in the disease. It was shown that 
copy number variants (CNVs) near HNRNPCL1 overlapped the coding portion of 
the gene in AD cases but not controls [190]. A region of epigenetic variation in 
ALLC was associated with AD neuropathology [161]. FAM21B, a retromer gene 
in the endosome-to-Golgi retrieval pathway, was associated with AD in a 
candidate gene study [191]. Vacuolar sorting proteins genes in this pathway 
including SORL1 have been functionally linked to AD through trafficking of Aβ 
[55]. One study demonstrated that WNT3 expression in the hippocampus was 
increased by exercise and alleviated AD-associated memory loss by increasing 
neurogenesis [162]. Expression of RPL9 is downregulated in severe AD [192]  
and significantly differs by sex among persons with the APOE ɛ4 allele [193]. 
XRCC2 was one of the candidate genes associated by linkage to AD [194]. GWS 
associations of variants in DEFB121 with regional brain volumes have been 
observed [195]. Significant evidence of association with a TRIM49B SNP was 
found in a genome-wide pleiotropy GWAS of AD and major depressive disorder 
(MDD) [196]. TMPRSS9 is a differentially expressed gene in mitochondrial 
function in AD [197] and is also associated with PD [198].  
HLA-DOB, which is one of the five distinct eGenes (BTNL3, FAM118A, 
HLA-DOB, HLA-DRB1, and HLA-DRB5) for significant ct-eQTLs shared between 
microglia and monocytes/macrophages, and is the target gene for three eSNPs 




myeloid cell types. These eSNPs have similar eQTL p-values in both cell types, 
but have slightly larger effect sizes in monocytes (Figure 4.2). The effect of 
rs3763355, which though not GWS, has previously been associated with AD (p= 
1.19E-03) [101], on expression is in opposite directions in monocytes and 
microglia which suggests HLA-DOB may be acting in different immune 
capacitates in AD in blood and brain. Though the functions of the genes BTNL3 
and FAM118A are unknown, a BTNL8-BTNL3 deletion has been correlated with 
TNF and ERK1/AKT pathways, which have an important role in immune 
regulation inducing inflammation, apoptosis, and proliferation, suggesting the 
deletion could be correlated to inflammatory disease [199]. This suggests that the 
majority of the shared myeloid cell types genes- the HLA genes and possibly 
BTNL3, are all immune-related. Ct-eQTLs involving microglia and 
monocytes/macrophages had a larger proportion of total intersection, an isolated 
set interaction and a statistically significant overlap (p<1.0E-314), demonstrating 
a stronger connection than other brain/blood cell types in this study and thus 
providing further evidence for importance of the immune system in AD.   
The proportions of significant ct-eQTLs in NK cells/CD8+T cells, 
monocytes/macrophages, and eosinophils are comparable to those observed in 
reference blood tissue [200, 201]. Similarly, significant eQTL distributions in 
endothelial cells, neurons, and glia are consistent with reference brain tissue 
[202]. The majority of significant blood eQTLs were type I interferon response 




pathogenesis of autoimmune diseases including AD and certain heart diseases 
[203-205] and the enrichment of interferon ct-eQTLs in this study could possibly 
be due to the high proportion of subjects these diseases in the FHS dataset. In 
contrast, the proportion of significant ct-eQTLs among glial cells is much lower in 
astrocytes and oligodendrocytes and much higher (3 times as many) in microglia 
than in reference brain tissue [202].. Because many AD risk genes are expressed 
in myeloid cells including microglia [110], the large number of microglia ct-eQTLs 
is consistent with the high proportion of AD subjects in the ROSMAP dataset.  
Several SNPs previously reported to be associated with AD at the GWS 
level were associated with eGenes that differ from genes ascribed to AD loci and 
thus may have a role in AD (Table S4.8). Karch et al. observed that the 
expression of PILRB, which is involved in immune response and is the activator 
receptor to its inhibitory counterpart PILRA, an established AD gene [206, 207], 
was highest in microglia [148]. CNN2, the eGene for eSNP rs4147929 located 
near the end of ABCA7, significantly alters extracellular Aβ levels in human 
induced pluripotent stem cell-derived neurons and astrocytes [208]. Rs4147929 
also targeted HMHA1 which plays several roles in the immune system in an HLA-
dependent manner [209]. The eSNP/GWAS SNP rs3740688 located in SPI1 also 
affects expression of MYBPC3 and MADD. MYBPC3 was recently identified as a 
target gene for eSNPs located in CELF1 and MS64A6A in a study of eQTLs in 
blood for GWS AD loci [210]. MADD is expressed in neurons [148], is involved in 




modulator [212].  Although eSNP rs113986870 in KANSL1 when paired with the 
nearby eGene LRRC37A2 was a significant brain eQTL and ct-eQTL, 
LRRC37A2 encodes a leucine rich repeat protein that is expressed primarily in 
testis and has no apparent connection to AD. However, rs113986870 also 
significantly influenced expression of another gene in this region, ARL17A, that 
was previously linked to progressive supranuclear palsy by analysis of gene 
expression and methylation [213].  
 Our study has several noteworthy limitations. The proxy genes individually 
or collectively may not accurately depict cell-type specific context. In addition, the 
comparisons of gene expression in blood and brain may yield false results 
because they are based on independent groups ascertained from a community-
based longitudinal study of health (FHS – blood) and multiple sources for studies 
of AD (ROSMAP – brain) which were not matched for age, sex, ethnicity and 
other factors which may affect gene expression. Also, findings in brain may 
reflect post-mortem changes unrelated to disease or cell-type different 
expression [11]. Moreover, some cell types are vastly under-represented 
compared to others. Because myeloid cell types are represented in only a small 
proportion of the total cell populations in brain and blood (generally ~10%), it is 
difficult to identify myeloid-specific signals [149]. Despite this limitation, many of 
the most significant and noteworthy results of this study involved 
monocytes/macrophages and microglia. Finally, some findings may not be AD-




In summary, our observation of cell-type specific expression patterns for 
established and potentially novel AD genes, finding of additional evidence for the 
role of myeloid cells in AD risk, and discovery of potential novel blood and brain 
AD biomarkers highlight the importance of cell-type specific analysis. Future 
studies that compare cell type specific differential gene expression among AD 
cases and controls using single cell RNA-sequencing or cell count data, as well 




Table 4.1: Proxy genes for cell types in blood and brain  
 
 
Proxy gene Tissue Cell-type Function/GO biological process 
STX3 Blood Neutrophils 1 Detection of bacterium 
FAM102A Blood CD4+ T-Cells T cell selection 
SAMD3 Blood NK cells / CD8+ T-Cells Cellular defense response 
TSPAN5 Blood Erythrocytes Hemoglobin metabolic process 
PATL1 Blood Monocytes / Macrophages Defense response to virus 
PACS1 Blood Unknown Unknown/ Nerve growth factor receptor signaling pathway  
SP140 Blood Interferon response(+)/ Anti-bacterial(-) 
Type 1 interferon response/Anti-
bacterial, Regulation of defense 
response 
FBXL5 Blood Neutrophils 2 Detection of bacterium 
STRBP Blood B-cells B cell receptor signaling pathway 
SIGLEC8 Blood Eosinophils Regulation of myeloid leukocyte mediated immunity 
CD34 Brain Endothelial Cells Lining blood vessels 
RELN Brain Neurons Main signaling units 
CD68 Brain Microglia Brain immune cells 
GFAP Brain Astrocytes Support neuronal growth, function and neurotransmitter recycling 






Table 4.2: eQTLs and ct-eQTLs in established AD loci appearing in both blood and brain 
A. eQTLs and ct-eQTLS in established AD genes in both blood and brain 
eGene Tissue Cell-type Lead eSNP Position MAF Beta Std Error P-value 





CR1 Blood NA rs7533408 1:207673631 0.25 0.059 0.006 3.60E-22 169 NA 
HLA-
DRB5 Blood NA rs9269008 6:32436217 0.17 -2.580 0.057 <1.0E-314 72 NA 
HLA-
DRB1 Blood NA rs9271058 6:32575406 0.14 -2.950 0.028 <1.0E-314 630 
Lead 
eSNP 
ECHDC3 Blood NA rs11257290 10:11780324 0.28 0.041 0.005 2.91E-19 115 NA 




Anti-bacterial(-) rs9269047 6:32438783 0.12 -7.120 0.335 3.04E-100 9 [all (-)] NA 
HLA-
DRB5 Blood Monocytes/ Macrophages rs9269047 6:32438783 0.12 
-
11.600 1.030 2.02E-29 1 NA 
HLA-
DRB5 Blood NK cells / CD8+ T-Cells rs9269047 6:32438783 0.12 -7.660 0.994 1.30E-14 1 NA 
HLA-
DRB1 Blood NK cells / CD8+ T-Cells rs9270928 6:32572461 0.15 -4.070 0.377 3.60E-27 287 rs9271058 
HLA-




Anti-bacterial(-) rs9271147 6:32577385 0.14 -5.510 0.250 1.19E-107 346 [260(-)/86(+)] rs9271058 
HLA-
DRB1 Blood Monocytes/ Macrophages rs9271148 6:32577442 0.13 -6.110 0.709 6.83E-18 222 rs9271058 
CR1 Brain NA rs12037841 1:207684192 0.17 -0.096 0.007 9.25E-44 64 rs6656401 
HLA-




DRB1 Brain NA rs73399473 6:32538959 0.26 -2.050 0.058 8.78E-272 10792 
rs9271058, 
rs9271192 
ECHDC3 Brain NA rs866770710 10:11784320 0.0002 -0.252 0.018 4.61E-44 45 NA 
WWOX Brain NA rs12933282 16:78124987 0.45 -0.133 0.017 1.13E-15 75 NA 
HLA-






DRB5 Brain Endothelial Cells rs67987819 6:32497655 0.14 -2.410 0.220 6.32E-28 343 NA 
HLA-








DRB1 Brain Endothelial Cells rs9269492 6:32542924 0.30 -2.250 0.243 2.06E-20 351 rs9271192 
HLA-
DRB5 Brain Neurons rs9270035 6:32553446 0.14 -2.520 0.137 1.46E-75 2540 
rs9271058, 
rs9271192 







B. eQTLs and ct-eQTLs involving AD GWAS association peak SNPs in both brain and blood 
eGene Tissue Cell-type eSNP+GWAS SNP Position MAF Beta 
Std 
Error P-value 
HLA-DRB1 Blood NA rs9271058 6:32575406 0.27 -2.950 0.028 <1.0E-314 
ARL17A Blood NA rs2732703 17:44353222 0.21 0.147 0.023 5.95E-11 
ARL17A Blood NA rs113986870 17:44355683 0.09 0.166 0.025 2.30E-11 
HLA-DRB1 Blood Interferon response(+)/ Anti-bacterial(-) rs9271058 6:32575406 0.27 -3.010 0.159 6.36E-80 
HLA-DRB1 Blood NK cells / CD8+ T-Cells rs9271058 6:32575406 0.27 -4.090 0.464 1.20E-18 
HLA-DRB1 Blood Monocytes / Macrophages rs9271058 6:32575406 0.27 -3.540 0.497 1.06E-12 
HLA-DRB1 Brain NA rs9271058 6:32575406 0.27 -1.690 0.054 1.94E-213 
HLA-DRB5 Brain NA rs9271058 6:32575406 0.27 -1.770 0.081 2.28E-106 
LRRC37A2 Brain NA rs2732703 17:44353222 0.21 1.370 0.053 4.13E-150 
LRRC37A2 Brain NA rs113986870 17:44355683 0.09 1.260 0.068 1.98E-76 
ARL17A Brain NA rs113986870 17:44355683 0.09 -0.326 0.047 4.96E-12 
HLA-DRB1 Brain Microglia rs9271058 6:32575406 0.27 -1.400 0.111 1.80E-36 
HLA-DRB1 Brain Neurons rs9271058 6:32575406 0.27 -1.650 0.135 2.37E-34 
HLA-DRB5 Brain Neurons rs9271058 6:32575406 0.27 -1.550 0.201 1.24E-14 
LRRC37A2 Brain Neurons rs2732703 17:44353222 0.21 1.520 0.140 1.84E-27 
LRRC37A2 Brain Microglia rs2732703 17:44353222 0.21 1.480 0.147 7.65E-24 
LRRC37A2 Brain Endothelial Cells rs2732703 17:44353222 0.21 1.750 0.233 5.88E-14 
LRRC37A2 Brain Microglia rs113986870 17:44355683 0.09 1.530 0.195 4.29E-15 
LRRC37A2 Brain Neurons rs113986870 17:44355683 0.09 1.400 0.184 2.77E-14 
*Position according to GRCh37 assembly; MAF = minor allele frequency of variant in 1000 Genomes Combined 





Table 4.3: Colocalized AD GWAS/lead eQTL SNP pairs 
Region * 
AD GWAS Variant Lead eQTL Variant eQTL type PP4 r
2  
rsID Nearest Gene MAF p-value 
eQTL 









3 CD2AP 0.72 1.77E-07 
2.32E-




104 NA 2.57E-07 
Blood 




3 CD2AP 0.72 1.77E-07 2.66E-09 CD2AP 







NK cells / 



























-28467686 rs9331896 CLU 0.61 3.62E-16 Not an eSNP 
rs655799













rs6656401 CR1 0.19 2.17E-15 1.05E-43 CR1 NA rs12037841 0.19 CR1 9.25E-44 NA 1.77E-15 
Brain 




5 CELF1 0.68 1.91E-05 Not an eSNP 
rs3523310
0 0.068 MADD 2.88E-10 NA 1.25E-03 
Brain 
eQTL 0.954 0.12 
11:5892350
8-60923508 rs983392 MS4A6A 0.59 4.76E-15 Not an eSNP 
rs1123056
3 0.35 CD6 
2.31E-
113 NA 0.48 
Brain 
eQTL 0.854 0.00 
19:4441194
1-46411941 rs429358 APOE 0.78 0.00E+00 Not an eSNP 
rs7425334








 * Map position within 1 Mb of AD GWAS SNP according to GRCh37 assembly; MAF = minor allele frequency; NA 






Table 4.4: 20 most significant ct-eQTLs in (A) monocytes/ macrophages and (B) in microglia 
 




SLC12A1 rs8037626 15:48606346 0.17 -3.340 0.219 1.62E-52 126 
DLG2 rs75798025 11:84018349 0.01 5.350 0.364 6.66E-49 597 
ABCA9 rs4147976 17:66925923 0.44 0.872 0.068 1.97E-37 48 
PTPRG rs116497321 3:62245373 0.01 2.650 0.221 3.96E-33 10 
CLNK rs5028371 4:10452986 0.50 1.060 0.092 7.66E-31 272 
NFXL1 rs10938499 4:47848377 0.33 -1.270 0.112 8.38E-30 73 
FCRL5 rs12760587 1:157526021 0.23 2.140 0.19 1.99E-29 93 
HLA-DRB5 rs9269047 6:32438783 0.12 -11.600 1.03 2.02E-29 1 
FMOD NA 1:203263699 NA 2.110 0.2 5.08E-26 42 
ABCA6 rs144031521 17:67162715 0.01 8.620 0.833 4.27E-25 9 
INPP5F rs181735165  10:121555618 0.02 7.150 0.701 1.99E-24 11 
RBMS3 rs192885607 3:29612955 0.00 2.570 0.257 1.52E-23 34 
ARHGAP44 NA 17:12750576 NA 1.760 0.177 2.69E-23 54 
C4BPA rs74148971 1:207275799 0.07 -2.300 0.234 8.44E-23 24 
DCLK2 rs114930380 4:150954757 0.03 1.630 0.169 5.16E-22 39 
PAM NA 5:102153433 NA -0.691 0.073 2.00E-21 47 
MYO1E rs146483144 15:59422810 0.03 4.300 0.453 2.26E-21 17 
DSP rs4960328 6:7495948 0.42 0.554 0.061 9.30E-20 6 
ROR1 rs1557596882  1:64453767 0.01 3.570 0.393 1.05E-19 31 







eGene Lead eSNP Position* MAF Beta Std Err P-value # significant eSNPs in gene/cell-type 
AC142381.1 rs199931530 16:33047273 0.45 -0.401 0.012 3.89E-233 43 
MLANA rs201480524 9:68457329 0.50 -0.176 0.007 4.82E-124 18 
AC015688.3 rs62058902 17:25303954 0.50 -0.213 0.009 1.94E-113 11 
HNRNPCL1 rs75627772 1:13182567 0.00 0.186 0.008 4.31E-113 8 
AL050302.1 rs3875276 21:14472722 0.50 -0.890 0.040 2.62E-111 142 
ALLC rs9808287 2:3624799 0.11 0.833 0.044 1.41E-79 12 
FAM21B NA 10:47917284 NA -2.210 0.118 2.88E-78 22 
WNT3 rs9904865 17:44908263 0.37 -1.570 0.084 3.90E-78 1 
RPL9 rs1458255 4:39446549 0.28 -2.370 0.137 4.76E-67 37 
HLA-DRB1 rs72847627 6:32538512 0.32 -2.130 0.125 4.15E-65 2305 
XRCC2 rs80034602 7:152104360 0.50 2.120 0.128 1.30E-61 5 
WI2-3308P17.2 rs4067785 1:120576209 0.50 -0.184 0.011 1.33E-58 9 
DEFB121 rs117541536 20:29422202 0.49 -7.420 0.460 1.56E-58 1 
GINS1 rs75374582 20:26109209 0.50 -33.200 2.060 1.95E-58 5 
EXOSC10 rs2580511 1:121113600 0.50 -4.390 0.276 5.78E-57 5 
TRIM49B rs202086299 11:48363026 0.50 0.205 0.013 2.16E-54 5 
TMPRSS9 rs7248384 19:23936403 0.48 -1.410 0.093 1.83E-52 1 
LDHC NA 11:18432033 NA 0.428 0.030 1.07E-47 73 
HLA-DOB rs201194354 6:32796857 NA 1.190 0.084 4.39E-46 70 
DEFB119 rs78099404 20:29617870 0.50 -0.377 3.51E-15 <1.0E-314 142 
 
* chromosome and map position according to GRCh37 assembly 





Table 4.5: Overlap of ct-eQTLs in myeloid cell types in brain and blood 
 
A. Unique eGenes shared in significantly associated ct-eQTLs in monocytes/ 
macrophages and microglia. Number below each gene represents significant 




B. eSNP-eGene pairs among ct-eQTLs significant in both monocytes/ 
macrophages and microglia	
* results from 2019 IGAP Summary Statistics [101] 






















* number in parentheses represent the proportion of ct-eQTLs for each cell type on the 
left that were also observed in either microglia or monocytes/macrophages 
 
BTNL3 FAM118A HLA-DOB HLA-DRB1 HLA-DRB5 
1 43 6 200 1 
  Monocytes/Macrophages Microglia  
eGene eSNP Position MAF Beta P-value Beta P-value AD GWAS P-value * 
HLA-
DOB rs3763355  6:32786882 0.06 -2.02 9.98E-15 0.938 3.89E-14 0.001 
HLA-
DOB rs3763354 6:32786917 0.15 -1.11 1.40E-10 -0.642 2.80E-13 0.652 
HLA-
DOB rs1183595100 6:32768232 NA -1.13 8.34E-11 -0.605 1.98E-11 
NA 
Cell-types Monocytes/ Macrophages Microglia 
Blood 
# ct-eQTLs 
common to cell 
type pair 
# ct-eQTLs 
unique to cell 
type pair 
# ct-eQTLs 
common to cell 
type pair 
# ct-eQTLs 
unique to cell 
type pair 
Neutrophils1     3 (0.3%) * 0 
CD4+T-Cells     3 (0.5%) 0 
NK/CD8+T-Cells     337 (12.9%) 0 
Erythrocytes     119 (5.6%) 0 
Monocytes/ Macrophages     251 (7.8%) 3 
Unknown     0 0 
Interferon/ Anti-bacterial     628 (3.3%) 63 
Neutrophils2     0 0 
B-cells     0 0 
Eosinophils     38 (5.2%) 0 
Brain         
Endothelial Cells 55 ( 0.5%) 0     
Neurons 250 (1.3%) 0     
Microglia 251 (1.6%) 3     
Astrocytes 0 0     




Figure 4.1 Significant gene-SNP eQTLs and ct-eQTLs in blood and brain tissue genomewide.  A) Venn diagram 
shows the number of overlapping eQTLs and ct-eQTLs in blood and brain. Gold color indicates significant eQTLs 
that are cell-type specific. Orange color indicates significant eQTLs that are shared between blood and brain. B) 











































Figure 4.2 Intersection of significant gene-SNP eQTL pairs between cell-types in blood and brain tissue.  A) Venn 
diagram showing overlap of ct-eQTL pairs in myeloid cell types (microglia and monocytes/macrophages). B) 
Number of significant eQTLs unique to and that overlap cell-types in blood and brain. Bar chart on the left side 
indicates the number of significant eQTLs involving each cell-type and bar chart above the matrix indicates the 
number of significant eQTLs that are unique to each cell type and set of cell-types. Pink colored bar indicates the 




























CHAPTER 5: Conclusions 
 To conclude, this dissertation further explains undiscovered AD genetic 
risk with novel findings by integrating multiple types of ‘omics data, yields 
similarities and differences in AD mechanisms in brain and blood cell types with 
the multi-tissue and cell-type analysis, and also highlights the importance of 
applying these different methods to analysis to improve our understanding of AD. 
Not only were numerous novel findings found with the different strategies 
implemented in these chapters, but when examining top findings within all results 
in this work, more interesting associations are seen.  
 Rare variant results for mutations occurring only in cases or only in 
controls, as found in Chapter 2, for findings in other chapters are seen Table 5.1. 
The table includes top findings and results with a MAC ≥7 from Chapters 3 and 4. 
The top MAC in cases only (n=9) was for zinc finger protein gene ZNF839, a 
shared blood and brain eQTL gene from Chapter 4. The next top MAC(n=8) gene 
include RNF39 which has a rare mutation in only 8 cases and zero controls. 
RNF39 was a top brain gene-level rare eQTL(p=7.71E-27) and has previously 
been seen as an AD-associated differentially methylated region [102]. These rare 
variant results include also include blood gene-level gene EXOC2(n=7), which 
has been identified as an AD age of onset modifier and also as one of the largest 
co-expressed modules in a weighted gene co-expression analysis of posterior 
cingulate (PC) astrocytes in AD [183]. Multiple significant pathway-level genes 




pathway are also seen: IFNAR, CXCR2, and RAF1. Top genes in monocyte and 
microglia ct-eQTLs had a high MAC in cases only, including TMPRSS9(n=8), 
ABCA6 (n=7), and genes that were potential AD candidates in Chapter 4 such as 
DLG2, MYO1E, and INPP5, further suggesting AD association with immune 
systems. The top results from Chapter 2, NOTCH3 and TREM2, did not have 
significant rare-eQTLs though as seen in Table S5.1. 
 There were multiple shared pathway genes between brain and blood in 
Chapter 3, which were also present in common and ct-eQTL results (Table 5.2). 
CXCL5 had a very significant eQTL in blood (p=	9.88E-144) and also had cell-
type specific eQTLs in microglia and oligodendroglia. Microglial activation and 
the subsequent changes in cytokines and chemokines such as CXCL5 are keys 
steps in the development of neuroinflammation [214]. CXCL5, CCL3, and CCL4 
are all cell-type specific in oligodendroglia, and both CXCL5 and CCL3 are 
present in both blood and brain eQTLs. In addition, pathway-level rare eQTL 
findings from Chapter 3 were seen in common and ct-eQTL results as well (Table 
5.3). ALOX5AP is seen in both gene-level and pathway-level rare eQTLs and 
common eQTLs all in blood. FPR2 has a very significant eQTL in blood (p=	
1.22E-240) and is also cell-type specific in blood interferon and anti-bacterial 
cells (p= 3.81E-17). IFNAR1 also has an eQTL in blood and is cell-type specific 
in the brain in endothelial cells. FPR2, ALOX5AP, IFNAR1, RAF1, GRB2, and 
CCL8 in this table are all associated with the Inflammation pathway. 




7.35E-73) and brain (p= 4.30E-36) eQTLs, though much more significant in the 
blood.  
 Throughout this dissertation, I have discovered rare and common variant 
eQTLs and cell-type specific eQTLs in both brain and blood. I explored the 
overlap of significant genes between these three types of eQTLs in each tissue 
(Figure 5.1). There are a total of 203 genes in blood and 40 genes in brain that 
have both common and rare-eQTLs (Table S5.2). There are 29 genes in blood 
and 28 genes in brain that have significant rare eQTLs and are cell-type specific 
(Table S5.3). Interestingly, there are 29 genes in blood and 21 genes in brain 
that are significant in rare, common, and ct-eQTLs (Table S5.4). When 
comparing these total intersects in both tissues, there is only one gene in both- 
HP. HP or haptoglobin was seen as shared gene in blood and brain gene-level 
rare-eQTL findings and has previously been found to have a much higher mean 
serum level in AD patients compared to healthy controls [125].  
 When examining all results and top findings together, there is further 
evidence for AD association for many top genes, bringing together genetic and 
genomic evidence. Collectively, these findings further explain the genetic basis of 






Table 5.1 Rare variants in cases only for other top findings 




score Top findings or Results MAC≥7 in 
ZNF839 14:102805285 9 Missense Moderate 10.83 Shared blood/brain eQTL genes 
RNF39 6:30043301 8 Missense Moderate 26.1 Brain gene-level rare eQTLs 
TAC3 12:57406650 8 Missense Moderate 17.66 Blood gene-level rare eQTLs 
RHCE 1:25718599 8 Missense Moderate 9.565 Blood gene-level rare eQTLs 
TMPRSS9 19:2405464 8 Missense Moderate 25.7 Top Microglia ct-eQTLs 
RARRES1 3:158428589 8 Missense Moderate 27.6 Shared blood/brain eQTL genes 
EXOC2 6:564588 7 Missense Moderate 25.1 Blood gene-level rare eQTLs 
ABCA6 17:67075361 7 Missense Moderate 26.9 Top Monocyte ct-eQTLs 
CNDP2 18:72168601 7 Missense Moderate 14.14 Shared blood/brain eQTL genes 
SPEF2 5:35740256 7 Missense Moderate 12.44 Shared blood/brain eQTL genes 
IFNAR1 21:34697424 5 In-frame deletion Moderate 21.7 Blood pathway-level rare eQTLs 
WWOX 16:78466539 5 Missense Moderate 22.4 Shared blood/brain AD gene 
CXCR2 2:218999633 4 Missense Moderate 0.455 Blood pathway-level rare eQTLs 
RAF1 3:12660099 4 Missense Moderate 25.2 Blood pathway-level rare eQTLs 
INPP5F 10:121551531 4 Missense Moderate 25.1 Top Monocyte ct-eQTLs 
INPP5F 10:121556381 4 Missense Moderate 23 Top Monocyte ct-eQTLs 
DLG2 11:84996317 4 Missense Moderate 24.8 Top Monocyte ct-eQTLs 
SLC12A1 15:48518739 4 Missense Moderate 21.6 Top Monocyte ct-eQTLs 
MYO1E 15:59464106 4 Missense Moderate 17.8 Top Monocyte ct-eQTLs 
 





Table 5.2 Common and ct-eQTLs for shared pathway genes in blood and brain 
 
Gene Tissue SNP Position Cell-Type P-value 
CXCL5 Blood 4:74857970 NA 9.88E-144 
CCL4 Blood 17:34431403 NA 1.35E-26 
CXCL5 Brain 4:7540518 Oligodendroglia 3.03E-24 
CXCL5 Brain 4:74601312 Microglia 1.23E-13 
CCL3 Brain 17:34591375 Oligodendroglia 3.77E-13 
HSPA6 Blood 1:161482520 NA 3.99E-12 
CCL4 Brain 17:34762804 Oligodendroglia 4.46E-12 






Table 5.3 Pathway-level rare eQTL findings in common and ct-eQTL results 
Gene Lead eSNP Cell-Type eQTL/ct-eQTL Tissue P-value 
Pathway-level 
Tissue 
FPR2 19:52276665 NA Blood 1.22E-240 Blood  
ALOX5AP 13:31312178 NA Blood 1.76E-158 Blood  
TNFRSF10C 8:22957606 NA Blood 7.35E-73 Blood  
TNFRSF10C 8:22941873 NA Brain 4.30E-36 Blood  
IFNAR1 21:34670242 NA Blood 6.58E-34 Blood  
CFLAR 2:201982693 NA Blood 1.58E-26 Blood  
STAT5A 17:40456010 NA Blood 1.11E-24 Blood  
ALAD 9:116167156 NA Blood 1.76E-22 Blood  
CCL8 17:3188133 Oligodendroglia Brain 3.71E-21 Brain  
UROD 1:45498181 NA Blood 3.65E-20 Blood  
GRB2 17:73271758 NA Blood 9.53E-20 Blood  
PAK1 11:77060092 NA Blood 1.32E-17 Blood  
FPR2 19:52269634 Interferon/Anti-bacterial cells Blood 3.81E-17 Blood  
IFNAR1 21:34370749 Endothelial Cells Brain 7.49E-14 Blood  
RPS6KA1 1:26883511 NA Blood 1.20E-13 Blood  
RAF1 3:12690343 NA Blood 1.33E-11 Blood  







Figure 5.1 Overlap of significant genes in rare gene-level, common, and cell-type eQTLs. The venn diagrams 






















Table S2.1 Characteristics of subjects in the ADSP WES Case-Control dataset 
 
 










ancestry 10,367 5,566 (54%) 4,574 (44%) 4,369 (42%) 5,998 (58%) 81.0 (9.1) 30% 
Caribbean 




Table S2.2 Known AD/Dementia genes 
Gene Disease Reference 
ABCA7 AD [74, 215, 216] 
ABCG1 AD [217] 
ABI3 AD [3] 
ACE AD [218] 
ADAM10 AD [219, 220] 
ADAMTS1 AD [221] 
AKAP9 AD [15] 
APOE AD [222, 223] 
APP AD [224] 
BIN1 AD [225] 
BZRAP1 AD [170] 
C1QTNF4 AD [226] 
CASP8 AD [227] 
CASS4 AD [58] 
CD2AP AD [58] 
CD33 AD [58] 
CELF1 AD [58] 
CHCHD10 FTD [228] 
CHMP2B FTD [229, 230] 
CLU AD [228] 
COBL AD [231] 
CR1 AD [58] 
CSF1R FTD [232] 
DSG2 AD [58] 
ECHDC3 AD [170] 
ECRG4 NP+NFT [233] 
EIF2B1 Leukodystrophy [234] 
EIF2B2 Leukodystrophy [235] 
EIF2B3 Leukodystrophy [235] 
EIF2B4 Leukodystrophy [234] 
EIF2B5 Leukodystrophy [235] 
EPHA1 AD [37, 236] 
FBXL7 AD [237] 
FERMT2 AD [58] 
FRMD4A AD [238] 
FUS FTD [239] 
GALNT7 AD [217] 
GLIS3 AD [57] 
GRN FTD [240, 241] 
HBEGF AD [170] 
HDAC9 NFT + CAA [233] 
HLA-DRB1 AD [58] 
HLA-DRB5 AD [242] 
IGHV1-67 AD [243] 
INPP5D AD [58] 
ITM2B FBD/FDD [244-246] 
KANSL1 AD [56] 




LMNB1 Leukodystrophy [247] 
LMX1B AD [248] 
MAPT AD [56] 
MEF2C AD [58] 
MS4A4A AD [37] 
MS4A6A AD [58] 
MTUS1 AD [249] 
MVB12B AD [250] 
NME8 AD [58] 
NOTCH3 CADASIL [39, 43] 
OSTN AD [57] 
PDGFRL AD [251] 
PFDN1 AD [170] 
PICALM AD [58] 
PILRA AD [206] 
PLCG2 AD [3] 
PLD3 AD [252] 
PLD4 AD [249] 
PLXNA4 AD [253] 
PPP2CB AD [254] 
PRNP CJD/GSS [255] 
PSEN1 AD [256] 
PSEN2 AD [256] 
PTK2B AD [58] 
RIN3 AD [257] 
SLC10A2 AD [231] 
SLC24A4 AD [58] 
SLC2A4A AD [249] 
SORCS1 AD [258, 259] 
SORCS2 AD [259] 
SORCS3 AD [259] 
SORL1 AD [50, 242] 
SRRM4 CSF Tau [249] 
TARDBP FTD [260] 
TM2D3 AD [261] 
TP53INP1 AD [243] 
TPBG AD [170] 
TRAPPC12 NFT + CAA [233] 
TREM2 AD [14, 69] 
TREML2 AD [57] 
TRIP4 AD [262] 
UNC5C AD [16] 
USP6NL AD [170] 
VCP FTD [263] 
ZCWPW1 AD [58, 207] 
ZNF804B AD [249] 
AD = Alzheimer disease; CAA = cerebral amyloid angiopathy; CADASIL = Cerebral Autosomal Dominant 
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy; CJD = Creutzfeldt-Jakob disease; FBD = 
Familial British dementia; FDD = Familial Danish dementia; FTD = fronto-temporal dementia; GSS = 
Gerstmann-Straussler syndrome; HPV = hippocampal volume; HS = hippocampal sclerosis; LMdT = logical 




Table S2.3 Filtering pipeline of rare variants  
 
# of 
Variants   
(# of Genes) 
Filtering Steps 
1,015,329 
(29,157) Total rare variants genome-wide after counts are calculated with PLINK 
75,716 
(15,702) 
Total rare variants genome-wide after filtering (to remove synonymous 
mutations, those with a count less than or equal to 2) and restricted to those 
with a high or moderate impact on disease (as classified by VEP annotation).  
4,854 
(3,619) 
Total rare variants genome-wide after filtering and with high impact on 
disease. 
10,249 (95) Total rare variants in known AD genes 
503 (83) Total rare variants in known AD genes after filtering and with high and moderate impact on disease. 




Table S2.4 Characteristics of AD Subjects in the ADSP WES dataset with the 
NOTCH3 rs149307620 mutation 
	








ADGC (ADC2)  F 71 33 NA 
ADGC (ADC3) M 76 33 6 
ADGC (ADC3) M 78 34 NA 
ADGC (ADC4) F 74 34 NA 
ADGC (ADC5) M 78 24 NA 
ADGC (Memory and Aging 
Project) M 84 33 NA 
ADGC (Texas Alzheimer's 
Research and Care 
Consortium) 
F 80 33 NA 
CHARGE M 79 33 NA 
CHARGE M 95 33 NA 
CHARGE F 84 33 NA 
 













Cases Controls % Female 
Mean Age 
(SD) 
% APOE e4 
carrier 
European ancestry 
ADSP Extension 1097 485 0 612 63.5% 78.4(7.4) 38.5% 
Caribbean Hispanic 
ADSP Extension 1018 493 0 525 55.1% 73.9(7.4) 29.4% 
African American 
ADSP Extension 977 454 0 523 55.1% 79.2(7.1) 43.3% 
European ancestry 
ADSP families 499 320 0 179 64.5% 73.4(10.6) 39.3% 
Caribbean Hispanic 
ADSP families 290 200 0 90 62.8% 70.6(10.1) 32.5% 
African American 
ADSP families 44 30 0 14 65.3% 69.1(12.1) 51.0% 
ADNI 809 239 321 249 44.8 76.3(8.1) 44.0% 




Table S2.6 Characteristics of AD Subjects with the TREM2 rs104894002 
mutation (Q33X) 
	
NA = not autopsied 
 










ADGC (ADC) M 75 23 5 5 




National Cell Repository 












Table S2.7 Genes with at least 3 distinct high/moderate disease impact rare 
variants each with a MAC ≥ 5 and occurring in only cases  







14:74754936:G:A 10 rs57773157 ABCD4 Missense Moderate 18.1 
14:74766360:T:C 10 rs58272575 ABCD4 Missense Moderate 15.7 
14:74763064:C:T 10 rs34992370 ABCD4 Missense Moderate 8.7 
14:74764675:G:A 8 rs61744947 ABCD4 Missense Moderate 22.4 
3:38125659:C:T 6 rs143610524 DLEC1 Missense Moderate 20.4 
3:38101245:C:T 6 rs34012183 DLEC1 Missense Moderate 18.1 
3:38101313:G:A 5 rs149190717 DLEC1 Missense Moderate 13.0 
1:225239279:G:A 6 Novel DNAH14 Missense Moderate 14.5 
1:225512438:G:A 5 rs566891789 DNAH14 Splice Acceptor High 25.7 
1:225458497:C:T 5 rs530417418 DNAH14 Missense Moderate 35 
7:111430638:G:A 5 rs377187510 DOCK4 Missense Moderate 28.8 
7:111617307:G:A 5 rs201242965 DOCK4 Missense Moderate 23.1 
7:111503433:T:C 5 Novel DOCK4 Missense Moderate 22.3 
9:133932442:C:T 7 rs113443891 LAMC3 Missense Moderate 17.7 
9:133945155:G:A 7 rs113785045 LAMC3 Missense Moderate 16.9 
9:133936490:A:G 6 rs36030184 LAMC3 Missense Moderate 12.0 
9:133948124:G:A 5 rs144118534 LAMC3 Missense Moderate 4.0 
14:64898328:A:G 6 rs139264994 MTHFD1 Missense Moderate 21 
14:64884726:C:T 6 rs199501976 MTHFD1 Missense Moderate 17.1 
14:64916188:C:T 6 rs17857382 MTHFD1 Missense Moderate 11.2 
1:228526693:C:T 5 rs370778898 OBSCN Missense Moderate 27.4 
1:228558959:G:A 5 rs191931829 OBSCN Missense Moderate 17.3 
1:228437675:C:T 5 rs199655077 OBSCN Missense Moderate 0.1 


















14:88892697:G:A 6 rs17124662 SPATA7 Missense Moderate 2.3 
14:88883100:A:G 6 rs61747004 SPATA7 Missense Moderate 2.1 
14:88895750:G:A 6 rs17124677 SPATA7 Missense Moderate 0.002 
14:88883173:T:G 5 rs35137272 SPATA7 Missense Moderate 0.02 
1:1269488:G:A 6 rs112507608 TAS1R3 Missense Moderate 6.3 
1:1268954:C:T 5 rs200679891 TAS1R3 Missense Moderate 11.0 
1:1268661:G:A 5 rs373494410 TAS1R3 Missense Moderate 10.7 
2:179499179:A:G 9 rs34706299 TTN Missense Moderate 22.1 
2:179412829:C:T 6 rs72648251 TTN Missense Moderate 16.2 
2:179452061:C:T 5 rs199505416 TTN Missense Moderate 21.6 
2:179457733:G:A 5 rs72646839 TTN Missense Moderate 20.1 
2:179440609:A:G 5 rs201836227 TTN Missense Moderate 18.8 




Table S2.8 High impact rare variants genome-wide with a MAC ≥ 7 and 








7:150389837:TC:T 10 GIMAP2 Novel Frameshift High 5.92 
19:39926486:A:G 8 RPS16 rs139109626 Splice donor High 22.4 
11:5758174:CAATT:C 8 OR56B1 Novel Frameshift High 14.8 
10:16979600:TGGTA:T 7 CUBN rs556462218 Frameshift High 40.0 
10:25313667:T:A 7 THNSL1 rs150653385 Stop gained High 37.0 
1:63063592:GAACTC:
G 
7 ANGPTL3 Novel Frameshift High 21.0 
17:72350672:C:T 7 KIF19 rs200837156 Stop gained High 20.6 
1:21904139:TG:T 7 ALPL Novel Frameshift stop 
lost 
High 12.9 











Figure S2.2 Haplotype Analysis of the rare NOTCH3 rs149307620 variant. All 10 subjects who have the 
rs149307620 mutation (marker 269) possess the GCCGC haplotype derived from five common SNPs (rs1548555, 
rs1044006, rs1043997, rs1043996, and rs1043994) spanning a region of ~24.8 kb. The haplotype has a frequency 
of 15.4% in AD cases and 14.7% in controls. Haplotypes and their corresponding frequencies are shown in the left 






Figure S2.3: Population substructure of the ADSP discovery sample. Population substructure in the non-
Hispanic European ancestry portion of the ADSP sample was evaluated by principal components (PC) analysis 
implemented in EIGENSTRAT79,80 using the smartpca program as described previously.2 For this analysis, variants 
were selected based on the following filtering criteria: MAF≥5%, call rate≥99%, and only one from each pair of 
variants with linkage disequilibrium (LD) of r2>0.5 in a 50-variant window. Participants with individual call rate<90% 
were excluded, and only one participant from every pair with estimated !">0.2 was selected. PCs were computed 
using the 1000 Genomes Phase 3 reference panel6 and a subset of 12,351 variants that met the above criteria and 
were found in both ADSP and 1000G subjects. PCs were computed using all unrelated ADSP and 1000G subjects 
and projected on individuals that were omitted from the PC computation due to high IBD or low call rate. The plot of 
the first two PCs (PCA1 and PCA2) shows that participants (each represented by a small dot) are distributed along 
a population substructure gradient. A large portion of the persons in the cluster on the right side of the plot 
(PC1>0.025) have a mitochondrial haplogroup (K1a1b1a = light blue dots, K1a9 = dark blue dots) that is common 
among Ashkenazi Jews suggesting that this cluster includes primarily Ashkenazi Jews. Eight of the ten AD 
participants who have the NOTCH3 rs149307620 mutation, including four persons with the K1a1b1a or K1a9 
haplogroup (dark red + symbol) and four persons lacking either Ashkenazi haplogroup (brown + symbol), are 














Figure S2.4 Haplotype Analysis of ABCD4 and CELSR1/GTSE1. A. All 10 subjects with ABCD4 rare variants 
rs57773157 (marker 55), rs34992370 (marker 130), and rs58272575 (marker 158) share an 8-SNP haplotype 
spanning ~12.9 kb that has a frequency of 0.3% in AD cases and 0% in controls. Eight of these subjects also have 
a fourth ABCD4 rare variant, rs61744947 (marker148) that is part of the same shared haplotype. B. All eight 
subjects with CELSR1 variants rs61741871 (marker 268) and rs75983687 (marker345) and GTSE1 variants 
rs34404175 (marker 74) and rs35503220 (marker84) share a 12 SNP-haplotype spanning ~77.6 kb that has a 
frequency of 0.1% in the ADSP population (0.1% in cases, 0.1% in controls). Haplotypes and their corresponding 
frequencies are shown on the left side of each panel. A measure of linkage disequilibrium (D’) between each pair of 














Table S3.1. Characteristics of subjects in the ROSMAP and ADNI datasets 
 
 
      
AD 








Dataset Race N 
ROSMAP  98% Caucasian, 






(4.8) 26% (Brain) 
2% African 
American, 
  < 0.01 % other 
ADNI 93% Caucasian, 






(8.1) 40.5% (Blood) 
4% African 
American, 




Table S3.2. Gene-level cis rare eQTL significant results in brain 
 
CHR BEGIN POS END POS NUM PASS VARS NUM SING VARS STATRHO P-VALUE GENE 
5 22985688 25142892 177 113 0 4.56E-49 C5orf17 
16 27512608 29486403 269 169 0 1.69E-30 IL27 
6 29051606 31043360 426 220 0 7.71E-27 RNF39 
19 18779631 20736620 248 173 0 2.19E-22 ZNF101 
1 147741039 149755790 186 69 0 2.42E-21 NBPF16 
4 89823539 91848018 153 96 0 1.49E-19 MMRN1 
19 18977711 20990019 221 155 0 7.45E-19 ZNF253 
1 25378602 27385983 482 320 0 1.96E-16 TRIM63 
9 138266509 140255330 553 352 0 7.16E-16 DNLZ 
7 43155135 45148545 252 162 0 1.56E-13 POLD2 
2 169503264 171547270 343 205 0 1.85E-13 CCDC173 
11 103966694 105967614 107 68 0 6.73E-13 CARD17 
14 73016786 75002697 423 267 0 2.34E-12 ACOT1 
16 13847527 15857759 298 191 0 1.64E-11 NPIPA2 
1 149958668 151965171 540 352 0 1.83E-11 ANXA9 
4 43689060 45457518 69 40 0 2.49E-11 GUF1 
16 69333666 71398570 474 316 0 3.54E-11 
RP11-
529K1.3 
15 81558119 83561556 184 106 0 6.95E-11 FAM154B 
1 53492087 55481065 460 281 0 1.06E-10 LDLRAD1 
7 127418124 129414750 519 310 0 1.07E-10 OPN1SW 
6 27300777 29323838 369 221 0 1.22E-10 ZSCAN31 
14 73783107 75825914 482 303 0 1.87E-10 VRTN 
19 9406430 11373256 444 293 0 1.87E-10 ICAM4 
6 29051606 31002490 425 219 0 2.38E-10 ZNRD1 
2 24400738 26360191 286 180 0 2.72E-10 POMC 
16 17417023 19440804 267 149 0 4.61E-10 NPIPA8 
6 31783750 33784748 926 480 0 1.24E-09 HLA-DOB 
2 60375560 62373811 538 337 0 1.65E-09 C2orf74 
12 53696863 55726368 853 532 0 1.81E-09 COPZ1 
16 71090452 73094829 741 461 0 2.28E-09 HP 
11 112263796 114271056 464 266 0 2.34E-09 ANKK1 
19 1941163 3942240 400 276 0 1.41E-08 ZNF77 
6 31496752 33476802 1053 565 0 3.58E-08 HLA-DRB5 
1 247920924 249234675 158 88 0 8.53E-08 LYPD8 
15 64039999 66063761 404 249 0 9.90E-08 RBPMS2 
12 9980142 11951867 155 98 0 1.02E-07 TAS2R9 
2 95333119 96830428 153 88 0 1.10E-07 ZNF514 
1 227399406 229357415 255 176 0 1.20E-07 C1orf145 
6 28909389 30908847 458 238 0 2.02E-07 HLA-A 




11 17434230 19468040 429 273 0 2.07E-07 LDHC 
22 41523734 43525652 369 245 0 2.49E-07 CYP2D6 
16 71090452 73110685 755 468 0 2.80E-07 HPR 
1 149349077 151447295 508 334 0 3.36E-07 RPRD2 
12 49721015 51789242 429 284 0 4.37E-07 FAM186A 
8 26682344 28667180 197 127 0 4.71E-07 ESCO2 
7 63347619 65355768 132 51 0 5.07E-07 ZNF273 
6 34447206 36438023 417 258 0 5.55E-07 RPL10A 
12 20680554 22677495 165 112 0 6.47E-07 C12orf39 
12 9062912 11038219 163 106 0 7.21E-07 KLRF2 
2 157116105 159166135 545 334 0 8.96E-07 GALNT5 
2 131958523 134009777 395 157 0 1.04E-06 ANKRD30BL 
1 39240400 41236581 492 310 0 1.69E-06 OXCT2 
14 44615125 46540143 233 140 0 1.73E-06 PRPF39 
6 82920251 85135804 241 160 1 1.79E-06 ME1 
1 44966476 46963603 600 383 0 1.85E-06 CCDC163P 
6 41942338 43929364 671 437 0 1.85E-06 GNMT 
10 62424318 64520825 669 426 0 1.95E-06 C10orf107 
6 31548925 33554557 1027 545 0 1.98E-06 HLA-DRB1 
16 67034867 69106452 714 482 0 1.98E-06 DUS2 
21 46707826 48118123 184 132 0 2.06E-06 YBEY 
6 30104753 32098106 830 448 0 2.49E-06 PSORS1C1 
14 74522315 76532783 500 308 0 2.53E-06 ACYP1 
22 36513231 38505189 446 289 0 2.64E-06 TMPRSS6 
7 35121219 37109559 238 133 0 3.24E-06 PP13004 
        
BEGIN POS : Beginning position of range for rare variants within 1 Mb of gene to be 
tested   
END POS : End position of range for rare variants within 1 Mb of gene to be tested   
NUM PASS VARS : Number of variants passing all thresholds for EPACTS software   
NUM SING VARS : Number of singletons among variants in NUM PASS 
VARS    
P-VALUE : P-value of burden 
tests      






Table S3.3. Gene-level cis rare eQTL significant results in blood 
 
CHR BEGIN POS END POS NUM PASS VARS NUM SING VARS STATRHO P-VALUE GENE 
11 70732846 72788214 555 359 0 6.01E-76 NUMA1 
2 170670625 172715732 637 363 0 1.49E-58 GAD1 
2 38209429 40345697 564 330 0 3.58E-48 SOS1 
7 55086655 57078144 158 102 0 2.29E-46 PSPH 
15 64039217 66064168 648 417 0 1.69E-36 RBPMS2 
2 85255429 87306752 528 333 0 3.04E-33 POLR1A 
17 78478854 80486162 791 535 0 5.77E-33 ACTG1 
5 51776562 53780492 582 357 0 4.02E-30 FST 
5 80571352 82573932 456 258 0 4.59E-29 RPS23 
12 123127921 125140714 635 411 0 9.87E-25 GTF2H3 
16 61524 1818783 808 529 0 1.63E-23 MSLN 
1 235681939 237713976 298 190 0 4.18E-23 LGALS8 
11 58939168 60942636 376 235 0 1.77E-22 MS4A6A 
8 132594914 134686827 307 192 0 2.55E-22 LRRC6 
1 9273158 11431909 1133 680 0 4.49E-21 KIF1B 
16 66485047 68513436 1116 744 0 9.74E-21 ATP6V0D1 
8 40131993 42165247 339 209 0 2.16E-20 SFRP1 
19 11036366 13088848 764 481 0 2.77E-20 ZNF763 
19 54671887 56671530 753 470 0 3.58E-20 DNAAF3 
17 71548271 73539560 784 472 0 6.33E-20 CD300C 
3 45557584 47620971 534 333 0 1.06E-19 LRRC2 
8 16021574 18080407 471 269 0 2.35E-19 ZDHHC2 
1 16393711 18445005 861 505 0 2.39E-19 PADI2 
17 79202744 81187821 773 520 0 7.46E-19 CSNK1D 
12 56404058 58422458 1451 906 0 1.29E-18 TAC3 
19 15989593 17988883 604 378 0 1.48E-18 SIN3B 
12 52215270 54223128 1347 802 0 4.65E-18 KRT79 
6 42023280 44026915 1038 652 0 2.20E-17 MRPL2 
6 41847740 43856400 1027 650 0 2.73E-17 RPL7L1 
1 24690676 26756608 745 472 0 3.35E-17 RHCE 
2 134813827 136932159 453 299 0 9.16E-17 RAB3GAP1 
1 201322470 203559602 728 478 0 1.22E-16 PPP1R12B 
16 1004369 2990074 1034 705 0 2.07E-16 RPL3L 
16 3522828 5543890 732 481 0 3.29E-16 NMRAL1 
17 28295809 30326755 480 298 0 1.33E-15 RNF135 
19 50630649 52626166 718 444 0 4.39E-15 SIGLEC9 
11 64647848 66650805 1295 869 0 5.37E-15 CTSW 
14 23440850 25472286 1326 849 0 7.75E-15 DHRS4L2 




11 70829916 72849142 553 361 0 1.24E-14 FOLR3 
9 110708672 112769529 599 366 0 1.24E-14 CTNNAL1 
1 9063435 11072775 1017 603 0 1.27E-14 RBP7 
4 5696136 7691291 292 190 0 2.98E-14 S100P 
15 67500977 69549021 704 452 0 4.46E-14 CLN6 
12 90496808 92504168 316 197 0 4.48E-14 LUM 
10 98528249 100529570 806 502 0 7.89E-14 SFRP5 
17 4195862 6288615 836 493 0 1.66E-13 RABEP1 
2 131234265 133248784 299 154 0 3.40E-13 MZT2A 
14 23424341 25438339 1335 851 0 4.37E-13 DHRS4 
16 85563797 87574899 545 338 0 4.92E-13 MTHFSD 
18 10989050 13030533 208 132 0 8.70E-13 IMPA2 
14 22034663 24048442 1162 730 0 8.93E-13 DAD1 
6 142384452 144659265 640 383 0 1.48E-12 AIG1 
5 56787482 58785678 296 177 0 2.15E-12 GAPT 
10 10786278 12803023 418 261 0 2.21E-12 ECHDC3 
2 84822866 86820639 537 346 0 2.46E-12 RNF181 
15 32058221 34486766 535 313 0 3.45E-12 FMN1 
4 56678367 58679994 501 295 0 3.49E-12 SPINK2 
6 137727849 139741886 561 347 0 4.07E-12 HEBP2 
6 28641615 30648131 571 303 0 4.25E-12 ZFP57 
1 16639761 18688663 821 473 0 4.77E-12 PADI4 
8 58499893 60572308 638 405 0 4.91E-12 NSMAF 
1 248112311 249234888 192 107 0 4.95E-12 SH3BP5L 
16 88786822 90291311 527 364 0 5.33E-12 ZNF276 
3 108047845 110054553 288 167 0 1.36E-11 DPPA4 
17 72937650 74962382 1013 668 0 1.56E-11 ACOX1 
10 59029408 61044084 351 203 0 1.67E-11 CISD1 
13 49236382 51263464 433 280 0 2.18E-11 EBPL 
14 22356192 24354883 1116 697 0 2.23E-11 REM2 
16 71089779 73094855 1206 750 0 2.43E-11 HP 
1 45869064 47878616 675 422 0 3.11E-11 FAAH 
19 51125939 53117574 543 342 0 3.20E-11 SIGLEC5 
5 111871020 113925487 405 243 0 4.23E-11 YTHDC2 
17 45623285 47623015 1361 872 0 4.44E-11 HOXB2 
19 47551714 49613137 887 559 0 6.68E-11 PLA2G4C 
4 73981642 76158280 209 135 0 7.03E-11 MTHFD2L 
1 166886211 168890090 377 228 0 7.80E-11 MPC2 
19 54104530 56098746 761 477 0 8.53E-11 LILRA2 
14 95858598 97952756 587 349 0 9.50E-11 AK7 
19 39358860 41439248 890 573 0 1.22E-10 FCGBP 




6 30380084 32375324 1233 679 0 1.82E-10 MICA 
1 149768998 151780099 936 581 0 1.87E-10 CTSK 
7 74626276 76669255 392 240 0 1.90E-10 STYXL1 
1 172873123 174883270 257 166 0 2.15E-10 SERPINC1 
1 19923475 21944440 460 272 0 2.15E-10 CDA 
19 10407094 12432117 704 470 0 2.16E-10 TSPAN16 
13 30317837 32332540 297 197 0 2.20E-10 ALOX5AP 
11 17434219 19472162 762 473 0 2.25E-10 LDHC 
17 37119254 39123468 1169 766 0 2.26E-10 GSDMA 
1 26323663 28326247 1184 776 0 2.26E-10 TRNP1 
10 91985080 94041672 410 267 0 2.28E-10 PCGF5 
17 44908286 46908429 1201 762 0 2.30E-10 MRPL10 
1 27696376 29823421 865 543 0 2.31E-10 PHACTR4 
1 24603413 26656184 711 436 0 2.32E-10 RHD 
4 94375046 96572455 673 395 0 2.32E-10 PDLIM5 
8 143956369 145948440 1209 826 0 2.40E-10 EPPK1 
3 125247802 127261444 317 208 0 2.47E-10 CHST13 
1 45161902 47213565 840 526 0 2.50E-10 IPP 
6 31136994 33145709 1239 619 0 2.55E-10 AGPAT1 
8 104345075 106478376 634 403 0 2.61E-10 DPYS 
2 69198931 71188824 509 312 0 2.70E-10 ASPRV1 
8 27461825 29603179 454 293 0 2.71E-10 EXTL3 
14 23780665 25780153 1063 669 0 2.90E-10 LTB4R 
1 202148429 204146674 594 373 0 3.13E-10 CHI3L1 
11 57296270 59344358 477 287 0 3.41E-10 LPXN 
2 160129032 162348252 912 534 0 3.42E-10 RBMS1 
6 30804471 32797847 1199 609 0 3.63E-10 HSPA1B 
6 9732498 11723589 611 368 0 3.67E-10 TMEM14C 
1 115186162 117240389 538 297 0 4.12E-10 VANGL1 
14 100008504 102050746 495 316 0 4.31E-10 BEGAIN 
11 119899661 121959886 692 433 0 5.25E-10 TBCEL 
1 205811842 207857291 559 337 0 5.47E-10 DYRK3 
4 87236280 89236066 352 230 0.1 6.33E-10 HSD17B13 
17 57125174 59155836 569 365 0.1 7.05E-10 HEATR6 
13 99260793 101548733 710 450 0 8.03E-10 CLYBL 
17 36619104 38719889 1321 853 0 1.53E-09 CDK12 
12 12134087 14147562 553 341 0 1.85E-09 HEBP1 
2 41990355 43989525 848 550 0.1 1.91E-09 OXER1 
17 73671194 75695368 747 477 0 2.24E-09 MXRA7 
6 159559020 161575294 277 176 0 2.31E-09 SLC22A1 
16 87881845 89877462 610 420 0 2.58E-09 APRT 




17 72258136 74262187 1074 697 0 3.57E-09 MRPS7 
6 51767239 53772775 414 260 0 3.93E-09 GSTA3 
6 70386105 72558800 365 223 0 4.05E-09 SMAP1 
11 65101255 67092273 1198 806 0 4.14E-09 RIN1 
1 92914779 95018518 493 307 0 5.56E-09 FNBP1L 
6 95509 1689616 331 208 0 6.19E-09 EXOC2 
10 45330925 47149308 284 163 0 6.59E-09 AGAP4 
22 40982244 42983560 667 434 0 6.98E-09 PMM1 
2 25624804 27679481 765 513 0 6.99E-09 DRC1 
4 109967852 112118290 612 378 0 7.14E-09 ELOVL6 
10 124767496 126850278 691 446 0 7.45E-09 CHST15 
22 18171776 20267960 610 373 0 9.78E-09 CLTCL1 
19 57982233 59117009 332 223 0 9.98E-09 ZNF324 
17 4402946 6515456 856 502 0 9.99E-09 NLRP1 
6 31165563 33157187 1240 622 0 1.10E-08 PBX2 
5 68370276 70370070 155 99 0 1.14E-08 SMN2 
3 47641477 49644176 779 538 0 1.18E-08 UQCRC1 
1 63063031 65124457 901 540 0 1.23E-08 PGM1 
5 110478344 112742221 502 314 0 1.23E-08 EPB41L4A 
17 76071253 78084624 639 405 0 1.25E-08 ENGASE 
3 47727545 49776626 933 637 0 1.30E-08 IP6K2 
16 65613470 67606351 904 543 0 1.33E-08 CMTM2 
3 93531524 94824356 202 117 0 1.39E-08 NSUN3 
14 22386204 24381055 1113 696 0 1.45E-08 RBM23 
8 144162639 146157862 1223 836 0 1.47E-08 MAF1 
5 130148476 132342594 474 288 0 1.54E-08 ACSL6 
17 57228408 59246103 625 390 0.1 1.55E-08 CA4 
11 9595099 11694454 663 385 0 1.79E-08 MRVI1 
10 110972056 113044163 567 322 0 1.79E-08 MXI1 
19 38293794 40288129 827 546 0 2.29E-08 LGALS4 
6 33760232 35848956 702 422 0 2.41E-08 UHRF1BP1 
12 120205104 122340955 867 537 0 2.68E-08 SPPL3 
4 185325054 187341177 353 225 0 2.70E-08 UFSP2 
7 129002356 130996151 533 353 0 2.70E-08 CPA5 
2 238758634 240770102 259 167 0 2.71E-08 TWIST2 
3 40291822 42996549 516 323 0 3.16E-08 ULK4 
17 73559874 75569998 802 528 0 3.27E-08 ST6GALNAC2 
4 73741064 75730068 213 142 0 3.35E-08 CXCL1 
1 150594650 152671502 825 497 0 3.36E-08 SNX27 
6 107882857 109999117 674 398 0 3.43E-08 FOXO3 
1 160555781 162646901 644 408 0 3.48E-08 FCGR2B 




17 43594358 45656854 375 252 0.1 3.69E-08 ARL17A 
17 47622779 49627679 1059 684 0 3.80E-08 SPATA20 
7 27339266 29865343 1008 571 0 4.00E-08 CREB5 
11 73529551 75657980 592 373 0 4.13E-08 XRRA1 
17 29814935 31814120 536 331 0 4.20E-08 CDK5R1 
15 54507848 56588718 359 227 0 4.29E-08 RAB27A 
17 71466756 73477465 720 436 0 5.25E-08 CD300A 
2 218135421 220200383 1140 691 0 5.41E-08 PNKD 
12 93963526 96040830 461 286 0.1 5.71E-08 TMCC3 
16 67022599 69106642 1085 723 0 6.41E-08 DUS2 
14 66767726 68826014 668 399 0 7.13E-08 ATP6V1D 
17 3618219 5622505 866 520 0 7.16E-08 ARRB2 
8 143390000 145325695 952 630 0 7.36E-08 TOP1MT 
5 51089439 53090866 561 358 0 7.58E-08 PELO 
11 64591825 66627942 1340 902 0.1 7.69E-08 CFL1 
1 27099837 29149659 924 584 0 8.19E-08 STX12 
1 5484853 7519049 719 443 0 8.78E-08 ESPN 
14 22433584 24425349 1108 692 0 8.89E-08 HAUS4 
22 31018975 33057577 584 357 0.1 9.31E-08 PISD 
11 87017 1756583 705 467 0 1.03E-07 TALDO1 
17 65256227 67417142 461 287 0 1.05E-07 ARSG 
12 80187578 82318213 427 261 0 1.05E-07 LIN7A 
6 143263546 145384478 486 290 0 1.18E-07 PLAGL1 
1 6906518 8909025 566 346 0 1.20E-07 UTS2 
4 145414020 147472940 727 462 0 1.22E-07 SMAD1 
3 121097698 123094128 484 315 0 1.25E-07 CCDC58 
6 29691139 31691972 840 448 0 1.30E-07 TUBB 
22 24616059 26622220 397 230 0 1.39E-07 CRYBB2 
8 16916427 18942485 422 259 0 1.46E-07 ASAH1 
14 64382441 66410464 632 397 0 1.48E-07 CHURC1 
5 140338131 142362129 1483 888 0 1.55E-07 RNF14 
8 27752679 29921408 443 283 0 1.58E-07 HMBOX1 
15 63448627 65449169 592 369 0 1.62E-07 SNX22 
6 34268704 36287380 677 413 0.1 1.64E-07 DEF6 
4 102792767 104802130 260 153 0 1.65E-07 CISD2 
1 206223875 208226181 599 362 0.1 1.67E-07 YOD1 
6 31782661 33805117 1338 711 0 1.71E-07 TAP2 
13 42600260 44682911 537 311 0 1.84E-07 DNAJC15 
1 204197394 206239482 788 505 0 1.90E-07 TMCC2 
4 355156 2349969 607 410 0.1 1.99E-07 UVSSA 
20 32826904 34862608 801 528 0 2.04E-07 MMP24 




9 122366515 124476684 763 445 0.1 2.14E-07 MEGF9 
2 134214696 136473148 448 287 0 2.15E-07 TMEM163 
20 43644056 45644897 761 468 0 2.38E-07 MMP9 
1 177994997 180044282 426 274 0 2.45E-07 FAM20B 
20 42882351 44881207 776 480 0 2.54E-07 SLPI 
10 72976939 74995025 650 376 0 2.55E-07 ANAPC16 
2 190212419 192235016 455 269 0 2.65E-07 INPP1 
6 41933605 43930372 1006 640 0 2.87E-07 GNMT 
4 100946158 103267117 256 149 0 2.97E-07 PPP3CA 
12 95367236 97389685 452 268 0 3.21E-07 HAL 
20 352623 2370071 516 308 0 3.38E-07 FKBP1A 
15 39736969 41758372 821 505 0 3.40E-07 BAHD1 
16 83734456 85813446 604 402 0.1 3.50E-07 USP10 
19 35399151 37398939 727 493 0 3.95E-07 TYROBP 
6 40205095 42206259 725 442 0 4.00E-07 TREML4 
11 129746599 131784377 801 481 0 4.02E-07 SNX19 
1 32790316 34896636 818 492 0 4.13E-07 PHC2 
12 132498057 133812414 294 184 0 4.29E-07 ZNF605 
7 131940825 134743940 832 495 0 4.36E-07 EXOC4 
19 38227885 40225031 839 554 0 4.39E-07 CAPN12 
7 140610651 142797254 521 329 0 4.40E-07 MGAM 
2 196636499 198664059 398 251 0 4.51E-07 GTF3C3 
7 75027314 77069054 463 285 0 4.62E-07 ZP3 
17 35337731 37357506 1003 604 0 4.76E-07 TBC1D3 
11 73041373 75107265 622 378 0 4.77E-07 PGM2L1 
6 132067998 134083309 668 391 0 4.82E-07 VNN2 
18 11309303 13338617 228 142 0.1 4.89E-07 TUBB6 
15 34509923 36838075 1135 670 0 5.06E-07 DPH6 
7 79006735 81304532 336 206 0 5.18E-07 CD36 
10 96480229 98636823 518 312 0 5.87E-07 ENTPD1 
5 175735135 177733908 734 455 0 6.02E-07 PRELID1 
16 68379570 70384938 760 474 0 6.25E-07 TMED6 
11 66071832 68076009 988 631 0 6.50E-07 SSH3 
3 10319976 12598571 492 295 0 6.59E-07 ATG7 
22 41909029 43914449 574 353 0 6.62E-07 RRP7A 
1 35622514 37612017 829 504 0 6.73E-07 TRAPPC3 
1 27218969 29241192 869 544 0 7.24E-07 RPA2 
1 149570886 151527784 889 548 0 7.32E-07 ADAMTSL4 
14 20757422 22802797 753 498 0 7.32E-07 RPGRIP1 
17 72205444 74223068 1081 702 0 7.52E-07 NUP85 
17 6483131 8479918 1589 1010 0 7.97E-07 CD68 




2 27615681 29637653 625 397 0 8.13E-07 FOSL2 
1 9097709 11240589 1095 654 0 8.28E-07 UBE4B 
1 153934779 155946585 1104 742 0.1 8.31E-07 SHC1 
18 27649902 29679343 402 260 0 8.36E-07 DSC2 
15 90427393 92438801 463 312 0 8.85E-07 FES 
16 1080758 3088511 1096 747 0 9.06E-07 SLC9A3R2 
7 126672632 128669786 916 580 0.1 9.14E-07 LRRC4 
10 71437956 73521781 659 379 0 9.49E-07 ADAMTS14 
12 68082264 70134035 301 190 0 9.55E-07 NUP107 
20 41091953 43090684 566 334 0 9.59E-07 SRSF6 
6 2154405 4151062 352 207 0 9.62E-07 TUBB2A 
17 78527249 80615149 813 545 0 1.00E-06 NPLOC4 
12 73945391 75920901 258 176 0 1.03E-06 ATXN7L3B 
18 2069112 4219138 251 154 0 1.13E-06 MYOM1 
6 29716711 31712032 854 453 0.1 1.21E-06 IER3 
1 118574322 120678835 580 357 0 1.26E-06 WARS2 
19 60658 2061656 1011 666 0 1.46E-06 ABCA7 
14 69517619 71641508 513 316 0 1.52E-06 SLC8A3 
17 45632482 47681054 1409 906 0.1 1.54E-06 HOXB3 
16 56507237 58519628 607 372 0 1.59E-06 DOK4 
1 9460183 11474259 1077 646 0 1.59E-06 PGD 
7 74163379 76368084 364 231 0 1.62E-06 HIP1 
22 19076970 21097036 557 357 0 1.63E-06 DGCR8 
20 59758487 61777231 448 279 0 1.80E-06 MTG2 
15 73836546 75890284 695 441 0.1 1.83E-06 ARID3B 
9 69994568 72144275 439 256 0 1.85E-06 PGM5 
18 8481285 10532788 353 232 0 1.86E-06 RALBP1 
3 156825879 159260741 886 540 0 1.89E-06 RSRC1 
7 75761306 77958641 498 316 0 1.91E-06 CCDC146 
3 43756435 45761010 351 228 0 1.95E-06 ZNF502 
2 23301174 25306970 730 458 0 2.01E-06 TP53I3 
19 54105293 56113555 768 479 0 2.04E-06 LILRA1 
1 224999010 227009199 398 234 1 2.07E-06 EPHX1 
6 41933605 43941175 1010 641 0 2.10E-06 PEX6 
3 49653871 51680484 962 627 0 2.11E-06 MAPKAPK3 
3 194947440 197014817 434 255 0 2.11E-06 PCYT1A 
7 63475980 65447211 195 108 0 2.16E-06 ZNF117 
20 24246411 26248963 154 89 0 2.21E-06 PYGB 
1 14487336 16546747 646 429 0 2.24E-06 TMEM51 
6 159237508 161238481 275 175 0 2.27E-06 PNLDC1 
1 20072025 22110160 439 261 0 2.37E-06 HP1BP3 




5 175912923 177923756 701 435 0 2.45E-06 PDLIM7 
1 170222420 172253389 459 293 0 2.49E-06 FMO1 
17 36921986 39020028 1232 802 0 2.51E-06 IKZF3 
19 3358556 5358897 727 481 0 2.53E-06 MPND 
1 39542280 41562630 883 545 0 2.57E-06 PPT1 
12 55614925 57615493 1157 716 0 2.58E-06 RNF41 
16 19636366 21709125 516 295 0 2.64E-06 ACSM1 
13 110295378 112345853 199 128 0 2.66E-06 CARS2 
5 174786329 176787075 507 303 0 2.78E-06 KIAA1191 
13 43398858 45449542 478 281 0 2.81E-06 CCDC122 
22 44559753 46567121 336 209 0.1 2.83E-06 NUP50 
22 23590811 25581023 428 260 0 2.89E-06 SUSD2 
8 144637367 146293075 1098 759 0 2.94E-06 SLC39A4 
14 50002945 52097847 565 360 0 2.98E-06 ATL1 
7 28038024 30228621 760 431 0 3.09E-06 CPVL 
15 88632760 90744964 697 441 0 3.11E-06 ABHD2 
        
BEGIN POS : Beginning position of range for rare variants within 1 Mb of gene to be tested  
END POS : End position of range for rare variants within 1 Mb of gene to be tested   
NUM PASS VARS : Number of variants passing all thresholds for EPACTS software   
NUM SING VARS : Number of singletons among variants in NUM PASS VARS   
P-VALUE : P-value of burden tests      






Table S3.4. Individual Gene-SNP eQTL significant results in brain 
 
Gene SNP P-value 
RP11-529K1 16:69600184 <1.0E-314 
ZNF101 19:19120659 3.96E-61 
COPZ1 12:54520272 1.30E-54 
COPZ1 12:53853136 1.30E-54 
COPZ1 12:54367799 1.30E-54 
COPZ1 12:54511341 1.30E-54 
COPZ1 12:54986339 1.30E-54 
TMPRSS6 22:38340452 1.68E-52 
TMPRSS6 22:38206144 1.68E-52 
TMPRSS6 22:38093050 1.68E-52 
LDLRAD1 1:55481065 1.02E-42 
ZNF253 19:19120659 7.47E-36 
VRTN 14:73943427 1.88E-35 
TMPRSS6 22:37823469 1.91E-34 
GALNT5 2:157192762 1.85E-32 
ICAM4 19:10742166 6.67E-30 
OPN1SW 7:128499675 1.04E-27 
RP11-529K1 16:70512234 6.26E-23 
TAS2R9 12:11802124 7.77E-23 
RPL10A 6:34462967 5.50E-18 
RPL10A 6:35543534 5.50E-18 
TMPRSS6 22:38412776 5.99E-17 
TRIM63 1:26869683 1.51E-16 
TRIM63 1:27028031 1.51E-16 
ZNF101 19:19529415 2.13E-16 
COPZ1 12:54623909 3.80E-15 
TRIM63 1:26872452 3.80E-15 
TRIM63 1:26485547 3.80E-15 
TRIM63 1:26560692 3.80E-15 
KLRF2 12:9268393 1.12E-12 
CARD17 11:104480278 1.19E-12 
VRTN 14:75707465 1.30E-12 
VRTN 14:75686993 1.30E-12 
ICAM4 19:10781827 4.81E-12 
ICAM4 19:10952607 2.62E-11 
ICAM4 19:11319636 7.40E-11 
TMPRSS6 22:36678827 8.40E-11 
ZNF253 19:19529415 3.43E-10 




FAM186A 12:51566637 1.59E-09 
DNLZ 9:139694595 1.92E-09 
C5orf17 5:23132477 3.25E-09 
GALNT5 2:157861592 5.11E-09 
LDLRAD1 1:54200597 6.58E-09 
OPN1SW 7:127668180 6.68E-09 
RPL10A 6:35436943 7.99E-09 
OPN1SW 7:127560949 2.14E-08 
C5orf17 5:24322422 3.23E-08 
POLD2 7:43489734 5.54E-08 
POMC 2:24583125 8.95E-08 
GALNT5 2:157716598 9.43E-08 
POLD2 7:44646209 1.23E-07 
C2orf74 2:60683420 2.32E-07 
C2orf74 2:60753967 2.32E-07 
DNLZ 9:140082242 6.08E-07 
OPN1SW 7:127696479 7.98E-07 
COPZ1 12:54673746 1.21E-06 
ICAM4 19:11034582 1.30E-06 
OPN1SW 7:128494922 1.41E-06 
LDHC 11:17867845 1.60E-06 




Table S3.5. Individual Gene-SNP eQTL significant results in blood 
 
Gene SNP P-value   Gene SNP P-value 
 MTHFD2L 4:74241201 4.09E-163   DAD1 14:23041489 2.70E-53 
MTHFD2L 4:75284312 4.09E-163   DAD1 14:23041518 2.70E-53 
FST 5:52778262 1.20E-147   RBPMS2 15:64991778 3.17E-53 
GAD1 2:171673464 1.09E-145   DPH6 15:34647703 2.61E-52 
GAD1 2:171679654 4.09E-145   DPH6 15:35333208 2.61E-52 
NUMA1 11:71714526 1.17E-133   DPH6 15:35514161 2.61E-52 
MSLN 16:824837 1.04E-114   DPH6 15:36699896 2.61E-52 
NUMA1 11:71822560 1.25E-112   GAD1 2:172144563 4.73E-48 
GAD1 2:171695387 4.06E-111   MS4A6A 11:59863104 4.36E-47 
SFRP1 8:41200160 5.46E-108   LRRC2 3:46878319 6.89E-47 
NUMA1 11:71706544 3.08E-72   ACTG1 17:79477190 1.49E-42 
RPL7L1 6:42857315 3.59E-71   MS4A6A 11:59863253 6.38E-42 
KRT79 12:52291229 5.45E-71   ADAMTS14 10:72509641 2.59E-39 
KRT79 12:52390683 5.45E-71   ADAMTS14 10:72699774 3.12E-39 
KRT79 12:52938512 5.45E-71   ADAMTS14 10:72898175 3.12E-39 
KRT79 12:53575608 5.45E-71   GAD1 2:172641848 8.57E-39 
KRT79 12:53808590 5.45E-71   PLAGL1 6:144385777 2.53E-38 
KRT79 12:53926760 5.45E-71   SFRP5 10:99644019 5.62E-38 
KRT79 12:53952253 5.45E-71   SFRP1 8:41792185 1.02E-37 
KRT79 12:54145225 5.45E-71   SFRP1 8:41154024 8.03E-37 
KRT79 12:52652265 1.10E-70   AK7 14:97272564 8.48E-37 
GAPT 5:57652956 5.01E-68   AK7 14:97399418 8.48E-37 
GAD1 2:171674182 5.88E-68   ACTG1 17:79477575 8.65E-37 
NUMA1 11:71726168 2.06E-64   ACTG1 17:79478617 8.65E-37 
TAC3 12:57398085 4.76E-62   CTSW 11:65631361 1.72E-36 
TAC3 12:57420802 4.76E-62   CTSW 11:65652177 1.72E-36 
TAC3 12:57464587 4.76E-62   CTSW 11:65659093 2.26E-36 
TAC3 12:57472766 4.76E-62   FST 5:52949030 2.98E-35 
TAC3 12:57483769 4.76E-62   KRT79 12:53724748 4.79E-35 
TAC3 12:57490491 4.76E-62   CTSW 11:65640259 1.28E-34 
TAC3 12:57492307 4.76E-62   FAAH 1:46508496 2.14E-34 
TAC3 12:57114418 1.60E-61   FAAH 1:46672262 2.14E-34 
TAC3 12:57115196 1.60E-61   SMAP1 6:71570880 7.55E-33 
TAC3 12:57595605 1.60E-61   SFRP1 8:41196024 1.04E-32 
TAC3 12:57620836 1.60E-61   KRT79 12:52388470 1.06E-32 
TAC3 12:58240986 1.60E-61   KRT79 12:52388505 1.06E-32 
TAC3 12:58347548 1.60E-61   TAC3 12:57865841 4.12E-31 
NUMA1 11:71645655 2.51E-59   DNAAF3 19:54675653 4.99E-30 




TRAPPC3 1:36602202 8.28E-59   DNAAF3 19:56189999 4.99E-30 
DAD1 14:23035455 2.70E-53   LGALS4 19:39616553 9.60E-30 
KRT79 12:54219108 2.51E-29   SLC39A4 8:145639654 1.16E-21 
ADAMTSL4 1:150524878 5.50E-29   IKZF3 17:37957632 1.25E-21 
LGALS8 1:236706278 2.85E-28   TWIST2 2:239772983 1.84E-21 
LGALS8 1:236706300 2.85E-28   KIF1B 1:10408850 2.03E-21 
MTHFSD 16:86603266 6.30E-27   RPL3L 16:1470825 2.25E-21 
FOLR3 11:71720030 1.22E-26   RPL3L 16:2086798 2.25E-21 
KRT79 12:52398857 1.93E-26   RPL3L 16:2223816 2.25E-21 
NMRAL1 16:4536354 3.76E-26   RPL3L 16:2284726 2.25E-21 
LRRC2 3:46140074 1.57E-25   RPL3L 16:2301527 2.25E-21 
KRT79 12:52824349 1.64E-25   CDK12 17:37755725 3.28E-21 
TIAM2 6:155577913 3.31E-25   POLR1A 2:86529625 4.54E-21 
TIAM2 6:155597134 3.31E-25   POLR1A 2:86293004 4.88E-21 
LGALS4 19:39162511 3.55E-25   RBPMS2 15:65042560 5.85E-21 
LGALS4 19:39390531 3.55E-25   PNLDC1 6:159420734 6.31E-21 
LGALS4 19:39804846 3.55E-25   LDHC 11:18627931 8.26E-21 
MPND 19:4359191 4.00E-25   PNLDC1 6:160372070 1.11E-20 
FAAH 1:46032307 6.50E-25   MZT2A 2:132290912 1.17E-20 
KRT79 12:52779003 6.65E-25   ZNF276 16:89644001 1.17E-20 
KRT79 12:52783593 6.65E-25   CSNK1D 17:80202204 1.27E-20 
KRT79 12:53652706 6.65E-25   CCDC146 7:76889524 1.68E-20 
GSDMA 17:38077938 9.23E-25   KIF1B 1:10271628 1.70E-20 
KRT79 12:53846595 1.20E-24   KIF1B 1:10273615 1.70E-20 
KRT79 12:53268234 3.76E-24   KIF1B 1:10314057 1.70E-20 
GTF2H3 12:124068015 3.89E-24   KIF1B 1:10334544 1.70E-20 
PDLIM5 4:95550822 4.48E-24   KIF1B 1:10352228 1.70E-20 
PDLIM5 4:95551261 4.48E-24   KIF1B 1:10357868 1.70E-20 
HSPA1B 6:31852604 6.06E-24   ZNF763 19:12059467 2.09E-20 
TRNP1 1:27272864 6.26E-24   RPS23 5:81013700 3.86E-20 
DPH6 15:34610561 7.39E-24   DNAAF3 19:55670651 4.18E-20 
ZNF276 16:89358050 1.91E-23   DNAAF3 19:55677886 4.18E-20 
FMO1 1:172062702 2.46E-23   GAD1 2:170675959 4.39E-20 
FMO1 1:172062773 2.46E-23   AK7 14:97906815 9.65E-20 
FMO1 1:172094477 2.46E-23   DHRS4L2 14:23468904 1.12E-19 
FMO1 1:172108518 2.46E-23   DHRS4L2 14:23537199 1.12E-19 
IKZF3 17:37938977 2.92E-23   DHRS4L2 14:23572193 1.12E-19 
CLYBL 13:100518634 6.14E-23   DHRS4L2 14:23857458 1.12E-19 
UQCRC1 3:48687271 6.44E-23   DHRS4L2 14:23990308 1.12E-19 
RPL7L1 6:42981633 8.03E-23   DHRS4L2 14:24015983 1.12E-19 
PSPH 7:55759098 9.72E-23   DHRS4L2 14:24523950 1.12E-19 




RPL3L 16:2813177 1.48E-22   DHRS4L2 14:24900671 1.12E-19 
RBPMS2 15:64792896 1.82E-22   DHRS4L2 14:24123454 1.31E-19 
FST 5:52386315 5.79E-22   TMED6 16:69304048 1.84E-19 
LDHC 11:18550693 1.12E-21   MSLN 16:1245453 3.37E-19 
GAD1 2:171568928 3.41E-19   KRT79 12:53899633 8.53E-16 
ADAMTS14 10:72687084 5.05E-19   FOLR3 11:71923660 8.73E-16 
CDK12 17:37557599 5.30E-19   RPL3L 16:2161117 8.97E-16 
GSDMA 17:38062503 7.17E-19   RPL3L 16:2240341 8.97E-16 
MTHFD2L 4:75579573 9.81E-19   LRRC2 3:46033545 1.00E-15 
ZNF276 16:89642150 1.11E-18   CTNNAL1 9:111679940 1.12E-15 
KIF1B 1:10218472 1.29E-18   CTNNAL1 9:111692163 1.12E-15 
SMN2 5:68898565 1.34E-18   CTNNAL1 9:111696795 1.12E-15 
GSDMA 17:37938977 1.37E-18   ABCA7 19:1009413 1.22E-15 
KRT79 12:52913822 1.71E-18   KRT79 12:53207721 1.24E-15 
CDK12 17:37557517 2.50E-18   UTS2 1:8137400 1.29E-15 
TAC3 12:58405892 2.67E-18   DNAAF3 19:54809236 1.38E-15 
KRT79 12:52311687 4.12E-18   SFRP5 10:100008317 1.64E-15 
SOS1 2:40117437 4.41E-18   PSPH 7:55902230 1.73E-15 
GSDMA 17:37957632 5.11E-18   GSDMA 17:38251933 1.80E-15 
FMO1 1:170431347 6.05E-18   PSPH 7:56327785 1.96E-15 
FMO1 1:170443845 6.05E-18   SFRP5 10:100248732 2.12E-15 
LRRC2 3:46759204 7.97E-18   DGCR8 22:20068723 2.18E-15 
CDK12 17:36720974 9.47E-18   RPL7L1 6:43182906 2.28E-15 
LRRC2 3:46786162 1.42E-17   CDK12 17:37792293 2.37E-15 
RPS23 5:82096819 1.49E-17   TAC3 12:57637604 2.39E-15 
RPS23 5:82100144 1.49E-17   TAC3 12:57654608 2.39E-15 
DHRS4L2 14:24647334 1.70E-17   TAC3 12:58120775 2.39E-15 
LRRC2 3:45987980 2.41E-17   KIF1B 1:9976862 3.53E-15 
PELO 5:52074164 3.44E-17   SOS1 2:39187008 3.61E-15 
GSDMA 17:37933468 3.50E-17   TAC3 12:57610460 3.64E-15 
GSDMA 17:37975856 3.50E-17   TAC3 12:57635879 3.64E-15 
DUS2 16:68072004 5.12E-17   TAC3 12:57637127 3.64E-15 
LIN7A 12:81331258 5.31E-17   LRRC2 3:45942686 4.01E-15 
LGALS8 1:236767288 5.94E-17   IKZF3 17:38062503 4.15E-15 
KRT79 12:52284538 6.34E-17   ELOVL6 4:110000229 4.98E-15 
PDLIM5 4:94574633 9.26E-17   ELOVL6 4:110127740 4.98E-15 
SOS1 2:38301803 1.70E-16   ELOVL6 4:110303078 4.98E-15 
IKZF3 17:37933468 2.04E-16   SFRP5 10:100245620 6.68E-15 
IKZF3 17:37975856 2.04E-16   TRNP1 1:27321880 8.18E-15 
TIAM2 6:155649950 2.06E-16   DHRS4L2 14:24457160 1.23E-14 
LPXN 11:58034597 2.86E-16   DPH6 15:35766600 1.48E-14 




POLR1A 2:86563488 3.04E-16   POLR1A 2:86333375 1.91E-14 
POLR1A 2:86832394 3.13E-16   POLR1A 2:87302514 2.27E-14 
MZT2A 2:132218737 3.30E-16   TAC3 12:57589784 2.30E-14 
CCDC122 13:44455493 4.64E-16   TAC3 12:57590869 2.30E-14 
FOLR3 11:71850152 5.31E-16   KIF1B 1:10271490 2.56E-14 
TAC3 12:58235544 7.22E-16   ZFP57 6:29638474 2.65E-14 
GCAT 22:38379774 3.66E-14   LPXN 11:58125774 5.77E-13 
IKZF3 17:37912268 3.79E-14   DNAAF3 19:55995299 5.87E-13 
RPL3L 16:1705955 4.00E-14   RAB3GAP1 2:135960616 6.11E-13 
DNAAF3 19:56369727 4.00E-14   RPL3L 16:1536140 6.24E-13 
DNAAF3 19:56631221 4.00E-14   RHCE 1:24792324 6.34E-13 
DUS2 16:67596482 4.26E-14   ZNF324 19:59082368 6.71E-13 
ZDHHC2 8:17017140 4.39E-14   RHCE 1:26203733 6.92E-13 
DUS2 16:67696365 4.40E-14   CD300C 17:73221439 7.13E-13 
KRT79 12:53729630 4.48E-14   DHRS4 14:23468904 7.25E-13 
RPL7L1 6:43188600 5.41E-14   DHRS4 14:23537199 7.25E-13 
MSLN 16:1560989 5.49E-14   DHRS4 14:23572193 7.25E-13 
UQCRC1 3:48506279 5.68E-14   DHRS4 14:23857458 7.25E-13 
PSPH 7:55944443 5.93E-14   DHRS4 14:23990308 7.25E-13 
TAC3 12:57472762 6.38E-14   DHRS4 14:24015983 7.25E-13 
KRT79 12:53700848 6.38E-14   DHRS4 14:24841978 7.25E-13 
DUS2 16:67860637 6.68E-14   DHRS4 14:24900671 7.25E-13 
DUS2 16:67867739 6.68E-14   CDK12 17:36945701 7.25E-13 
UQCRC1 3:48463799 7.93E-14   MSLN 16:846041 8.78E-13 
RNF181 2:85824251 8.38E-14   CSNK1D 17:79871981 1.05E-12 
RPL3L 16:1262014 9.33E-14   DYRK3 1:207793338 1.07E-12 
DPH6 15:35581602 1.04E-13   NUP107 12:69080770 1.10E-12 
DPH6 15:35673786 1.04E-13   NUP107 12:69080771 1.10E-12 
MTHFSD 16:86539482 1.10E-13   ZNF763 19:12089805 1.16E-12 
SNX22 15:64392388 1.24E-13   GCAT 22:38328597 1.16E-12 
SNX22 15:64392389 1.24E-13   GCAT 22:38221141 1.22E-12 
LGALS4 19:38719246 1.48E-13   DHRS4L2 14:24179039 1.34E-12 
PNLDC1 6:160174463 1.67E-13   DHRS4L2 14:24179040 1.34E-12 
PNLDC1 6:160183445 1.67E-13   SOS1 2:38750325 1.43E-12 
CDK12 17:37826249 1.96E-13   KRT79 12:52984733 1.63E-12 
CDA 1:20960385 2.15E-13   FMO1 1:171605526 1.68E-12 
CDK12 17:36831189 2.31E-13   CSNK1D 17:79892586 1.74E-12 
DHRS4 14:24457160 2.72E-13   DNAAF3 19:56303806 1.75E-12 
GAPT 5:58735345 2.78E-13   IMPA2 18:11987767 2.01E-12 
DHRS4L2 14:24676498 3.07E-13   GTF2H3 12:123593218 2.27E-12 
RPS23 5:81830253 3.14E-13   LGALS4 19:39421274 2.28E-12 




LUM 12:91316180 3.59E-13   POLR1A 2:86297105 2.45E-12 
DUS2 16:67516945 4.11E-13   DPYS 8:106337440 2.56E-12 
CTNNAL1 9:111678508 4.44E-13   DPYS 8:106349393 2.56E-12 
RAB3GAP1 2:136170213 4.50E-13   CDK12 17:38312249 2.93E-12 
TAC3 12:58141938 4.80E-13   S100P 4:6548580 2.95E-12 
ZDHHC2 8:16885062 5.07E-13   S100P 4:6728934 2.95E-12 
DHRS4 14:24123454 5.08E-13   DNAAF3 19:56111573 3.27E-12 
DHRS4 14:24523950 5.64E-13   RHCE 1:25773026 3.49E-12 
RHCE 1:25803162 3.49E-12   CHURC1 14:65322673 1.07E-11 
GTF2H3 12:124135814 3.67E-12   MSLN 16:1279694 1.07E-11 
POLR1A 2:86564490 3.70E-12   MMP24 20:33879965 1.22E-11 
CD68 17:7469015 3.87E-12   LPXN 11:58377817 1.24E-11 
FST 5:53236938 4.57E-12   ENTPD1 10:97583002 1.36E-11 
ATP6V0D1 16:67262775 5.02E-12   IPP 1:46126179 1.79E-11 
ATP6V0D1 16:67264629 5.02E-12   DUS2 16:67386135 1.82E-11 
ATP6V0D1 16:67329327 5.02E-12   SPATA20 17:48603434 1.87E-11 
ATP6V0D1 16:67393428 5.02E-12   RPS23 5:82395106 1.92E-11 
PBX2 6:32143223 5.12E-12   IPP 1:46145295 2.02E-11 
PBX2 6:32149260 5.12E-12   CTSK 1:150789864 2.06E-11 
ZDHHC2 8:16925729 5.44E-12   PBX2 6:32147478 2.07E-11 
PPP1R12B 1:202573179 5.81E-12   CDK12 17:38137213 2.15E-11 
CDK12 17:37427426 6.08E-12   TRNP1 1:27468318 2.27E-11 
CDK12 17:37780786 6.08E-12   TRNP1 1:27472451 2.27E-11 
CDK12 17:37816702 6.08E-12   PGM2L1 11:74550031 2.31E-11 
CDK12 17:37822739 6.08E-12   FST 5:51794332 2.62E-11 
CDK12 17:37910592 6.08E-12   KRT79 12:52652088 2.62E-11 
CDK12 17:37912069 6.08E-12   SOS1 2:38735689 2.86E-11 
CDK12 17:38020470 6.08E-12   CLYBL 13:100513203 3.00E-11 
CDK12 17:38051979 6.08E-12   ENTPD1 10:97516401 3.18E-11 
CDK12 17:38122591 6.08E-12   TAC3 12:57396842 3.39E-11 
CDK12 17:38471182 6.08E-12   ASAH1 8:17731611 3.45E-11 
CDK12 17:38519592 6.08E-12   POLR1A 2:86668341 3.47E-11 
CDK12 17:38597395 6.08E-12   NMRAL1 16:4417160 3.78E-11 
CDK12 17:38601823 6.08E-12   DUS2 16:67269998 3.80E-11 
CDK12 17:38703987 6.08E-12   SIN3B 19:17355669 3.80E-11 
SOS1 2:38366689 6.16E-12   DUS2 16:68395522 3.91E-11 
MTHFSD 16:86510183 6.62E-12   GAD1 2:171547270 4.14E-11 
DHRS4L2 14:24042936 6.80E-12   SOS1 2:38525660 4.26E-11 
POLR1A 2:85981797 7.08E-12   DUS2 16:67357938 4.36E-11 
FMO1 1:171177988 7.29E-12   GTF2H3 12:123282708 4.74E-11 
GSDMA 17:37912268 7.59E-12   GTF2H3 12:123378754 4.74E-11 




GAD1 2:171260887 8.86E-12   SPINK2 4:58397567 5.44E-11 
DPYS 8:105405411 9.27E-12   SPINK2 4:58397610 5.44E-11 
SIN3B 19:17654384 9.31E-12   FNBP1L 1:94792971 5.59E-11 
DHRS4L2 14:23862997 9.86E-12   SIN3B 19:16038111 5.85E-11 
MMP24 20:33575613 1.02E-11   NMRAL1 16:4422744 5.91E-11 
MMP24 20:34526720 1.02E-11   ATP6V0D1 16:67475439 6.04E-11 
MMP24 20:34755884 1.02E-11   ATP6V0D1 16:67492248 6.04E-11 
MMP24 20:34767630 1.02E-11   RHCE 1:24902925 6.12E-11 
MMP24 20:34833404 1.02E-11   DHRS4 14:24647334 6.27E-11 
MMP24 20:34862450 1.02E-11   FMO1 1:170561948 6.60E-11 
ALOX5AP 13:31127975 6.68E-11   EXOC2 6:598588 2.33E-10 
SLC22A1 6:160557643 6.85E-11   AK7 14:96195958 2.35E-10 
RNF181 2:85846329 7.07E-11   FMO1 1:172053810 2.43E-10 
GAPT 5:57653771 7.28E-11   CREB5 7:29045305 2.43E-10 
SOS1 2:39462104 7.35E-11   KRT79 12:52312870 2.62E-10 
CTSK 1:150550924 8.16E-11   SPINK2 4:58405566 2.78E-10 
SIN3B 19:17007363 8.33E-11   SPINK2 4:58407594 2.78E-10 
TMEM14C 6:10687746 8.42E-11   SPINK2 4:58420910 2.78E-10 
DNAAF3 19:56111377 9.23E-11   SOS1 2:38709757 2.83E-10 
SLC8A3 14:70653758 1.10E-10   SPATA20 17:48614426 2.83E-10 
LRRC6 8:133621081 1.11E-10   LRRC2 3:46916051 3.07E-10 
GSDMA 17:37884176 1.19E-10   TMEM14C 6:9820723 3.31E-10 
RBP7 1:11072691 1.20E-10   RAB27A 15:55489250 3.31E-10 
FNBP1L 1:93579198 1.24E-10   RPS23 5:81952164 3.41E-10 
ULK4 3:41715859 1.30E-10   MSLN 16:1359037 3.41E-10 
BAHD1 15:40760444 1.39E-10   GTF2H3 12:123970370 3.59E-10 
DOK4 16:58011727 1.41E-10   LILRA1 19:55998281 3.89E-10 
SIN3B 19:17727401 1.54E-10   TRNP1 1:26394301 3.93E-10 
SNX22 15:65158047 1.57E-10   DYRK3 1:205902130 4.01E-10 
TSPAN16 19:11436221 1.61E-10   FOLR3 11:71800166 4.10E-10 
RHCE 1:24742263 1.62E-10   RPS23 5:81472669 4.26E-10 
LILRA1 19:54275574 1.62E-10   TAC3 12:57912041 4.45E-10 
LILRA1 19:54677876 1.62E-10   DHRS4 14:24676498 4.49E-10 
LILRA1 19:54678025 1.62E-10   KRT79 12:52946594 4.54E-10 
LILRA1 19:54866992 1.62E-10   LUM 12:91643350 4.68E-10 
LILRA1 19:55598927 1.62E-10   LRRC2 3:45786881 4.71E-10 
LILRA1 19:55659519 1.62E-10   TMED6 16:69377470 4.74E-10 
LILRA1 19:56011880 1.62E-10   DNAAF3 19:54848685 4.82E-10 
CHI3L1 1:202301584 1.66E-10   DNAAF3 19:54848686 4.82E-10 
CHI3L1 1:202537552 1.66E-10   RHCE 1:25573797 4.97E-10 
RBPMS2 15:64753826 1.70E-10   PGM2L1 11:74842610 5.26E-10 




ZFP57 6:29691582 1.77E-10   RPS23 5:81741089 5.60E-10 
ACOX1 17:73958795 1.79E-10   RPS23 5:81763218 5.60E-10 
LILRA1 19:54974607 1.83E-10   GAD1 2:171361376 5.66E-10 
RPS23 5:82154463 1.91E-10   LILRA2 19:54420959 5.75E-10 
CAPN12 19:38719964 2.02E-10   SFRP5 10:100234305 5.87E-10 
CAPN12 19:38958397 2.02E-10   POLR1A 2:85383138 6.45E-10 
CAPN12 19:39039058 2.02E-10   CD300C 17:73263012 6.68E-10 
CAPN12 19:39416898 2.02E-10   RNF135 17:29061941 7.05E-10 
SFRP5 10:99523005 2.06E-10   TUBB6 18:12378679 7.17E-10 
AK7 14:97580202 2.12E-10   SPINK2 4:57215989 7.21E-10 
CAPN12 19:39340412 2.20E-10   SPINK2 4:58104786 7.21E-10 
CAPN12 19:39875359 2.20E-10   SPINK2 4:58459198 7.21E-10 
RNF135 17:29894457 7.47E-10   TAC3 12:57619341 1.97E-09 
RHCE 1:25942070 7.65E-10   CTSK 1:150943873 2.07E-09 
MRPL2 6:43040666 7.93E-10   FOSL2 2:27975744 2.13E-09 
SMAD1 4:146480111 7.95E-10   PHACTR4 1:28830349 2.27E-09 
ZNF324 19:59074429 8.13E-10   FOSL2 2:27746230 2.31E-09 
MRPL2 6:42933526 8.16E-10   NUDT2 9:34400980 2.38E-09 
GTF2H3 12:124092033 8.25E-10   SOS1 2:39204965 2.49E-09 
GTF2H3 12:124144359 8.25E-10   SOS1 2:39695138 2.49E-09 
GTF2H3 12:124499652 8.28E-10   SOS1 2:39731853 2.49E-09 
GTF2H3 12:124856569 8.28E-10   CTSW 11:64882506 2.50E-09 
MRPS7 17:73472561 8.41E-10   SIN3B 19:17450038 2.51E-09 
ZNF763 19:12790506 8.46E-10   PNLDC1 6:159688848 2.55E-09 
ZNF763 19:12792377 8.90E-10   LUM 12:91346671 2.58E-09 
DUS2 16:67424412 9.60E-10   LUM 12:91347999 2.58E-09 
CAPN12 19:39904557 9.60E-10   TRNP1 1:26861894 2.66E-09 
LGALS8 1:236723074 9.89E-10   NLRP3 1:247614657 2.69E-09 
LGALS8 1:236737983 9.89E-10   TRNP1 1:27024226 2.88E-09 
RPS23 5:82388211 1.01E-09   DHRS4 14:24042936 2.89E-09 
GSDMA 17:37911048 1.06E-09   TAC3 12:57872983 2.94E-09 
HP 16:72088431 1.12E-09   ZNF324 19:58907700 2.96E-09 
ECHDC3 10:12644023 1.13E-09   CTSW 11:64944795 2.97E-09 
POLR1A 2:86371233 1.18E-09   FNBP1L 1:93913579 3.05E-09 
LRRC6 8:133242503 1.22E-09   SOS1 2:39403006 3.12E-09 
GAD1 2:172110323 1.30E-09   RBPMS2 15:65369947 3.17E-09 
POLR1A 2:86848893 1.37E-09   PDLIM5 4:95442673 3.22E-09 
SOS1 2:38893450 1.39E-09   DHRS4L2 14:23743265 3.43E-09 
GTF2H3 12:123568888 1.39E-09   FCGBP 19:40502943 3.71E-09 
POLR1A 2:86323339 1.40E-09   FCGR2B 1:161882189 3.90E-09 
CPA5 7:129938259 1.46E-09   BAHD1 15:40759347 3.99E-09 




SFRP1 8:40330425 1.48E-09   RPL3L 16:1638013 4.25E-09 
GSDMA 17:38460198 1.48E-09   RPL3L 16:2835376 4.25E-09 
ZNF763 19:12812169 1.48E-09   MRPL2 6:42980218 4.31E-09 
SUSD2 22:24544631 1.50E-09   RHCE 1:24743223 4.40E-09 
AGAP4 10:46258869 1.57E-09   AGAP4 10:46321905 4.45E-09 
HP1BP3 1:21106416 1.75E-09   ATL1 14:51186527 4.65E-09 
RHCE 1:25664799 1.83E-09   ESPN 1:6520668 4.74E-09 
S100P 4:5857909 1.86E-09   DYRK3 1:207221096 4.77E-09 
DPYS 8:105601451 1.88E-09   MSLN 16:737278 4.84E-09 
PCYT1A 3:195965344 1.90E-09   MSLN 16:747032 4.84E-09 
CTSK 1:150894082 1.97E-09   MSLN 16:1255223 4.84E-09 
CTSK 1:150939883 1.97E-09   DPH6 15:36165056 4.91E-09 
CTSK 1:150940308 1.97E-09   RABEP1 17:5037281 4.96E-09 
ANAPC16 10:73964243 1.97E-09   RBPMS2 15:65790090 5.01E-09 
PPP1R12B 1:201952244 5.02E-09   ECHDC3 10:11789382 1.13E-08 
CISD1 10:59956041 5.02E-09   PADI2 1:17594457 1.16E-08 
SOS1 2:38842988 5.03E-09   PLA2G4C 19:48558159 1.18E-08 
ZDHHC2 8:16767217 5.23E-09   RHCE 1:24706965 1.19E-08 
AK7 14:96181934 5.33E-09   RBPMS2 15:64458405 1.20E-08 
RABEP1 17:5044794 5.53E-09   DPH6 15:35008509 1.21E-08 
HEATR6 17:58177769 5.66E-09   CMTM2 16:67262775 1.22E-08 
ACSM1 16:20587568 5.93E-09   CMTM2 16:67264629 1.22E-08 
SPINK2 4:57425674 6.13E-09   CMTM2 16:67329327 1.22E-08 
MRPL2 6:43128519 6.49E-09   CMTM2 16:67393428 1.22E-08 
MRPL2 6:43147861 6.49E-09   IP6K2 3:47933439 1.31E-08 
MRPL2 6:43155458 6.49E-09   PADI2 1:16950389 1.32E-08 
RABEP1 17:4849384 6.56E-09   LRRC4 7:126738011 1.32E-08 
LRRC2 3:47322700 7.06E-09   DUS2 16:67058614 1.32E-08 
STX12 1:28028261 7.14E-09   GTF2H3 12:124102329 1.33E-08 
MICA 6:31378864 7.15E-09   ELOVL6 4:111134733 1.34E-08 
SPINK2 4:58407327 7.32E-09   DPH6 15:34678870 1.34E-08 
AGAP4 10:46282089 7.34E-09   PPT1 1:40425935 1.38E-08 
MRPL2 6:42307884 7.70E-09   RNF135 17:28749880 1.38E-08 
MRPL2 6:42308855 7.70E-09   RNF135 17:28853723 1.38E-08 
MRPL2 6:43019429 7.70E-09   FNBP1L 1:93128629 1.39E-08 
MRPL2 6:43472947 7.70E-09   FNBP1L 1:93489164 1.39E-08 
MRPL2 6:43501753 7.70E-09   FNBP1L 1:93586068 1.39E-08 
MRPL2 6:43815319 7.70E-09   FNBP1L 1:94091316 1.39E-08 
TAC3 12:57997777 8.18E-09   FNBP1L 1:94399522 1.39E-08 
MRPL2 6:43214786 8.38E-09   FNBP1L 1:94514104 1.39E-08 
TAP2 6:32782112 8.64E-09   CTSW 11:65407886 1.39E-08 




MRPL2 6:42072698 8.92E-09   HSPA1B 6:32041661 1.46E-08 
TAC3 12:58011859 9.04E-09   DPYS 8:105800979 1.46E-08 
DPPA4 3:109068774 9.24E-09   DPYS 8:106155586 1.46E-08 
MXRA7 17:74730843 9.45E-09   RPS23 5:81848038 1.50E-08 
MXRA7 17:74734323 9.45E-09   RPS23 5:82026884 1.50E-08 
ELOVL6 4:111543944 9.69E-09   RPS23 5:82026923 1.50E-08 
PMM1 22:42305583 1.02E-08   RPS23 5:82026956 1.50E-08 
PMM1 22:42318560 1.02E-08   RPS23 5:82027004 1.50E-08 
LGALS8 1:236852150 1.03E-08   PCGF5 10:93976268 1.54E-08 
PPP1R12B 1:203198939 1.05E-08   RHCE 1:24945855 1.59E-08 
DYRK3 1:207197770 1.07E-08   RSRC1 3:157882744 1.60E-08 
ZNF763 19:12807066 1.07E-08   DHRS4 14:23743265 1.61E-08 
DPH6 15:36505553 1.08E-08   MRPL2 6:43029288 1.65E-08 
FES 15:91427692 1.09E-08   MRPL2 6:43705287 1.66E-08 
FMN1 15:33384440 1.10E-08   RNF14 5:140353867 1.72E-08 
RABEP1 17:5271763 1.10E-08   MAF1 8:145169485 1.83E-08 
LGALS4 19:38876263 1.86E-08   SOS1 2:39948037 3.58E-08 
LGALS4 19:39797885 1.86E-08   LRRC2 3:46037405 3.64E-08 
ZNF763 19:12668495 1.87E-08   RBP7 1:10582127 3.67E-08 
AGPAT1 6:32136771 1.95E-08   RNF135 17:29710070 3.71E-08 
FOLR3 11:72140415 1.96E-08   CISD2 4:102796668 3.84E-08 
ZDHHC2 8:16132332 1.97E-08   CXCL1 4:74431049 3.97E-08 
IP6K2 3:49455909 2.04E-08   HOXB2 17:46484307 3.99E-08 
ACOX1 17:73511629 2.04E-08   RAB3GAP1 2:135676246 4.12E-08 
RBP7 1:10848564 2.05E-08   KRT79 12:53681883 4.22E-08 
PNLDC1 6:160174540 2.14E-08   LRRC6 8:133953740 4.23E-08 
DHRS4L2 14:24034818 2.14E-08   LGALS4 19:38713687 4.25E-08 
LRRC6 8:133621091 2.18E-08   GTF2H3 12:124069213 4.27E-08 
PADI2 1:16403208 2.20E-08   GTF2H3 12:124086620 4.27E-08 
PBX2 6:31976833 2.20E-08   PHACTR4 1:28864435 4.31E-08 
MXI1 10:111819970 2.22E-08   PCGF5 10:92035440 4.32E-08 
CISD1 10:60082379 2.28E-08   DAD1 14:23475868 4.34E-08 
ATP6V0D1 16:67964361 2.34E-08   DAD1 14:23479347 4.34E-08 
SIN3B 19:17844227 2.34E-08   DHRS4 14:24179039 4.39E-08 
PGM2L1 11:73936474 2.39E-08   DHRS4 14:24179040 4.39E-08 
PGM2L1 11:75005087 2.39E-08   DYRK3 1:207200372 4.47E-08 
RPS23 5:81493931 2.47E-08   ZNF763 19:12813683 4.51E-08 
HOXB2 17:46626924 2.48E-08   MRPS7 17:73520485 4.61E-08 
DNAAF3 19:55727510 2.48E-08   SOS1 2:39924139 5.24E-08 
FMO1 1:170312936 2.54E-08   SOS1 2:39938065 5.24E-08 
PLA2G4C 19:47743147 2.54E-08   VANGL1 1:116185512 5.32E-08 




DPH6 15:35958803 2.55E-08   RPL7L1 6:43225363 5.64E-08 
IP6K2 3:49063555 2.60E-08   PMM1 22:41996481 5.66E-08 
IP6K2 3:49318208 2.60E-08   CAPN12 19:38880107 5.68E-08 
IP6K2 3:49456758 2.60E-08   TMCC3 12:95299263 5.74E-08 
RPL3L 16:2940941 2.60E-08   CHST15 10:126632419 5.86E-08 
MRPL2 6:43173907 2.64E-08   RNF14 5:141308037 5.88E-08 
MRPL2 6:43173908 2.64E-08   POLR1A 2:85965280 5.94E-08 
PBX2 6:32052255 2.72E-08   S100P 4:5908481 5.95E-08 
TBCEL 11:120450321 2.79E-08   S100P 4:7435996 5.95E-08 
SNX27 1:152486860 3.01E-08   MXRA7 17:74730188 5.95E-08 
DNAAF3 19:55652584 3.07E-08   MXRA7 17:74738016 5.95E-08 
HAUS4 14:23402422 3.10E-08   FOXO3 6:108516159 5.96E-08 
AIG1 6:142618616 3.11E-08   STX12 1:28038660 6.10E-08 
POLR1A 2:86364653 3.35E-08   UQCRC1 3:48501929 6.21E-08 
SOS1 2:38491910 3.36E-08   GSDMA 17:37822757 6.26E-08 
ZNF763 19:12781358 3.37E-08   GSDMA 17:37840860 6.26E-08 
KRT79 12:53671264 3.44E-08   GCAT 22:37962646 6.46E-08 
PADI2 1:16955106 3.48E-08   SERPINC1 1:173703928 6.53E-08 
SERPINC1 1:173779018 6.53E-08   LRRC6 8:134107312 9.10E-08 
SERPINC1 1:173839435 6.53E-08   CFL1 11:65624490 9.17E-08 
LUM 12:90725563 6.98E-08   ECHDC3 10:11797467 9.40E-08 
DNAAF3 19:55597178 7.26E-08   AK7 14:96342629 9.41E-08 
FNBP1L 1:93250370 7.37E-08   CSNK1D 17:79879743 9.57E-08 
DAD1 14:22787449 7.43E-08   ADAMTSL4 1:151006406 9.64E-08 
DYRK3 1:207196544 7.66E-08   MSLN 16:685313 9.64E-08 
SOS1 2:38830131 7.68E-08   IPP 1:46383020 9.91E-08 
DYRK3 1:206099780 7.79E-08   MMP24 20:33146457 1.02E-07 
TOP1MT 8:144864231 7.92E-08   TBCEL 11:120418441 1.03E-07 
TSPAN16 19:11461486 8.03E-08   IPP 1:46595615 1.05E-07 
AGPAT1 6:32145399 8.06E-08   NUMA1 11:71725144 1.05E-07 
DPH6 15:34985075 8.10E-08   NUMA1 11:71726122 1.05E-07 
CTSK 1:150059869 8.27E-08   SUSD2 22:25334184 1.06E-07 
CTSK 1:150318987 8.27E-08   MPC2 1:167744168 1.14E-07 
CTSK 1:151735504 8.27E-08   SHC1 1:154938235 1.14E-07 
SLPI 20:43687355 8.36E-08   SHC1 1:154946517 1.14E-07 
ANAPC16 10:74014728 8.50E-08   SHC1 1:154947496 1.14E-07 
ELOVL6 4:109979306 8.52E-08   RBMS1 2:161080519 1.14E-07 
PNKD 2:219083353 8.55E-08      
CLYBL 13:100645581 8.72E-08      
RPS23 5:82281007 8.85E-08      
NUMA1 11:71816766 8.92E-08      




Table S3.6. Brain WGCNA co-expressed gene modules 
 
Gene module Module color* # of genes   
M0** grey 2851   
M1 turquoise 4481   
M2 blue 1305   
M3 brown 960   
M4 yellow 566   
M5 green 413   
M6 red 390   
M7 black 373   
M8 pink 262   
M9 magenta 260   
M10 purple 223   
M11 greenyellow 176   
M12 tan 169   
M13 salmon 168   
M14 cyan 159   
M15 midnightblue 125   
M16 lightcyan 52   
M17 grey60 38   
     
*Module colors are the colors WGCNA uses for labeling the modules 







Table S3.7. Blood WGCNA co-expressed gene modules 
 
Gene module Module color* # of genes 
M0** grey 7433 
M1 turquoise 2065 
M2 blue 1235 
M3 brown 911 
M4 yellow 447 
M5 green 439 
M6 red 358 
M7 black 260 
M8 pink 232 
M9 magenta 188 
M10 purple 171 
M11 greenyellow 162 
M12 tan 158 
M13 salmon 154 
M14 cyan 149 
M15 midnightblue 146 
M16 lightcyan 132 
M17 grey60 126 
M18 lightgreen 124 
M19 lightyellow 122 
M20 royalblue 121 
M21 darkred 115 
M22 darkgreen 103 
M23 darkturquoise 100 
M24 darkgrey 99 
M25 orange 90 
M26 darkorange 90 
M27 white 83 
M28 skyblue 70 
M29 saddlebrown 68 
M30 steelblue 56 
M31 paleturquoise 40 
M32 violet 39 
M33 darkolivegreen 31 
M34 darkmagenta 29 
   
*Module colors are the colors WGCNA uses for labeling the modules 











 ME1 0.574 
 ME2 0.593 
 ME3 0.516 
 ME4 0.440 
 ME5 0.547 
 ME6 0.510 
 ME7 0.431 
 ME8 0.473 
 ME9 0.489 
 ME10 0.445 
 ME11 0.493 
 ME12 0.453 
 ME13 0.447 
 ME14 0.522 
 ME15 0.530 
 ME16 0.401 












 ME1 0.280 
 ME2 0.441 
 ME3 0.450 
 ME4 0.426 
 ME5 0.484 
 ME6 0.482 
 ME7 0.417 
 ME8 0.501 
 ME9 0.488 
 ME10 0.420 
 ME11 0.481 
 ME12 0.481 
 ME13 0.440 
 ME14 0.405 
 ME15 0.448 
 ME16 0.428 
 ME17 0.442 
 ME18 0.443 
 ME19 0.459 
 ME20 0.429 
 ME21 0.424 
 ME22 0.424 
 ME23 0.435 
 ME24 0.469 
 ME25 0.450 
 ME26 0.454 
 ME27 0.444 
 ME28 0.540 
 ME29 0.441 
 ME30 0.466 
 ME31 0.427 
 ME32 0.493 
 ME33 0.498 






Table S3.10. Shared genes in shared enriched pathways in brain and blood 
BRAIN          
CHR BEGIN POS END POS NUM PASS VARS NUM SING VARS STATRHO P-VALUE* GENE MODULE PATHWAY GENE 
1 160523750 162496199 426 268 0 1.00E+00 7 
Apoptosis signaling 
pathway HSPA6 
8 21946761 23968674 494 330 0 6.03E-01 7 
Apoptosis signaling 
pathway TNFRSF10C 
20 43645152 45637945 450 278 0 8.32E-01 7 CCKR signaling map MMP9 
          
BLOOD          
1 160518049 162494496 616 397 0.2 3.66E-02 5 
Apoptosis signaling 
pathway HSPA6 
8 21946761 23968794 817 520 0.1 8.77E-05 5 
Apoptosis signaling 
pathway TNFRSF10C 
20 43644056 45644897 761 468 0 7.73E-04 5 CCKR signaling map MMP9 
          
          
BEGIN POS : Beginning position of range for rare variants within 1 Mb of gene to be tested    
END POS : End position of range for rare variants within 1 Mb of gene to be tested     
NUM PASS VARS : Number of variants passing all thresholds for EPACTS software     
NUM SING VARS : Number of singletons among variants in NUM PASS VARS     
P-VALUE : P-value of burden tests       
   STATRHO: represents the RHO value from SKAT-O test,  rho = 1 (burden) and rho = 0 (SKAT)      
          
*Bonferronni significant threshold: P < 6.49 x 10-4 in brain, P < 5.0 x 10-4 in blood     




Table S3.11. Genes shared between the inflammation pathway gene modules in brain and blood 










Figure S3.1. WGCNA gene module and eigengene network plots. A describes WGCNA networks in brain and B in blood. 
1) Gene hierarchical clustering dendrogram with the color row underneath indicating module membership with module colors. 
The branches correspond to true modules. 2) Hierarchical clustering of module eigengenes that summarize gene modules. 
Branches group together eigengenes that are positively correlated. 3) Eigengene networks shown as heatmaps labeled with 
red denoting high adjacency (positive correlation) and blue denoting low adjacency (negative correlation). 









Figure S3.2. Heatmaps for gene overlap in enriched brain and blood shared pathways. The 3 shared 
pathways, A) Apoptosis Signaling Pathway, B) CCKR Signaling Map, and C) the Inflammation Signaling pathway 
are seen in blood and brain in heatmaps with the magenta blocks indicting gene membership in pathways. The 
yellow highlighted blocks and highlighted gene names illustrate the shared genes in shared pathways.  





































Table S4.1 Characteristics of subjects in the Framingham Heart Study (FHS) and 
Religious Orders Study (ROS)/ Memory and Aging Project (MAP) datasets 
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Chr Pos (hg37) rsID Nearest Gene Method* Trait† p-value Ref 
1 1:207692049 rs6656401 CR1 G AD 5.7 × 10−24 [58] 
1 1:227058273 N/A PSEN2 L,C AD NA [264, 265] 
2 2:106642554 rs34487851 ECRG4 G NP + 
NFT 
2.4 × 10−8 [233] 
2 2:127892810 rs6733839 BIN1 G AD 6.9 × 10−44 [58] 
2 2:202149628 rs146286958 CASP8 RVG AD 8.6 x 10-5 a [227] 
2 2:234068476 rs35349669 INPP5D G AD 3.2 × 10−8 [58] 
2 2:3474085 rs35067331 TRAPPC12 G NFT + 
CAA 
5.8 × 10−8 [233] 
2 NA NA ADI1 GB NFT + 
CAA 
<1 × 10−6 b [233] 
3 3:178257562 rs9637454 KCNMB2 G AD 7.1 × 10−8 [217] 
3 3:190951729 rs9877502 OSTN G CSF tau 4.9 × 10−9 [57] 
4 4:174094940 rs62341097 GALNT7 G NP 6.0 × 10-9 [217] 
4 4:7353052 rs13110208 SORCS2 CG,F AD 9.0 × 10-3 [259] 
4 4:95170280 rs137875858 UNC5C L,CG,F AD 9.5 × 10-3 c [16] 
5 5:139707439 rs11168036 PFDN1, 
HBEGF 
G AD 7.1 × 10−9 [170] 
5 5:15669858 rs75002042 FBXL7 G AD 6.2 x 10-9 [237] 
5 5:88223420 rs190982 MEF2C G AD 3.2 × 10−8 [58] 
6 6: 83072923 rs547721664 TPBG G AD 1.8 × 10−6 [170] 
6 6:32575406 rs9271058 HLA-DRB1 G AD 5.1 × 10−8 [101] 
6 6:32578530 rs9271192 HLA-DRB5 G AD 2.9 × 10−12 [58] 
6 6:	41034000 rs114812713 OARD1 G AD 2.1x10-13 [6] 
6 6:41129252 rs75932628 (R47H) TREM2 G,F AD 2.9 × 10−12 [57, 101] 
6 6:41186912 rs9381040 TREML2 G,F AD 6.3 × 10−7 [57, 58] 
6 6:41368363 rs6922617 NCR2 G AD 3.6 × 10−8 [57] 
6 6:47487762 rs10948363 CD2AP G AD 5.2 × 10−11 [58] 
7 7:100004446 rs1476679 ZCWPW1 G AD 5.6 × 10−10 [58] 
7 7:132110923 rs277470 PLXNA4 G AD 4.1 × 10-8 [253] 
7 7:143110762 rs11771145 EPHA1 G AD 1.1 × 10−13 [58] 
7 7:154988675 NA AC099552.4 RVG AD 1.2 × 10−7 d [17] 
7 7:18698331 rs79524815 HDAC9 G NFT + 
CAA 
1.1 × 10−8 [233] 
7 7:37841534 rs2718058 NME8 G AD 4.8 × 10−9 [58] 
7 7:51578022 rs112404845 COBL G AD 3.8 × 10-8 [231] 
7 7:88406552 rs73705514 ZNF804B G LMdT 2.9 × 10−9 [249] 
7 7:91709085 rs144662445 AKAP9 RVG,F AD 2.2 x 10-3 c [15] 
7 NA NA PILRA GB AD 2.3 × 10−6 e [206, 207] 
8 8:145138063 rs138412600 GPAA1 G AD 7.8 × 10-8 f [266] 
8 8:17496561 rs4921790 PDGFRL / MTUS1 G HPV 4.6 × 10−9 [249] 
8 8:27195121 rs28834970 PTK2B G AD 7.4 × 10−14 [58] 
8 8:27467686 rs9331896 CLU G AD 2.8 × 10−25 [58] 
8 8:95958637 rs1713669 TP53INP1 GB AD 1.4 × 10−6 g [243] 




9 9: 3929424 rs514716 GLIS3 G CSF tau 3.2 ×10−9 [57] 
10 10:107013252 rs7920533 SORCS3 CG,F AD 1.0 × 10-2 [259] 
10 10:108562008 rs12248379 SORCS1 CG,F AD 3.0 × 10-3 [259] 
10 10:115489177 rs1116437863 CASP7 G AD 2.4 × 10-10 [18] 
10 10:11720308 rs7920721 ECHDC3 G AD 2.3 × 10−9 [101] 
10 10:11720308 rs7920721 USP6NL G AD 3.0 × 10−8 [170] 
10 10:13966445 rs2446581 FRMD4A G AD 1.1 × 10−10 [238] 
11 11:121435587 rs11218343 SORL1 G,CG AD 2.7 × 10−8 [55, 58, 
101] 
11 11:47380340 rs3740688 SPI1 G AD 9.7 × 10−11 [101] 
11 11:47557871 rs10838725 CELF1 G AD 1.1 × 10−8 [58] 
11 11:59923508 rs983392 MS4A6A G AD 6.1 × 10−16 [58] 
11 11:59936926 rs7933202 MS4A2 G AD 2.2 × 10−15 [101] 
11 11:60021948 rs1582763 MS4A4A G AD 1.15 × 10-15 [267] 
11 11:85867875 rs10792832 PICALM G AD 9.3 × 10−26 [58] 
11 NA NA OR8G5 GB AD 4.7 × 10−7 h [266] 
12 12:119390525 rs10775009 SRRM4 G CSF Tau 1.6 × 10−9 [249] 
13 13:103663945 rs16961023 SLC10A2 G AD 4.6 × 10-8 [231] 
14 14:105385352 rs2819438 PLD4 G CSF Tau 6.9 × 10−9 [249] 
14 14:106236128 rs12890621 IGHG3 G AD 9.8 × 10−7 [17] 
14 14:106680831 rs2011167 IGHV1-67 G AD 7.9×10−8 g [243] 
14 14:53400629 rs17125944 FERMT2 G AD 7.9 × 10−9 [58] 
14 14:73637653 rs63749824 PSEN1 L,C AD NA [268] 
14 14:92926952 rs10498633 SLC24A4 / RIN3 G AD 5.5 × 10−9 [58] 
14 14:92932828 rs12881735 SLC24A4 G AD 7.4 × 10−9 [101] 
14 NA NA IGHV3-7 GB AD 9.75 × 10−16 [266] 
15 15:101646763 rs139709573 TM2D3 RVG AD 6.6 × 10-9 [269] 
15 15:59045774 rs593742 ADAM10 G AD 6.8 × 10−9 [101] 
15 15:64433291 rs74615166 TRIP4 G AD 9.7 × 10−9 [262] 
16 16:19808163 rs7185636 IQCK G AD 2.4 × 10−8 [101] 
16 16:79355857 rs62039712 WWOX G AD 3.7 × 10−8 [101] 
16 16:81942028 rs72824905 PLCG2 G AD 5.4 × 10−10 [3] 
17 17:44353222 rs2732703 MAPT G AD 5.8 × 10−9 [56] 
17 17:44355683 rs113986870 KANSL1 G AD 1.3 × 10−8 [56] 
17 17:47297297 rs616338 ABI3 G AD 4.6 × 10−10 [3] 
17 17:56409089 rs2632516 BZRAP1 G AD 4.4×10−8 [170] 
17 17:61569732 rs4351 ACE G AD 5.3×10-9 [270] 
19 19:1063443 rs4147929 ABCA7 G AD 1.1 × 10−15 [58] 
19 19:15302421 rs149307620 NOTCH3 RVG,F AD NA [83] 
19 19:18546678 rs2303697 ISYNA1 G AD 4.6 × 10−7 f [266] 
19 19:40877595 rs145999145 PLD3 RVG,F AD 1.4 × 10-11 [252] 
19 19:45411941 rs429358 APOE L,CG AD 2.1 × 10−47 [271] 




20 20:55018260 rs7274581 CASS4 G AD 2.5 × 10−8 [58] 
20 NA NA SLC24A3 GB AD 2.7 × 10−12 [266] 
21 21:28915457 rs1487586185 APP CG AD NA [224] 
21 21:28156856 rs2830500 ADAMTS1 G AD 2.6 × 10−8 [101] 
21 21:43678066 rs142544282 ABCG1 G NP 8.0×10−9 [217] 
 
*Method: G = GWAS; RVG = Rare Variant GWAS; C =Cloning; CG = Candidate Gene; L = 
Linkage; F =Functional evidence; GB = Gene-based; 
 
 
*Trait: AD = Alzheimer disease, HPV = hippocampal volume, LMdT = logical memory – delayed 
recall, NFT = neurofibrillary tangle, NP = neuritic plaque 
 
Study-wide significance level: a 8x10-4, b 2.7x10-6; c 0.05, d 3.1x10-7, e  0.0014, f  2.8x10-7, g 2.5x10-





Table S4.3 Number of significant cis eQTLs and ct-eQTLs in blood and brain 
tissue data as seen in genome-wide analysis 
 
 Blood eQTL Blood ct-eQTL Brain eQTL Brain ct-eQTL 
Total # of tests 8,662,143 86,621,430 304,732,096 1,523,660,480 
# significant eQTL pairs 847,429 30,405 173,857 51,098 
p-value threshold 1 5.77E-09 5.77E-10 1.64E-10 3.28E-11 
# unique eGenes in eQTL pairs 6033 502 1,301 799 










Table S4.4 Significant eGenes shared between blood and brain tissues.  
















































































































































































































































































































































































































Table S4.5: Pathway analysis of 386 distinct eGenes shared in blood and brain 
 
PANTHER Pathway # Genes Annotated to Pathway 








Apoptosis signaling pathway 115 6 2.12 2.83 + 2.28E-02 
Wnt signaling pathway 317 1 5.84 0.17 - 3.36E-02 
General transcription by RNA 
polymerase I 17 2 0.31 6.39 + 4.55E-02 
 
PANTHER = Protein ANalysis THrough Evolutionary Relationships) Classification System; *Expected probability of 
observing at least x number of genes out of the total n genes in the PANTHER list annotated to a particular 





Table S4.6: Distinct eGenes shared by all blood and brain eQTLs and ct-eQTLs 


























Table S4.7 AD loci genes in significant results 
eGene Tissue Cell-type Lead eSNP Position* MAF Beta Std Error P-value 




Distance (bp) between 
eSNP and eGene  
[Nearest gene] 
CR1 Blood NA rs7533408 1:207673631 0.25 0.059 0.006 3.60E-22 169 0 
PSEN2 Blood NA rs1289395 1:227042462 0.37 -0.020 0.003 2.77E-12 49 15423 
TRAPPC12 Blood NA rs71281795 2:3487331 NAV -0.040 0.005 1.10E-15 104 0 
ADI1 Blood NA rs57139325 2:3519283 0.18 0.127 0.008 8.45E-58 123 0 
BIN1 Blood NA rs1060743 2:127826533 0.29 -0.060 0.003 2.48E-99 355 0 
CASP8 Blood NA rs7560328 2:202164837 0.39 0.028 0.003 1.06E-18 54 12403 [In FLACC1] 
INPP5D Blood NA rs7581787 2:234077240 0.44 0.026 0.003 5.79E-16 158 0 
GALNT7 Blood NA rs1006003 4:174092791 0.50 -0.034 0.003 5.07E-24 102 0 
HLA-DRB5 Blood NA rs9269008 6:32436217 0.17 -2.580 0.057 <1.0E-314 72 48903 [HLA-DRB9 (5060)] 
HLA-DRB1 Blood NA rs9270815 6:32569859 0.14 -5.430 0.044 <1.0E-314 630 12234 
TREML2 Blood NA rs6933231 6:41163700 0.37 -0.034 0.004 5.39E-16 34 0 
CD2AP Blood NA rs4711880 6:47480676 0.25 -0.146 0.007 1.36E-104 331 0 
NME8 Blood NA rs71527594 7:37875986 NAV 0.117 0.006 1.84E-81 304 12213 
EPHA1 Blood NA rs3935067 7:143104331 0.33 0.039 0.003 5.29E-34 50 0 
MTUS1 Blood NA rs117496663 8:17660151 0.02 -0.290 0.009 9.94E-218 325 1725 
PTK2B Blood NA rs28834970 8:27195121 0.34 -0.068 0.003 1.48E-100 339 0 
CLU Blood NA rs9331950 8:27454682 0.22 -0.059 0.010 3.15E-09 1 0 
TP53INP1 Blood NA rs6987752 8:95966531 0.46 -0.035 0.004 8.43E-19 145 4892 [In NDUFAF6] 
USP6NL Blood NA rs968455032 10:11697424 NAV 0.066 0.009 5.12E-12 61 43671 
ECHDC3 Blood NA rs11257290 10:11780324 0.28 0.041 0.005 2.91E-19 115 4041 
FRMD4A Blood NA rs1409327 10:13747195 0.41 0.023 0.003 3.40E-13 11 0 
SORCS3 Blood NA rs1404786 10:106740404 0.05 -0.067 0.007 9.04E-20 223 0 
CASP7 Blood NA NAV 10:115439640 NAV -0.072 0.005 8.00E-52 201 0 
MS4A2 Blood NA rs514266 11:59877697 0.46 -0.094 0.011 5.74E-18 63 14253 




MS4A4A Blood NA rs2162254 11:60039917 0.40 0.109 0.016 2.62E-12 44 8097 
PICALM Blood NA rs7131120 11:85690012 0.22 -0.051 0.006 7.47E-15 41 0 
PSEN1 Blood NA rs214260 14:73662629 0.16 0.076 0.004 1.28E-80 251 0 
RIN3 Blood NA rs17783630 14:92955385 0.46 0.037 0.002 3.73E-50 67 24733 [In SLC24A4 ] 
SLC24A4 Blood NA rs17783630 14:92955385 0.46 0.063 0.004 2.82E-45 73 0 
TM2D3 Blood NA rs12907459 15:102225621 0.44 0.062 0.004 3.60E-63 134 33027 [In TARS3] 
WWOX Blood NA rs7202722 16:78282458 0.40 0.023 0.003 2.60E-14 45 0 
PLCG2 Blood NA rs7187863 16:81964977 0.23 0.038 0.004 1.61E-19 68 0 
KANSL1 Blood NA rs2732716 17:44323046 0.36 -0.087 0.006 4.75E-43 1767 20313 [MAPK8IP1P1(636)] 
ABCA7 Blood NA rs12462842 19:1100976 0.49 0.017 0.002 2.88E-13 29 35405 [GPX4(2960)] 
PLD3 Blood NA rs201739636 19:40851678 0.02 0.019 0.003 3.58E-12 8 2685 [In C19orf47] 
CD33 Blood NA rs200656 19:51724326 0.22 0.038 0.005 1.42E-15 5 3994 
SLC24A3 Blood NA rs3827978 20:19281291 0.36 0.043 0.004 1.42E-34 182 0 
CASS4 Blood NA rs6014740 20:55045843 0.35 0.040 0.005 1.50E-17 78 11447 [In RTF2] 
APP Blood NA rs8131895 21:27503527 0.36 -0.044 0.004 1.52E-22 126 0 
ADAMTS1 Blood NA rs373460567  21:28215827 0.22 0.072 0.006 9.18E-38 27 0 
ABCG1 Blood NA rs9976024 21:43641657 0.14 -0.030 0.004 2.01E-11 43 0 
HLA-DRB5 Blood Interferon response(+)/ Anti-bacterial(-) rs9269047 6:32438783 0.12 -7.120 0.335 3.04E-100 9 [all (-)] 
46337 [HLA-DRB9 
(2494)] 
HLA-DRB5 Blood Monocytes/ Macrophages rs9269047 6:32438783 0.12 -11.60 1.030 2.02E-29 1 46337 [HLA-DRB9 (2494)] 
HLA-DRB5 Blood NK cells / CD8+ T-Cells rs9269047 6:32438783 0.12 -7.660 0.994 1.30E-14 1 46337 [HLA-DRB9 (2494)] 
HLA-DRB1 Blood NK cells / CD8+ T-Cells rs9270928 6:32572461 0.15 -4.070 0.377 3.60E-27 287 14836 
HLA-DRB1 Blood Eosinophils rs9270994 6:32574250 0.14 -2.700 0.415 7.72E-11 42 16625 
HLA-DRB1 Blood Interferon response(+)/ Anti-bacterial(-) rs9271147 6:32577385 0.14 -5.510 0.250 1.19E-107 346 [260(-)/86(+)] 
19760 [HLA-
DQA1(18571)] 
HLA-DRB1 Blood Monocytes/ Macrophages rs9271148 6:32577442 0.13 -6.110 0.709 6.83E-18 222 19817 [HLA-DQA1(18514)] 
CR1 Brain NA rs12037841 1:207684192 0.18 -0.096 0.007 9.25E-44 64 0 




HLA-DRB1 Brain NA rs73399473 6:32538959 0.26 -2.050 0.058 8.78E-272 10792 7587 
ECHDC3 Brain NA rs866770710  10:11784320 0.0004 -0.252 0.018 4.61E-44 45 45 
WWOX Brain NA rs12933282 16:78124987 0.45 -0.133 0.017 1.13E-15 75 8323 
MAPT Brain NA rs2950011 17:43666385 0.23 -0.134 0.020 1.65E-11 186 305363 [DND1P1(2090)] 
OARD1 Brain Endothelial Cells rs17825664 6:405873 0.08 -0.812 0.120 1.32E-11 6 40595493 [In IRF4] 
HLA-DRB5 Brain Microglia rs67987819 6:32497655 0.14 -1.900 0.137 9.82E-44 754 0 
HLA-DRB5 Brain Endothelial Cells rs67987819 6:32497655 0.14 -2.410 0.220 6.32E-28 343 0 
HLA-DRB1 Brain Microglia rs72847627 6:32538512 0.28 -2.130 0.125 4.15E-65 2305 8034 
HLA-DRB1 Brain Neurons rs115480576 6:32538570 0.26 -2.210 0.153 2.72E-47 3263 7976 
HLA-DRB1 Brain Endothelial Cells rs9269492 6:32542924 0.23 -2.250 0.243 2.06E-20 351 3622 
HLA-DRB5 Brain Neurons rs9270035 6:32553446 0.14 -2.520 0.137 1.46E-75 2540 55382 [In HLA-DRB1] 
ECHDC3 Brain Neurons rs866770710  10:11784320 0.0004 0.328 0.045 3.13E-13 2 45 
NA = not applicable; NAV = not available; * Chromosome and map position according to GRCh37 assembly; MAF 




Table S4.8 AD association peaks in significant results 
eGene Tissue Cell-type eSNP+GWAS SNP Position * MAF Beta Std Error P-value Nearest AD Gene 
TRAPPC12 Blood NA rs35067331 2:3474085 0.29 0.021 0.003 1.23E-10 TRAPPC12 
BIN1 Blood NA rs6733839 2:127892810 0.38 -0.040 0.003 7.42E-38 BIN1 
INPP5D Blood NA rs35349669 2:234068476 0.46 0.025 0.003 7.88E-14 INPP5D 
HLA-DRB1 Blood NA rs9271058 6:32575406 0.27 -2.950 0.028 <1.0E-314 HLA-DRB1 
CD2AP Blood NA rs10948363 6:47487762 0.25 -0.146 0.007 2.32E-104 CD2AP 
NME8 Blood NA rs2718058 7:37841534 0.37 0.078 0.006 1.64E-43 NME8 
PILRB Blood NA rs1476679 7:100004446 0.30 0.109 0.008 1.15E-46 ZCWPW1 
TAS2R60 Blood NA rs11771145 7:143110762 0.36 -0.376 0.010 3.29E-274 EPHA1 
EPHA1 Blood NA rs11771145 7:143110762 0.36 -0.029 0.004 1.90E-14 EPHA1 
PTK2B Blood NA rs28834970 8:27195121 0.34 -0.068 0.003 1.48E-100 PTK2B 
TRIM35 Blood NA rs28834970 8:27195121 0.34 0.018 0.003 3.72E-10 PTK2B 
TP53INP1 Blood NA rs1713669 8:95958637 0.36 -0.029 0.004 1.21E-12 TP53INP1 
MADD Blood NA rs3740688 11:47380340 0.46 0.017 0.003 4.06E-09 SPI1 
MYBPC3 Blood NA rs3740688 11:47380340 0.46 -0.020 0.002 4.47E-18 SPI1 
MS4A6A Blood NA rs983392 11:59923508 0.41 0.072 0.006 1.22E-33 MS4A6A 
MS4A6A Blood NA rs7933202 11:59936926 0.39 0.079 0.006 4.40E-40 MS4A2 
MS4A4A Blood NA rs1582763 11:60021948 0.36 0.107 0.016 1.44E-11 MS4A4A 
SLC24A4 Blood NA rs10498633 14:92926952 0.21 -0.044 0.006 2.60E-14 SLC24A4/RIN3 
SLC24A4 Blood NA rs12881735 14:92932828 0.22 -0.044 0.006 9.19E-15 SLC24A4 
FAM63B Blood NA rs593742 15:59045774 0.32 -0.086 0.006 8.18E-45 ADAM10 
ARL17A Blood NA rs2732703 17:44353222 0.21 0.147 0.023 5.95E-11 MAPT 
ARL17A Blood NA rs113986870 17:44355683 0.09 0.166 0.025 2.30E-11 KANSL1 
SUPT4H1 Blood NA rs2632516 17:56409089 0.47 -0.036 0.004 5.14E-22 BZRAP1 
CNN2 Blood NA rs4147929 19:1063443 0.19 -0.121 0.011 7.17E-28 ABCA7 
HMHA1 Blood NA rs4147929 19:1063443 0.19 -0.030 0.004 1.62E-12 ABCA7 
LRRC25 Blood NA rs2303697 19:18546678 0.35 0.043 0.003 8.37E-57 ISYNA1 




HLA-DRB1 Blood NK cells / CD8+ T-Cells rs9271058 6:32575406 0.27 -4.090 0.464 1.20E-18 HLA-DRB1 
HLA-DRB1 Blood Monocytes / Macrophages rs9271058 6:32575406 0.27 -3.540 0.497 1.06E-12 HLA-DRB1 
CR1 Brain NA rs6656401 1:207692049 0.17 -0.096 0.007 1.05E-43 CR1 
HLA-DRB5 Brain NA rs9271058 6:32575406 0.27 -1.690 0.081 2.28E-106 HLA-DRB1 
HLA-DRB1 Brain NA rs9271058 6:32575406 0.27 -1.770 0.054 1.94E-213 HLA-DRB1 
HLA-DRB5 Brain NA rs9271192 6:32578530 0.27 -1.680 0.080 5.27E-107 HLA-DRB5 
HLA-DRB1 Brain NA rs9271192 6:32578530 0.27 -1.760 0.054 2.82E-213 HLA-DRB5 
KNOP1 Brain NA rs7185636 16:19808163 0.16 0.513 0.031 2.26E-60 IQCK 
LRRC37A2 Brain NA rs2732703 17:44353222 0.21 1.370 0.053 4.13E-150 MAPT 
ARL17A Brain NA rs113986870 17:44355683 0.09 1.260 0.047 4.96E-12 KANSL1 
LRRC37A2 Brain NA rs113986870 17:44355683 0.09 -0.326 0.068 1.98E-76 KANSL1 
HLA-DRB1 Brain Neurons rs9271058 6:32575406 0.27 -1.400 0.135 2.37E-34 HLA-DRB1 
HLA-DRB5 Brain Neurons rs9271058 6:32575406 0.27 -1.650 0.201 1.24E-14 HLA-DRB1 
HLA-DRB1 Brain Microglia rs9271058 6:32575406 0.27 -1.550 0.111 1.80E-36 HLA-DRB1 
HLA-DRB1 Brain Endothelial Cells rs9271192 6:32578530 0.27 -1.400 0.245 2.96E-12 HLA-DRB5 
HLA-DRB1 Brain Neurons rs9271192 6:32578530 0.27 -1.650 0.135 2.37E-34 HLA-DRB5 
HLA-DRB5 Brain Neurons rs9271192 6:32578530 0.27 -1.550 0.201 1.24E-14 HLA-DRB5 
HLA-DRB1 Brain Microglia rs9271192 6:32578530 0.27 -1.710 0.110 4.17E-37 HLA-DRB5 
LRRC37A2 Brain Microglia rs2732703 17:44353222 0.21 1.520 0.147 7.65E-24 MAPT 
LRRC37A2 Brain Neurons rs2732703 17:44353222 0.21 1.480 0.140 1.84E-27 MAPT 
LRRC37A2 Brain Endothelial Cells rs2732703 17:44353222 0.21 1.750 0.233 5.88E-14 MAPT 
LRRC37A2 Brain Neurons rs113986870 17:44355683 0.09 1.530 0.184 2.77E-14 KANSL1 
LRRC37A2 Brain Microglia rs113986870 17:44355683 0.09 1.400 0.195 4.29E-15 KANSL1 
          
Known AD gene            
 
NA = not applicable; * Chromosome and map position in base pairs; MAF = minor allele frequency; Cell-type 




Table S4.9 Cell-type distribution in significant ct-eQTL results 
 




Reference % in tissue1 
Blood    
   Neutrophils.1 1,007 3.3 53.8±6.1 of leukocytes2 
   Neutrophils.2 50 2.4 53.8±6.1 of leukocytes 
   CD4+ T-cells 562 1.8 14.6±3.5 of leukocytes 
   NK cells / CD8+T-cells 2,611 8.6 
NK cells=4.4±2.4 of leukocytes 
CD8+ T cells=6.8±1.3 of 
leukocytes 
Erythrocytes 2,130 7.0 93-96% of blood cells 
Monocytes/macrophages 3,234 10.6 8.4±1.3 of leukocytes 
Interferon response /  
     Anti-bacterial cells 19,331 63.6 NA 
   B-cells 89 0.3 5.2±2.3 of leukocytes 
   Eosinophils 735 2.4 3.2±1.6 of leukocytes 
   Unknown 646 2.1 NA 
Brain    
   Endothelial cells 10,597 20.7 ~2:1 glia3 to endothelial cells 
   Neurons 18,930 37.0 1:1 ratio of glia to neurons 
   Microglia 15,560 30.4 10% of glial cells 
   Astrocytes 1,040 2.0 19–40% of glial cells 
   Oligodendrocytes 4,971 9.7 45–75% of glial cells 
 
1 References in blood [200, 201] and in brain [202, 272] 
2 Leukocytes: 0.1-0.2% of blood cells 
























secretase pathway 67 5 0.41 12.06 + 8.18E-05 1.34E-02 
Oxytocin receptor mediated 
signaling pathway 58 4 0.36 11.15 + 5.78E-04 4.74E-02 
Thyrotropin-releasing 
hormone receptor signaling 
pathway 
60 4 0.37 10.78 + 6.52E-04 3.56E-02 
5HT2 type receptor 
mediated signaling pathway 67 4 0.41 9.65 + 9.64E-04 3.95E-02 
 
PANTHER = Protein ANalysis THrough Evolutionary Relationships) Classification System; * Expected probability of 
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Figure S4.2 Regional plots for colocalized AD GWAS/lead eQTL variant pairs. A) rs10948363 CD2AP/	rs4711880 
CD2AP; B) rs28834970 PTK2B/ rs6557994 PTK2B; C) rs9331896 CLU/ rs6557994 PTK2B; D) rs10838725 

















Table S5.1 Rare eQTLs for top rare variant genes in NOTCH3 and TREM2 
 
 
CHR BEGIN POS END POS NUM PASS VARS NUM SING VARS P-VALUE STATRHO GENE TISSUE 
19 14270543 16308917 659 416 0.1309 0 NOTCH3 BLOOD 
6 40133725 42130917 716 436 0.12376 0 TREM2 BLOOD 
6 40133952 42130904 452 288 0.39207 0 TREM2 BRAIN 
 
 
BEGIN POS : Beginning position of range for rare variants within 1 Mb of gene to be tested 
END POS : End position of range for rare variants within 1 Mb of gene to be tested 
NUM PASS VARS : Number of variants passing all thresholds for EPACTS software 
NUM SING VARS : Number of singletons among variants in NUM PASS VARS 
P-VALUE : P-value of burden tests 




Table S5.2 Intersect of rare and common eQTLs in blood and brain 
 
Blood  Brain 
ABCA7 DPPA4 LRRC6 RNF181  ACOT1 
ABHD2 DSC2 MAF1 RPA2  ADAL 
ACOX1 EBPL MAPKAPK3 RPS23  ANKK1 
ACSL6 ECHDC3 MEGF9 RSRC1  ANKRD30BL 
ACSM1 ENGASE MGAM S100A12  ANXA9 
ADAMTSL4 ENTPD1 MMP24 S100P  C10orf107 
AGPAT1 EPB41L4A MMP9 SHC1  C2orf74 
AIG1 ESPN MPC2 SIGLEC5  C5orf17 
ALOX5AP EXOC2 MRPL10 SIGLEC9  CCDC163P 
APRT EXOC4 MRPS7 SIN3B  CCDC173 
ARID3B FAAH MRVI1 SLC22A1  CYP2D6 
ARL17A FCGBP MS4A6A SLPI  DNLZ 
ARRB2 FCGR2B MXI1 SMAD1  FAM154B 
ARSG FKBP1A MYOM1 SMAP1  GNMT 
ASAH1 FNBP1L MZT2A SNX19  GUF1 
ASPRV1 FOLR3 NLRP1 SPATA20  HLA-A 
ATG7 FST NLRP3 SPPL3  HLA-DOB 
ATL1 GAD1 NMRAL1 SSH3  HLA-DRB1 
ATP6V0D1 GCAT NSMAF ST6GALNAC2  HLA-DRB5 
ATP6V1D GSTA3 NUDT2 STYXL1  HP 
ATXN7L3B GSTA4 NUMA1 TAC3  HPR 
BEGAIN GTF3C3 NUP107 TAP2  IL27 
CARS2 HAL NUP50 TIAM2  LDHC 
CCDC122 HAUS4 PADI2 TMCC3  LYPD8 
CCDC146 HEATR6 PADI4 TMED6  MMRN1 
CD300A HEBP1 PBX2 TMEM163  NBPF16 
CD300C HEBP2 PCYT1A TMEM51  NPIPA2 
CD36 HIP1 PDLIM5 TOP1MT  NPIPA8 
CDA HMBOX1 PEX6 TP53I3  OPN1SW 
CDK5R1 HOXB2 PGM1 TREML4  POMC 
CFL1 HOXB3 PGM2L1 TSPAN16  PSORS1C1 
CHI3L1 HP PGM5 TUBB  RBPMS2 
CHURC1 HP1BP3 PISD TUBB2A  RNF39 
CISD1 HSD17B13 PLA2G4C TUBB6  RPRD2 
CISD2 HSPA1B PLAGL1 UBE4B  TRIM63 
CLN6 IER3 PNKD UFSP2  YBEY 
CLTCL1 IKZF3 PNLDC1 UHRF1BP1  ZNF253 
CLYBL IMPA2 POLR1A ULK4  ZNF514 
CPA5 INPP1 PPP3CA UQCRC1  ZNRD1 
CPVL IP6K2 PPT1 USP10  ZSCAN31 
CREB5 KIAA1191 PYGB UTS2   
CTNNAL1 KIF1B RAB27A UVSSA   
CTSK LDHC RABEP1 VNN2   
CTSW LGALS4 RALBP1 WARS2   
CXCL1 LGALS8 RBM23 XRRA1   
DAD1 LILRA1 RBMS1 YTHDC2   
DEF6 LILRA2 RBP7 ZDHHC2   
DGCR8 LIN7A RBPMS2 ZNF502   
DHRS4 LPXN RHD ZNF605   
DNAJC15 LRRC2 RIN1 ZP3   
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